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ABSTRACT 
 
Drooling management in the neurologically impaired pediatric population is a 
challenge. Surgery is considered an invasive procedure, while behaviour 
modification techniques, correction of situational factors and oral-motor therapy 
do not always produce sustained improvement. In recent years Botox® has been 
investigated. This study comprised analyses of clinical data obtained from a 
Drooling Treatment Project (DTP) conducted at a school for special needs 
children in South Africa. The aims of the DTP were to establish the response of 
drooling in a number of different contexts, following bilateral submandibular 
salivary gland injections of Botox®. Two groups of children were involved, 7 
children with cerebral palsy and 2 children with operculum syndrome. Drooling 
was assessed in 5 different situations and at different time points pre- and post 
Botox® injection up to 6 months. Parents/primary caregivers’ perceptions of 
drooling and treatment with Botox® were also measured using an interview form 
and a quality of life questionnaire. Results showed that drooling was reduced in 
all situations, with significant reductions in the general and communicating 
situations. These results indicate that the context in which drooling occurs is an 
important factor and suggest the value of considering the situational context when 
making drooling judgements. Further, there was a difference in the pattern of 
response between the 2 groups. This finding has implications, not only for future 
research, but also for models of explanation of the effects of Botox®. Most 
parents/primary caregivers felt their children’s lives and their own had improved 
following the Botox® injection and would repeat the treatment. Clinical and 
research implications are discussed, with reference to the South African context.  
 
 
 
 
KEY WORDS; Cerebral palsy, operculum syndrome, drooling, salivary glands, 
Botulinum toxin type A, Botox®, quality of life, drooling measures, severity and 
frequency rating scales. 
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CHAPTER 1 
 
INTRODUCTION 
 
The management of drooling in the neurologically impaired population is a 
challenge to all who work and live within this field. Ear, nose and throat surgeons 
(ENT’s), speech, language and hearing therapists, plastic surgeons, neurologists, 
radiologists, medical doctors, dentists, physiotherapists, occupational therapists, 
nurses and last but by no means least, parents and neurologically impaired 
individuals, are just some of the people involved in the challenge. Correction of 
situational factors, behaviour modification techniques, oral-motor therapy, 
pharmacologic treatment, and surgery have been advocated to improve drooling.  
 
While correction of situational factors, behaviour modification techniques and 
oral-motor therapy should be the first line of attack, not all individuals respond 
favourably. In a study by Thomas-Stonell and Greenberg (1988) only 66% of 
patients treated conservatively had improved drooling. Anti-cholinergic 
medications can produce a decrease in drooling, but often have debilitating side 
effects, resulting in patients discontinuing their use. Surgical options in the 
treatment of drooling include removal of salivary glands, rerouting of salivary 
ducts and denervation of the salivary glands. Reid, Johnstone, Westbury, Rawicki 
and Reddihough (2008) report an 80% success rate with surgery at their 
institution. This can be considered an excellent outcome. However, surgery is an 
invasive procedure, not without risk and side effects can be unpleasant. 
Depending on the procedure there may also be a return to previous levels of 
drooling.  
 
As a practising speech, language and hearing therapist in daily contact with 
children who drool and in frequent contact with their parents/primary caregivers, I 
have had the opportunity to discover their perceptions towards drooling 
treatments. It seems nowadays that parents/primary caregivers and the children 
themselves are looking for less drastic/invasive means to improve drooling, when 
conservative methods have not produced the desired results. 
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Since 1999 Botulinum toxin type A (Botox®, Allergan Inc. Irvine, California, 
USA) has been used by a variety of researchers in an attempt to find a minimally 
invasive method to reduce drooling in the neurologically impaired population.  
 
Initial studies used adults with diseases such as Parkinson’s disease (Pal, Calne, 
Calne and Tsui, 2000). Research then moved onto the use of neurologically 
impaired children with severe drooling. These children were usually diagnosed 
with mental retardation, cerebral palsy and/or operculum syndrome (Bothwell, 
Clarke, Dooley, Gordon, Anderson, Wood, Camfield and Camfield, 2002; 
Jongerius, van den Hoogen, van Limbeek, Gabreëls, van Hulst and Rotteveel, 
2004; Savarese, Diamond, Elovic and Millis, 2004; Suskind and Tilton, 2002). 
Results from these studies proved to be favourable.  
 
In 2006 I was involved in a Drooling Treatment Project (DTP) that was conducted 
at a school for learners with special education needs (LSEN) in Gauteng, South 
Africa. Nine neurologically impaired children, seven diagnosed with different 
types of cerebral palsy and two diagnosed with operculum syndrome, were 
included in the project. The aims of the DTP were to investigate the response of 
drooling to bilateral submandibular salivary gland injections of Botox® under a 
number of different situations and over a period of six months. The present study 
is a record review and an analysis of the clinical data obtained from the DTP. 
 
At that time, Botox® had been used in South Africa in the neurologically 
impaired population, but not to treat drooling in children. As far as I know, this 
report on the DTP is a first for South Africa. Previous published studies have 
looked at parental perceptions of a reduction in drooling. Van der Burg, Jongerius, 
van Limbeek, van Hulst and Rotteveel (2006a) investigated parental perceptions 
of decreased drooling in different situations, as part of their study on the impact of 
drooling on daily life, social interaction and self-esteem. However, the opinions of 
speech, language and hearing therapists on a reduction of drooling, following 
Botox® injections in different daily situations, have not been considered.  
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The consequences of drooling for children and their families are numerous. There 
can be clinical, social, educational and emotional issues (Lal & Hotaling, 2006). 
With the emphasis on the biopsychosocial model of disability (WHO, 2001), it is 
important to consider these issues and the possible effects of drooling on the 
quality of life (QoL) of the drooling child and his/her family. South Africa has a 
unique socio-demographic people and at this stage very little is known about the 
QoL of South African neurologically impaired children and their parents/primary 
caregivers.  
 
In South Africa there are frequent challenges of poverty, disease and often basic 
health, welfare and educational needs are not catered for. We do not know 
whether South African parents/primary caregivers consider drooling to be a 
contributing factor to a negative quality of life. The relevance of international 
published studies that do consider drooling to have a negative influence has yet to 
be assessed in the South African context. The viability of using Botox® injections 
to reduce drooling in children in South Africa is also unknown. The essential 
question is: can the use of Botox® injections to reduce drooling be relevant in our 
society, where the majority of families with a disabled child do not receive 
sufficient fundamental support?  
 
Recently some authors have encouraged South African speech, language and 
hearing therapists to make our research socially relevant (Barratt, 2007; Kathard, 
Naude, Pillay & Ross, 2007). The Malamulele Onward-Ongoing support for 
Africa’s Children project and the training of caregivers at the LSEN School where 
I work, a project funded by The Nelson Mandela Children’s Fund, are excellent 
examples of socially relevant work that is being carried out by therapists in this 
country. I believe the review of the clinical data from the DTP is socially relevant 
as it has provided the following:  
· some insight into South African parents’/primary caregivers’ perceptions 
of drooling; 
· insight into the impact drooling has on their child’s life as well as their 
own; 
 4
· information regarding the effect on drooling of Botox® injections to the 
salivary glands, in a number of daily situations encountered by all South 
African neurologically impaired children; 
· how long the effect of Botox® can be expected to last; 
· information that paves the way for speech, language and hearing therapists 
in South Africa to be able to make informed decisions with regards to the 
possible treatment of drooling with the use of Botox®. 
 
The National Health Plan for South Africa (African National Congress, 1994, p.7) 
states “….every person has the right to optimal health care.” If for some drooling 
individuals Botox® is the optimal treatment, then those individuals have the right 
to access that treatment, irrespective of their age, gender, race, or socio-economic 
status. It is our job, as socially responsible professionals working in the field of 
neurologically impaired individuals, to facilitate that access. This facilitation may 
mean: approaching pharmaceutical companies for sponsorship or even continued 
research to find an easier, cheaper mode of drug administration; or lobbying 
education and health departments at a national level to include Botox® on the list 
of available items that are on government tender at hospitals. 
 
If the use of Botox® to control drooling is the way forward, we as practicing 
clinicians are bound to ensure that our conclusions and ultimately our petitions are 
based on sound scientific research. Perhaps clinicians, in order to stay relevant, 
especially in a context such as South Africa, should become clinician-researchers 
and take on board scientific methods for measuring effectiveness (Penn, 2007; 
Swanepoel, 2007). I propose to do this.  As Penn (2007, p.16) clearly states “we 
cannot afford to be lukewarm about scientific endeavour.” If we are, we will only 
have ourselves to blame if we are viewed in this negative light; “it is the 
therapist’s personality and approach to her patients rather than what she does 
which is to their advantage” (Leary, 1997 in Penn, 2007, p.14). More importantly 
we will have committed a grave disservice to those we swore an oath to help. 
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The following outline is a guide to what is included in each chapter. 
 
Chapter 2 provides a literature review on cerebral palsy and operculum syndrome, 
with reference to the unique South African context. Quality of life, measures 
thereof and the impact drooling has on quality of life, once again considering the 
South African situation are also discussed. Chapter 3 examines the functions of 
saliva and factors that affect saliva production. Drooling, techniques to measure 
drooling and treatment strategies are also considered. Botulinum toxin type A 
(Botox®) is described and the use of Botox® in a variety of neurological 
problems, but specifically its use to reduce drooling is critically discussed. The 
research methodology is explained in chapter 4 and chapter 5 deals with the 
results and discussion. Chapter 6 presents the clinical implications, areas for 
future research, limitations of the study and concluding remarks. 
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CHAPTER 2 
 
TWO CHILDHOOD NEUROLOGICAL IMPAIRMENTS AND THE 
EFFECT ON QUALITY OF LIFE  
 
The focus of this study is on two childhood neurological impairments, which are 
discussed in this chapter with reference to their definitions, causes, site of lesions, 
prevalence within South Africa, speech characteristics and feeding problems. The 
role of the speech, language and hearing therapist and the South African 
perspective on childhood disability is considered. Thereafter I discuss quality of 
life (QoL), the various definitions and measures of QoL, QoL in South Africa, 
with reference to neurologically impaired children, the ‘disability paradox’, and 
the relationship between drooling and QoL. 
 
2.1. Cerebral Palsy 
 
Definitions of Cerebral Palsy 
 
There have been many definitions of cerebral palsy and much discussion by 
eminent authorities on the subject of a definition of cerebral palsy and its 
classification. In 1964 Bax (p. 295) defined it as “a disorder of movement and 
posture due to a defect or lesion of the immature brain.” Karel Bobath’s definition 
was as follows: “The brain lesion is nonprogressive and causes variable 
impairment of the coordinated muscles of action, with resulting inability of the 
child to maintain normal postures and perform normal movements. This central 
motor handicap is frequently associated with affected speech, vision and hearing, 
with various types of perceptual disturbances, some degree of mental retardation 
and/or epilepsy” (1980, p. 1). Mutch and his colleagues modified the definition of 
cerebral palsy in 1992 to include the concepts of an “umbrella term,” and a “group 
of non-progressive, but often changing motor impairments” (Mutch, Alberman, 
Hagberg, Kodama & Velickovic, 1992, p. 549). 
 
 7
An international workshop on the definition and classification of cerebral palsy 
was held in the United States of America in July 2004. From this workshop The 
Definition and Classification of Cerebral Palsy April 2006 arose, compiled by 
Peter Rosenbaum and colleagues. It states the following: “cerebral palsy (CP) 
describes a group of permanent disorders of the development of movement and 
posture, causing activity limitation, that are attributed to non-progressive 
disturbances that occurred in the developing fetal or infant brain. The motor 
disorders of cerebral palsy are often accompanied by disturbances of sensation, 
perception, cognition, communication and behaviour; by epilepsy and by 
secondary musculoskeletal problems” (Rosenbaum, Paneth, Leviton, Goldstein & 
Bax, 2007, p. 9). This definition is relevant for the speech, language and hearing 
therapist working with a cerebral palsied child who drools, as drooling is often 
caused by impaired oral neuromuscular control, and can be exacerbated by poor 
body positioning, inadequate head control and diminished oral tactile sensitivity.  
 
Rosenbaum et al’s (2007) definition follows concepts introduced by the World 
Health Organization’s International Classification of Functioning, Disability and 
Health, ICF (WHO, 2001). The ICF puts the notion of ‘health’ and ‘disability’ in 
a new light and acknowledges that every person can experience a decrease in 
health, resulting in some degree of disability. By shifting the focus from cause to 
impact and function, all health conditions are considered equal and disability is 
brought into the mainstream and recognized as a universal human experience. As 
can be seen from Figure 2.1.1 on the following page, the ICF takes into account 
the social aspects of disability and does not see disability only as a ‘medical’ or 
‘biological’ dysfunction. It acknowledges the importance of both the individual 
and the environment in which the individual lives (Schneider & Saloojee, 2007).  
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Figure 2.1.1: The ICF Model of Human Functioning and Disability (WHO, 2001) 
 
 
Classification of Cerebral Palsy 
 
Rosenbaum et al’s (2007) components of CP classification are shown in Table 
2.1.1. Of particular importance to the speech, language and hearing therapist is 
section 1B – Functional Motor Abilities, which includes the oral-motor and 
speech functions and section 2 – Accompanying Impairments, which includes 
communicative deficits. Difficulties in these areas can produce important activity 
limitations, including activity limitations imposed by excessive drooling. As yet, 
there is no activity limitation scale for such functions. Rosenbaum et al (2007) 
feel there is a high research priority to develop a scale for speech and pharyngeal 
activity limitation in cerebral palsy. 
 
 
 
 
 
 
 
 
Health condition 
Activity Participation Body structure 
and functions 
Environmental factors Personal factors 
 9
Table 2.1.1: Components of CP Classification (Rosenbaum et al, 2007) 
 
1. MOTOR ABNORMALITIES 
A. NATURE AND TYPOLOGY OF THE MOTOR DISORDER: The observed 
tonal abnormalities assessed on examination (eg. Hyper or hypotonia) as well as 
the diagnosed movement disorder present, such as spasticity, ataxia, dystonia, 
athetosis. 
B. FUNCTIONAL MOTOR ABILITIES: The extent to which the individual is 
limited in his/her motor function, including oral-motor and speech function. 
2. ACCOMPANYING IMPAIRMENTS 
The presence or absence of later-developing musculoskeletal problems and/or 
accompanying non-motor neurodevelopmental or sensory problems, such as seizures, 
hearing or vision impairments, or attentional, behavioural, communicative and/or 
cognitive deficits, and the extent to which impairments interact in individuals with 
cerebral palsy. 
3. ANATOMICAL AND NEURO-IMAGING FINDINGS 
A. ANATOMIC DISTRIBUTION: The parts of the body affected by motor 
impairments or limitations. 
B. NEURO-IMAGING FINDINGS: The neuroanatomic findings on CT or MRI 
imaging, such as ventricular enlargement, white matter loss or brain anomaly. 
4. CAUSATION AND TIMING 
Whether there is a clearly identified cause, as is usually the case with post-natal CP 
(eg. Meningitis, head injury) or when brain malformations are present and the 
presumed time frame during which the injury occurred, if known. 
 
 
 
Types of Cerebral Palsy 
 
According to Howle (2002) cerebral palsy can be classified into five types, related 
to the associated muscle tone and movement characteristics of the individual. As 
can be seen from Table 2.1.2 there are four main types of CP, with the fifth type 
being a mixed type where symptoms of more than one type of involvement are 
present. 
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Table 2.1.2: Characteristics of the Types of Cerebral Palsy (Howle, 2002) 
 
TYPE CHARACTERISTICS 
Spastic Stiff muscles. Muscle tone increased with velocity-dependent resistance to 
passive movement. Selective motor control reduced. Abnormal and limited 
movement patterns. Excessive co-activation of muscular activity. Limited 
range of motion. Slow muscle activation and postural responses. 
Dyskinetic Movements appear uncontrolled and involuntary. Includes athetosis, rigidity 
and tremor. Resistance seen through range of movement in rigidity. 
Movements are abnormal in timing, direction and spatial characteristics. 
Reversal of movement and/or latency of movement. Impaired postural 
stability. Fluctuating muscle tone. 
Hypotonic Diminished resting muscle tension. Decreased ability to generate voluntary 
muscle force. Excessive joint flexibility. Postural instability. Flaccid, low 
toned muscles. Often transient with evolution to spasticity or athetosis. 
Ataxic Impaired postural control. Disordered balance. Imprecise control in timing 
of coordinated movement. Frequently associated with hypotonia. Decreased 
force during active movement. Tremor may be present. 
 
 
 
In addition to classifying CP into types, the degree or distribution of limb 
involvement can also be categorized: monoplegia meaning one extremity; 
hemiplegia meaning the arm and leg on the same side of the body; diplegia 
meaning all extremities, but the legs more involved than the arms; quadriplegia 
meaning all extremities, arms and legs equally involved, or the arms and upper 
body more involved than the legs; triplegia meaning three limbs involved; and 
paraplegia meaning only the legs involved (Workinger, 2005). Rosenbaum et al 
(2007) suggest the discontinuation of the terms diplegia and quadriplegia, as the 
imprecision of these terms in clinical practice has been documented. Rather the 
terms bilateral or unilateral should be used. However, in South Africa the terms 
diplegia and quadriplegia are still used. 
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Neurophysiology of Cerebral Palsy 
 
According to Bax, Flodmark and Tydeman (2007) spastic diplegia can be caused 
by white matter damage of immaturity (WMDI) including periventricular 
leukomalacia and periventricular haemorrhage. Spastic quadriplegia can be caused 
by more extensive WMDI and cortical-subcortical lesions. Hemiplegia is caused 
by stroke, periventricular leukomalacia and asymmetrical WMDI, as a result of 
damage to one side of the brain. With athetoid CP the lesion is in the basal ganglia 
and thalami. Ataxic CP, the least common type, is usually associated with genetic 
syndromes rather than discrete anatomic lesions. 
 
Severity of Cerebral Palsy 
 
The severity of CP can be classified using the Gross Motor Functional 
Classification System (GMFCS) (Palisano, Rosenbaum, Walter, Russell, Wood, 
& Galuppi, 1997). Table 2.1.3 illustrates the five levels of classification with the 
associated abilities. From this table it can be seen that the system is useful to 
determine the functional mobility irrespective of the type or distribution of the 
motor disorder. However, it has limited value for the speech, language and 
hearing therapist in determining oral-motor functioning and drooling severity and 
frequency.  
 
Table 2.1.3: Overview of the Gross Motor Functional Classification System  
                    (Palisano et al, 1997)  
 
LEVEL ABILITY 
I Walks without assistance 
II Walks without assistive devices, limitations outdoors and in the community 
III Walks with assistive devices, limitations outdoors and in the community, 
requiring wheelchair use in these settings 
IV Self-mobility in wheelchair with limitations, transported or uses power 
mobility in a community 
V Very limited self-mobility, even with assistive technology 
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Although Thomas-Stonell and Greenberg (1988) found a strong association 
between mobility and a positive treatment outcome for drooling, this does not 
imply that because a child can walk, he/she does not drool. The relationship and 
possible correlation between gross motor functional level and the ability to control 
saliva has not been investigated in depth. One might assume that a child classified 
on level V would exhibit severe deficits in saliva control and subsequent drooling 
problems. However, this is not always the case. 
 
Causes of Cerebral Palsy 
 
CP does not have a single cause. The many causes can be classified into two 
groups – acquired and congenital. 
 
a). Acquired Cerebral Palsy 
Children who sustain brain damage during the first two years of life before 
anatomical or physiological maturation of the brain is complete are considered to 
have acquired CP.  
 
b). Congenital Cerebral Palsy 
In this group the damage occurs in the prenatal, perinatal or immediate postnatal 
periods. Historically the primary cause of CP was considered to be birth trauma. 
Nowadays with improved diagnostic methods, improved prenatal care and 
improved care for at-risk newborn infants, birth trauma is no longer the main 
cause. Low birth weight, survival of a premature birth and birth asphyxia are the 
risk factors most closely associated with a diagnosis of CP (Workinger, 2005). 
 
Prevalence of Cerebral Palsy in South Africa 
 
Levin (2006) asserts that tuberculosis meningitis, malaria, particularly cerebral 
malaria, and HIV/AIDS are primary causes of CP in South Africa. In addition the 
high rate of road accidents in South Africa also adds to the number of children 
suffering from acquired CP. Near drowning or accidental choking can also lead to 
a diagnosis of CP. 
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In South Africa the situation with regards to the resultant neurodevelopmental 
outcomes from premature birth or low birth weight are comparable to overseas. 
However, what makes South Africa unique is the fact that large sectors of the 
population are poor, cannot afford pre-natal care, live in unsanitary circumstances, 
have inadequate nutrition, simply do not have access to specialized care and 
intervention, and lack the necessary knowledge about basic social, health and 
educational services. This situation is mostly due to illiteracy and inadequate/non-
existent education (Intergrated National Disability Strategy, White Paper on 
Disability, 1997). 
 
The prevalence of CP in South Africa, according to governmental reports, is very 
high (Statistics South Africa, 2007). Accurate numbers are unavailable, but a 
study by Couper (2002) put the approximate number at 10/1000 children under 
the age of ten years in Kwa-Zulu-Natal. The World Health Organization 2005 
report (WHO, 2005) indicated that 10% of the 18 million children in South Africa 
have some form of neurological impairment from a variety of etiologies.  
 
2.2. Operculum Syndrome 
 
Neurophysiology of the Operculum 
 
In order to understand the resultant anarthria/dysarthria that occurs in operculum 
syndrome and the possible relationship found in this study between articulation, 
drooling and the use of Botox®, it is necessary to have an overview of the 
neurophysiology of the operculum. The operculum, short for the operculum 
insulae, is the area of the brain that covers the insula Reili. It is made up of 
frontal, parietal and temporal cortical convolutions (Bruyn & Gathier, 1969; 
Christen, Hanefeld, Kruse, Imhäuser, Ernst & Finkenstaedt, 2000). Figure 2.2.1 
shows the position of the operculum within the brain. The extent of the operculum 
insulae has been indicated by the green area. 
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Figure 2.2.1: The Operculum Insulae of the Left Hemisphere with Areas 44 and  
                      45 (Wikipedia, 2007) 
 
In 1969 Bruyn and Gathier argued that the connections between the opercula and 
other parts of the brain had been established only in part, despite the fact that 
areas 44 and 45 approximately constituted Broca’s motor speech area. Major input 
to Broca’s region arrives through corticocortical fibers of the arcuate fascicle, 
which originates in Wernicke’s area of the temporal lobe. Efferents from areas 44 
and 45 terminate in the face region of the primary motor cortex. Broca’s region 
controls the complex motor pattern of neuronal assemblies in the face region of 
the primary motor cortex, which in turn command the motor cranial nerve nuclei 
for the muscle activity during vocalization (Zilles, 2004).  
 
In the 1940’s studies were conducted that clearly showed connections between the 
different opercula regions, i.e. temporal, parietal and frontal, as well as 
connections to the insulae Reili (McCulloch, 1944, 1949, in Bruyn & Gathier, 
1969). Connections with other parts of the brain have also been shown, 
45 
44 
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particularly the thalamus. Pritchard and Norgren (2004) gave a description of the 
likely pathways for the human gustatory system, from peripheral innervation, via 
the VII facial nerve, the IX glossopharyngeal nerve, and the X vagus nerve to the 
nucleus of the solitary tract (Sol) in the medulla, to the ventroposteromedial 
nucleus (VPMpc) of the thalamus. From the thalamus, the pathway seems to go to 
the insula. Most recent studies implicate this area as the taste cortex. As discussed 
in the following section on drooling, saliva is necessary to be able to taste. 
However, Bornstein (1940, in Pritchard & Norgren, 2004, p. 1181) placed the end 
destination “firmly in the parietal operculum.”  
 
Electrophysiological studies, conducted on monkeys, have shown that stimulation 
of the chorda tympani and glossopharyngeal nerves produces evoked potentials 
from the insula and inner operculum (Pritchard & Norgren, 2004). The word 
‘likely’ has been used deliberately, as at this stage, most information on the 
pathway of the gustatory system has come from experiments conducted on 
nonhuman primates, with a few published clinical human studies providing 
corroborating evidence.  
 
Symptoms of Operculum Syndrome 
 
The clinical symptoms of opercular lesions were first reported by Magnus in 
1837, but it was not until 1926 that the clinical picture was described in the 
neurological literature by the French neurologists Foix, Chavany and Marie. A 
congenital type was described by the neurologist Worster-Drought in 1953, giving 
rise to the Worster-Drought syndrome (Christen et al, 2000).  
 
The Foix-Chavany-Marie syndrome (FCMS) has a unique clinical picture of a 
supranuclear (pseudobulbar) palsy, an upper motor neuron disorder, caused by 
bilateral anterior opercular lesions. FCMS is therefore also known as bilateral 
anterior operculum syndrome. FCMS represents the cortical type of 
supranuclear/pseudobulbar palsy. A bilateral interruption of the connections, 
known as the corticobulbar fibers, between the cortical motor areas and the brain 
stem nuclei of the V trigeminal nerve, VII facial nerve, IX glossopharyngeal 
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nerve, and X vagus nerve, is needed to bring up the symptomatology of FCMS, as 
the connections are ipsilateral and contralateral. The XII hypoglossal nuclei are 
also affected, although most of their fibers are crossed (Bruyn & Gathier, 1969; 
Christen et al, 2000; Greenstein & Greenstein, 2000). 
 
Presenting symptoms are as follows: facial paralysis and paralysis of the 
pharyngeal, laryngeal, and lingual muscles; severe spastic dysarthria or anarthria; 
impairment of chewing and swallowing; impassive open mouth and constant often 
excessive drooling; automatic- voluntary dissociation of the orofacial muscles, ie. 
automatic, involuntary, emotional movements are preserved, such as smiling at a 
joke, but voluntary movements are impaired, such as showing your teeth on 
command; exaggerated jaw reflex; preserved gag reflex; however, signs of tongue 
atrophy and fasciculation are missing (Bruyn & Gathier, 1969; Christen et al, 
2000).  
 
Causes of Operculum Syndrome  
 
FCMS may be congenital or acquired as well as persistent or intermittent. In 
adults, the main cause of FCMS appears to be multiple subsequent strokes 
affecting the anterior operculum bilaterally. This area is predisposed to ischaemic 
lesions, as it is the final destination of the medial cerebral artery (Weller, 1993). In 
children, the causes of FCMS are different. Congenital bilateral dysgenesis of the 
perisylvian region, epileptic disorders, meningoencephalitis with the herpes 
simplex virus as the agent of infection, and perinatal difficulties have been 
proposed as causes (Christen et al, 2000; Koeda, Takeshita & Kisa, 1995; 
Nakajima, 2004; Van der Poel, Haenggeli & Overweg-Plandsoen, 1995).  
 
Prevalence of Operculum Syndrome in South Africa 
 
At present there are no statistics available to determine the prevalence of 
operculum syndrome within the South African population. What is possible is that 
children with operculum syndrome are misdiagnosed as having CP or 
developmental apraxia of speech. In the DTP two children presented with 
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operculum syndrome, one of whom had previously been diagnosed as a child with 
CP. Both children had severe and constant drooling, as rated on the Thomas-
Stonell and Greenberg scale (1988) by qualified speech, language and hearing 
therapists. Clinically I have observed that their drooling has a negative impact on 
their participation within the classroom, relationships with other children and 
adults, and speech clarity. 
 
2.3. Speech Characteristics of Cerebral Palsied Children and Operculum  
Syndrome Children 
 
Normal speech production results from the combined functions of the respiratory 
system, the laryngeal system, the velopharyngeal system and the orofacial system. 
As CP has been described as a movement and posture disorder, it is not surprising 
that many CP children exhibit speech disorders. The most frequently occurring 
speech disorder is dysarthria. Darley, Aronson and Brown (1975, p. 2) state that 
dysarthria  is “a collective  name for a group of speech disorders that are due to 
disturbances in muscular control of the speech mechanism resulting from 
impairment of any the basic motor processes involved in the execution of speech.” 
The speech characteristics of the CP child are dependent on the type and severity 
of the CP. Slow rate, dysrhythmia, reduced stress, inappropriate voice stoppage, 
breathy voice quality, a strained and strangled voice quality, monopitch, 
monoloudness, hypernasality, and a decreased number of words per breath, are all 
symptoms of CP speech. Some CP children are incapable of producing intelligible 
speech and the use of an alternative, augmentative communication device (AAC) 
is the only means of communication for them. 
 
As Broca’s motor speech area, areas 44 and 45, appear to be part of the operculum 
and the X vagus nerve, the V trigeminal nerve, the VII facial nerve and the XII 
hypoglossal nerve are all involved in the production of speech (Darley et al, 1975) 
it is understandable that severe dysarthria is a major presenting symptom of 
FCMS. The speech characteristics associated with developmental apraxia of 
speech are often used to describe the speech of individuals with operculum 
syndrome. The quality of voice is often nasal, as movement of the velopharynx is 
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limited. The production of sibilant/fricative sounds, eg. ‘s’, ‘sh’, and ‘f’ is difficult 
and often impossible. Speech is therefore unintelligible in many cases and an 
AAC system is often warranted. 
 
2.4. Feeding Problems in Cerebral Palsied Children and Operculum 
Syndrome Children 
 
A feeding and swallowing dysfunction and a failure to thrive are common in CP 
children. Moreover, gastro-esophageal reflux, constipation and pneumonia due to 
aspiration can be complications. Poor oral-motor skills and oral sensitivity to 
different food textures can also make feeding the CP child difficult. These 
children often require help to develop safe feeding and swallowing. Correct body 
positioning, head positioning with a chin tuck, oral control, finger feeding, cut-out 
cups, and a graduated introduction to differing textures of food are just some 
examples of techniques that can be used to ensure safe eating and drinking in the 
CP population.  
 
Clinically I have found that the automatic-voluntary dissociation causes a unique 
method for swallowing food/drink in children with operculum syndrome. In the 
oral stage, which requires voluntary movement of the tongue, lips and cheeks to 
chew food, the children display limited chewing ability and they are unable to 
propel the bolus towards the back of the mouth. Therefore they tip their heads 
back to allow gravity to propel the bolus backwards towards the pharynx where 
automatic, reflexive swallowing in the pharyngeal stage can occur. Due to 
paralysis of the muscles of the face, lips and tongue chewing is restricted to an up-
down movement, with minimal lateral, rotary movement. These children often use 
their fingers to remove food from the buccal cavities, or to push food between 
their teeth for chewing. 
 
2.5. The Role of The Speech, Language and Hearing Therapist 
 
In South Africa the most common and popular approach, used by speech, 
language and hearing therapists, to treat neurological disabilities, particularly CP, 
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is NeuroDevelopmental Therapy, NDT (Bobath, 1980). NDT treatment 
emphasizes the whole body and focuses on developing functional abilities of the 
individual. Therapeutic handling is used to facilitate correct body positioning, 
alignment and movement. For the NDT trained speech, language and hearing 
therapist this means that to achieve better speech production or safe, correct eating 
and drinking patterns, the individual needs to be seated correctly, and the use of 
oral control may be necessary. A team approach, where physiotherapists, 
occupational therapists and speech, language and hearing therapists work together, 
is the ultimate approach advocated by NDT proponents. However, for many 
disabled individuals, especially in South Africa, this combined therapeutic 
approach is just a dream. NDT trained speech, language and hearing therapists are 
expected to be able to facilitate the correct body and head positioning of their 
clients, before they work on oral-motor skills, feeding and drinking patterns, or 
indeed language development. 
 
Speech, language and hearing therapists also work on developing the language 
skills of their disabled children. This often means assessing the child and selecting 
the most appropriate AAC device for that child. Teaching the child and his/her 
parent/primary caregiver how best to facilitate communication is a most important 
part of a speech, language and hearing therapist’s job. Knowing how to make a 
simple communication book using pictures from magazines or newspapers, as 
well as knowing how the latest computer aided AAC device works, is all part of 
the job. Watching the smile on a child’s face when she can finally ‘tell’ her 
mother, by pointing to a picture of a glass of water, that she wants a drink, is an 
experience I wouldn’t have missed. 
 
Finally, our job entails improving the quality of life for our children and their 
parents/primary caregivers and that may mean working on decreasing drooling.    
 
2.6. The South African Perspective on Childhood Disability 
 
Whilst knowledge of prevalence rates is important, it is more important to 
recognize and understand that within South Africa the majority of neurologically 
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impaired children have “unmet health, welfare and educational needs” (Saloojee, 
Phohole, Salojee & IJsselmuiden, 2006, p. 230). It is often the case that 
parents/primary caregivers of a disabled child cannot afford the myriad of extras 
that caring for that child entails, even if the child is lucky enough to attend a 
specialized school. Overseas disabled children and their families have access to a 
variety of social and welfare grants, services and help, including access to 
‘respite’ care. This type of care enables a parent/primary caregiver to relinquish 
the responsibility of caring for a disabled child for a short while, knowing that the 
child will be well looked after. In South Africa ‘respite’ care is unavailable, unless 
other family members, friends or neighbours are prepared to take over the burden 
of care for a period of time. In many cases this help is not forthcoming. Barratt 
(2007) found that in rural South Africa parents/primary caregivers often felt 
desperate and isolated from their communities.     
 
Social grants are available to families of disabled children, but usually only cover 
the basic costs of living. In addition, to obtain a social grant, a parent of a disabled 
child needs that child’s official birth certificate and/or identity document and 
numerous forms need to be completed. Many parents, especially in rural areas or 
informal settlements, do not have the relevant official birth documents. This 
necessitates an application to the Department of Home Affairs to obtain the 
relevant documents and the wheels of officialdom turn slowly. As found in 
Salojee et al’s study (2006) a main reason for parents not receiving a social grant 
was administrative and bureaucratic obstacles.  
 
Funding for the ‘extras’ which would allow a disabled child to participate more 
within his/her community or would facilitate a more independent lifestyle, has to 
be obtained from donations and private funding. Splinting, AAC devices, 
wheelchairs, not to mention electric wheelchairs, all cost a great deal of money. 
Certain wheelchairs are available on state tender and can be obtained via a state 
hospital, as can splinting. AAC devices are not available via a state hospital.  
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In recent years the Gauteng Department of Education has allocated a certain 
amount of money towards AAC devices for individual learners who are indigent. 
This has to be applied for by the individual’s school. The vast majority of disabled 
children in South Africa do not benefit from educational funding or special 
services available in a school, as the vast majority of disabled children are not in 
school. The Department of Education in 2001 (White Paper 6, 2001) put the figure 
at approximately 76% of disabled children not in school. Saloojee et al (2006) 
found that 56% of disabled children, aged 7 to 15 years, from an informal 
settlement were not in school. The Education Department’s 20 year plan for 
inclusion hopefully will allow more disabled learners to be educated, but one has 
to ask how are teachers supposed to cope with children whose needs are very 
specialized, unless they themselves receive additional specialized training? Just as 
important, what happens to the vast majority of disabled children not receiving 
education now? Do they become another lost generation? 
 
As mentioned previously, QoL is a concept of considerable importance to the 
speech, language and hearing therapist. It is therefore appropriate to discuss QoL 
in relation to disability, drooling and with reference to the South African 
perspective. 
 
2.7. Quality of Life 
 
Definitions of Quality of Life 
 
Quality of life (QoL) is an individual, subjective concept. What is important to 
one person may not be important to another. It depends on factors such as 
lifestyle, past experiences, hopes for the future, dreams and ambitions (Eisner & 
Morse, 2001). Further, what is important to an adult may not be important to a 
child.  
 
The multifaceted nature of QoL has resulted in a variety of theories and 
definitions. Lindstrom and Eriksson (1993) associated QoL with success, wealth, 
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productivity and happiness in four spheres of life: the global sphere, (ecology, 
society and politics); the external sphere, (employment, education and 
independent living); the interpersonal sphere, (marriage and relationships); and 
the personal sphere, (self-esteem and self-concept). The discrepancy theory 
proposed that a poorer QoL results from the discrepancies between the child’s 
actual self and the ideal self (Eisner, Vance & Seamark, 2000). In the utility 
theory, health states are given different values by experts or lay people. These 
values can be between zero, equivalent to death, and one, perfect health (Feeny, 
Furlong & Barr, 1998).  
 
Davis, Waters, Mackinnon, Reddihough, Graham, Mehmet-Radji and Boyd  
(2006) in their review of pediatric quality of life instruments, clearly state why 
these three theories of QoL are not particularly appropriate. Lindstrom’s model 
does not take into account the child’s physical, social or emotional well-being, nor 
does it have a child self-report section. The discrepancy theory does not determine 
which factors contribute to a low or high quality of life and therefore does not 
provide guidelines for interventions to increase QoL. Finally the utility theory is 
best suited to measuring cost effectiveness of treatment, rather than QoL per se. 
As children often have difficulty distinguishing between quantity versus quality, 
this theory is rarely applied to children’s QoL (Davis et al, 2006). Davis et al 
(2006) recommend that a pediatric theory of QoL be developed and evaluated 
across cultures and countries.  
 
I agree that a child self-report section must be included, but suggest that it is vital 
to include countries in the evaluation, such as South Africa, that have a diverse 
population, with large semi-urban and rural groups of people, whose socio-
economic development is poor. In 1993, the WHO defined quality of life, as “the 
perception by individuals of their position in life, in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, 
standards and concerns.”  
 
It has been shown that individuals in a rural setting may have different views on 
QoL (Walker, Winkelstein, Land, Lewis-Boyer, Quartey, Pham & Butz, 2008). 
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This is especially true in South Africa. Support, including medical, financial and 
social, is often lacking in the lives of our semi-urban and rural populations. Poor 
nutrition, inability to work, inaccessibility to medical resources, lack of education, 
different cultural beliefs and practices, and above all poverty, contribute to a 
differing QoL in the semi-urban and rural populations. As Levin (2006, p. 290) 
states “it is critical to address the specific needs of rural communities.”  
 
In relation to child disability, initial definitions of QoL focused on the health 
status of the child, with an emphasis on the physical functioning of the child. 
Several instruments measuring health-related quality of life (HRQoL) have been 
developed (King, Schwellnus, Russell, Shapiro & Aboelele, 2005). With the 
introduction of the WHO’s definition of health (2001) as being more than the 
absence of disease, but also encompassing physical, social and psychological 
aspects of health, the concept of QoL widened to include these aspects. 
  
QoL is most often described in terms of well-being across a variety of domains 
(Bjornson & McLaughlin, 2001). These domains consist of health domains and 
non-health domains. HRQoL can therefore be considered a sub-domain of QoL 
(Spilker & Revicki, 1996, in Waters, Maher, Salmon, Reddihough & Boyd, 2005).  
According to Davis et al’s review (2006) the most common domains of QoL are 
those that refer to: emotions, social interactions, medical/treatment, cognition, 
activities, school, family, independence/autonomy, pain, behaviour, the future, 
leisure, and body image.  
 
No general QoL or HRQoL measure seems to take into consideration the effect of 
drooling on the QoL in a pediatric population. Van der Burg et al (2006a) have 
developed a questionnaire designed specifically to investigate drooling severity 
and its consequences for a child and the family. They looked at the impact 
drooling has on specific life situations, daily care, economic consequences, social 
interactions, emotional development and self-esteem. The results of this study are 
discussed later in the chapter.   
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Measures of Quality of Life/Health-Related Quality of Life 
 
From the literature it seems evident that there are two types of QoL/HRQoL 
measures, generic and condition-specific. Generic measures are designed to be 
relevant to all population groups and are useful for comparing QoL/HRQoL 
between population groups with different conditions. They provide a superficial 
evaluation of a person and tend not to identify the specific effects of a certain 
disease (Schneider, Gurucharri, Gutierrez & Gaebler-Spira, 2001). Disease or 
condition specific measures are designed for a specific disease and are useful for 
detecting changes in symptoms, problems or side-effects associated with a 
particular disease. They are also more sensitive in detecting treatment effects 
(Schneider et al, 2001; Waters, Maher et al, 2005). Both generic and condition-
specific measures have been used with the cerebral palsied population.  
 
Research on children’s QoL used to rely on parental or proxy reports, but it is now 
realised that the child’s view is just as important. Measures often include a child 
report section as well as the parent report section. Unfortunately these measures 
do not allow for the non-verbal child to communicate his/her opinions. 
 
Several reviews of QoL/HRQoL measures have been published, citing their 
usefulness and relevance to the cerebral palsied population. Foremost of these is 
the review by Davis et al (2006) where 14 generic and 25 condition-specific 
measures are identified.  
 
A detailed critique of QoL measures is not the aim of this research report; suffice 
it to say there are many such measures, for example, the Child Health 
Questionnaire, CHQ (Landgraf, Abetz & Ware, 1996 in Waters et al 2005); the 
Lifestyle Assessment Questionnaire, LAQ (Mackie, Jessen & Jarvis, 1998); and 
the Pediatric Quality of Life Questionnaire Cerebral Palsy Module, PedsQL 
(Varni, Burwinkle, Berrin, Sherman, Artavia, Malcarne & Chambers, 2006). 
However, Waters et al (2005) feel that these instruments measure the absence of 
health difficulties or limitations rather than well-being.  
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A recently developed QoL questionnaire, designed specifically for cerebral 
palsied children, CP QOL-Child, assesses “the aspects of life that parents and 
children think are important, including friends, family, school and health” 
(Waters, Davis, Boyd, Reddihough, Mackinnon, Graham, Lo, Wolfe, Stevenson, 
Bjornson, Blair & Ravens-Sieberer, 2006, p. 1). It is designed for children aged 4-
12 years and has two versions; the parent proxy version, for parents of children 
aged 4-12 years, and the child self-report version, for children aged 9-12 years. As 
parents and children may report different levels of QoL, both versions should be 
used (Waters, Davis et al, 2006).  
 
The development of the questionnaire was based on 13 themes of quality of life, 
extracted from discussions with parents and children (Waters, Maher et al, 2005). 
Table 2.7.1 lists the 13 themes and gives a definition for each theme. All the 
domains of health as identified by the WHO (2001), including physical well-
being, i.e. physical health, mental well-being, i.e. emotional well-being and self-
esteem, and social well-being, emerged as themes.  In addition, themes specific to 
children, i.e. family health and themes specific to cerebral palsy, i.e. body 
pain/discomfort emerged. Some themes appeared to consider the practicalities of 
having a cerebral palsied child, i.e. access to services, supportive environments, 
family financial stability and acceptance in the community. The latter themes 
would appear to be particularly relevant to the semi-urban and rural South African 
population.  
 
However, as can be seen from Table 2.7.1, the definition of financial stability does 
not take into account the severe effects of poverty, such as the ability to provide 
basic necessities, for example, food and clothing. Of interest to me is the fact that 
no reference to drooling is made and in the questionnaire there is no specific 
section or questions that deal with the effects of drooling on the quality of life.  
 
 
 
 
 Table 2.7.1: Quality of Life Themes Important to Parents and Cerebral Palsied Children (Waters, Maher et al, 2005). 
 
Physical health Gross/fine motor skill, ability to use aides, overall physical health. 
Body pain & discomfort Stiffness & soreness in joints, pain associated with therapy. 
Daily living tasks Ability to carry out normal tasks including dressing, feeding, toileting and being independent.  
Participation in physical & social 
activities 
Participating in school, sporting and community activities. 
Emotional well-being & self-
esteem 
Being happy, being able to achieve goals, being satisfied with one’s body and emotions. 
Interaction with the community Being socially accepted, being a valued member of the community, being treated ‘normally.’ 
Communication Communication skills with family, peers and people in the community. 
Family health Parental emotional health, family relations, restrictions on the family to go out socially. 
Supportive physical environment Supportive school, family and community environments, having the necessary equipment and 
devices. 
Future Quality of Life Opportunities to do everything they desire, being able to do things as well as their peers, being able 
to make choices in their lives. 
Provision of and access to services Access to therapy, respite and having the support required. 
Financial stability Earning capacity of parents, ability to cover the expenses of equipment and treatment. 
Social well-being Ability to interact with family members, peers and people in the community. 26 
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2.8. Quality of Life in South Africa 
 
The diverse nature of the people of South Africa means that quality of life for one 
group is very different from that of another group. The population differs in terms 
of cultures, languages and religions. More importantly there is a wide divide 
between the socio-economic status of our people. South Africa’s population can 
be split into a section that resembles the population of well developed countries 
and a much larger section that resembles the population of poor, under developed 
countries.  
 
This division usually follows racial lines (Makiwane & Kwizera, 2006). The 
policy of apartheid, defined as the separate development of people based on their 
colour, under which South Africa operated until 1994, meant that the majority of 
South African people experienced restricted access to education, health care, 
residence and employment opportunities (Westaway, Olorunju & Rai, 2007). Due 
to this legacy, despite being one of the richest countries on the African continent, 
South Africa is still struggling to provide its entire people with a better quality of 
life. According to The South African Quality of Life Project (Møller & Dickow, 
2002. p. 267) “In most democratic countries around the globe, the average citizen 
says he or she is satisfied with life in general. In South Africa this is not the case.”  
 
Westaway et al (2007) suggest that happiness and life satisfaction, elements of 
quality of life, are related to race in South Africa. From 1983 to 1999 white South 
Africans were happier and more satisfied with their lives than black South 
Africans. The quality of life and perceived happiness for older, black South 
Africans has been made bleaker by the fact that they are often the principle 
caregiver for their families. They become the principle caregiver as a result of the 
death of the parents, which is often due to AIDS/HIV, or because both parents 
have to work leaving ‘granny’ to look after the children. A disabled child is often 
sent to live with the grandmother in a rural area. Makiwane and Kwizera (2006) 
found the quality of life of older, black people in Mpumalanga to be poor and 
attributed this poor quality of life to low income, few household amenities, the 
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legacy of life long poverty and the heavy burden of caring for children, disabled 
children and sick adults. 
 
Barratt (2007) found a number of themes emerged from black, rural caregivers’ 
experiences of caring for a child with cerebral palsy. These themes included the 
impact of gender on care giving, the influence of traditional beliefs and practices, 
and the experience of western medicine. Within the theme of gender, Barratt 
(2007) found that most of the care giving was performed by the mothers or 
grandmothers, although some fathers were involved with their disabled child. She 
comments further that “a distinct absence of men” was noticed in the homes and 
community (Barratt, 2007, p. 113). More importantly, the effects of poverty 
influenced every aspect of care giving. Caregivers felt a sense of isolation from 
their communities, experienced fear for the future and depression. A sense of 
desperation at the heavy burden they carried was experienced by some caregivers. 
These factors would seem to indicate a poor quality of life for the caregivers and 
their children. Jelsma and Ferguson (2004) contend that the disabled are still in 
the lowest socio-economic group, despite South Africa’s National Disability 
Strategy (1997). This strategy aims at the full integration of people with 
disabilities into society. 
 
As already stated, there appears to be a difference in the quality of life between 
urban and rural populations (Hammal, Jarvis, & Colver, 2004; Walker et al, 
2008). The factors that affect the semi-urban and rural populations certainly make 
for a bleaker QoL in South Africa. 
 
2.9. Quality of Life for Neurologically Impaired Children  
 
There appears to be some dissent in the literature as to whether there is a 
difference in the quality of life or well-being between a CP child and a ‘normal’ 
child. Some authors feel there is a difference (Vargus-Adams, 2006; Varni, 
Burwinkle, Sherman, Hanna, Berrin, Malcarne & Chambers, 2005). Livingston, 
Rosenbaum, Russell and Palisano (2007) reviewed assessments of well-being in 
CP individuals, conducted over a period of ten years. In their opinion, several 
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themes emerged. First, the well-being of CP individuals can be considered to be 
lower than the ‘normal’ population. Second, gross motor functioning has an effect 
on physical well-being. Third, there is very little literature on the factors that 
affect well-being for adolescents. At this stage there is little research on the well-
being of South African children with neurological disabilities. Several models for 
assessing South African children’s well-being have been discussed (Bray & 
Dawes, 2007). A South African Rights-Based Approach to Monitoring Child 
Well-Being (Dawes, Bray & Van der Merwe, 2007) has been proposed, while 
Schneider and Saloojee (2007) considered aspects of monitoring childhood 
disability. As yet, no study using this approach seems to have been published. 
 
The issue of pain and its effect on quality of life in the CP population have been 
investigated (Houlihan, O’Donnell, Conaway & Stevenson, 2004). It seems 
obvious that quality of life would be decreased if there is constant pain. Some 
authors have found that individuals classified with moderate to severe CP have 
lowered scores on a quality of life measure (Liptak, O’Donnell, Conaway, 
Chumlea, Worley, Henderson, Fung, Stallings, Samson-Fang, Calvert, 
Rosenbaum & Stevenson, 2001). 
 
Conversely, certain literature seems to suggest that the quality of life for CP 
children is not necessarily poorer than for children in the general population 
(Dickinson, Parkinson, Ravens-Sieberer, Schirripa, Thyen, Arnaud, Beckung, 
Fauconnier, McManus, Michelsen, Parkes & Colver, 2007). The Study of 
Participation of Children with Cerebral Palsy Living in Europe (SPARCLE) 
investigated the self-reported quality of life of CP children. They looked at 
parental employment and educational qualifications, area of domicile, the child’s 
gross motor function, fine motor function, seizures, feeding, communication, 
intellect, schooling, family dynamics and CP type. The findings from this study 
indicated that “children with cerebral palsy had similar QoL to children in the 
general population in all domains except schooling, in which evidence was 
equivocal, and physical well-being, in which comparison was not possible” 
(Dickinson et al, 2007, p. 2171).  
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A systematic review of the self-concept in children with CP compared with 
children without disability was unable to establish whether self-concept was lower 
in the disabled children compared to the non-disabled children (Shields, Murdock, 
Loy, Dodd & Taylor, 2006).  
 
Levels of functioning and their effects on quality of life have been researched 
(Shelly, Davis, Waters, Mackinnon, Reddihough, Boyd, Reid & Graham, 2008). 
This study differentiated between physical well-being domains of QoL and 
psychosocial well-being domains and found that a child with poor functioning, 
although he/she may report poor physical well-being, may have good social and 
emotional well-being. The study by Majnemer, Shevell, Rosenbaum, Law and 
Poulin (2007, p. 470) found that quality of life is “highly variable….with about 
half experiencing a life quality similar to typically developing children.”  
 
It would appear that whether the quality of life of a CP child is found to be good 
or poor, the same or different to the general population, depends on the type of 
instrument used to measure quality of life and the domains of quality of life being 
studied.  
 
Studies of children with a variety of disorders such as: 
· physical impairments (Grue, 2003); 
· behaviour and learning difficulties (Watson & Keith, 2002); 
· speech and language difficulties (Markham & Dean, 2006); 
· traumatic brain injury (Hameed, Miller, Curran, Pauldhas, Mccarter, Hunt    
                                           & Sharples, 2008); 
· and asthma (Walker et al, 2008)  
 
also provide conflicting evidence about how the quality of life of these children 
compares with that of the general population. What is clear is that health care 
workers, speech, language and hearing therapists included, need to take 
cognizance of the quality of life of the children with whom they work, so that 
their treatments are appropriate and worthwhile.  
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2.10. The ‘Disability Paradox’ 
 
The idea that individuals with disabilities can have a good quality of life has been 
called the ‘disability paradox’ (Albrecht & Devlieger, 1999). In their article ‘The 
disability paradox: high quality of life against all odds’ Albrecht and Devlieger 
(1999) argue that quality of life must be viewed as a holistic notion of well-being, 
not just health related. Quality of life encompasses more than just activity 
limitations, health and disease categories. It must include the social, psychological 
and spiritual domains for a true reflection of the quality of life of disabled 
individuals to be gained.  
 
Their explanation for the ‘disability paradox’ lies in the disabled individual’s 
ability to establish and maintain a sense of balance between the body, mind and 
spirit and with the individual’s social context and environment. For example, 
individuals who: understand their condition; take control and introduce order and 
predictability in their lives; are able to set realistic goals; have a positive and 
supportive social context; can have a good quality of life. However, those who are 
unable to maintain a balance due to their health condition, limited resources, lack 
of knowledge or environmental constraints are likely to have a poor quality of life.  
 
This explanation of what is involved in a good or poor quality of life has 
implications for disabled individuals in South Africa. As most disabled South 
African individuals are in the lower socio-economic group, live in semi-urban or 
rural areas, have limited resources, generally lack knowledge about their 
disability, the implication is that their QoL is poor.  
 
At this stage it is impossible to comment accurately on the quality of life for 
disabled or CP children in South Africa. We have no central data base giving 
accurate numbers of disabled/CP children in this country to start with. Secondly, 
although studies have looked at QoL for specific South African communities 
(Barratt, 2007; Hinks & Gruen, 2007; Jelsma & Ferguson, 2004; Makiwane & 
Kwizera, 2006; Møller & Dickow, 2002; Westaway, 2006), and the “unmet needs 
of disabled children in a poor township” (Saloojee et al, 2006, p. 230) there does 
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not appear to be any specific research into the quality of life for South African 
disabled/CP children.  
 
2.11. The Relationship between Drooling and Quality of Life 
 
According to Hockstein, Samadi, Gendron & Handler (2004) the impact of 
drooling on an individual’s QoL is the most important factor in determining the 
necessity for treatment. Blasco (2002, p. 780) states “the ultimate test of whether 
treatment (for drooling) will be continued or not is whether it makes the 
caregiver’s life easier and the child’s life is improved.” Van der Burg et al (2006b) 
investigated parental perceptions of drooling on daily life, and the social 
interaction and self-esteem of 45 cerebral palsied children following treatment for 
severe drooling. Table 2.11.1 indicates the results from their study. As can be 
seen, drooling clearly has an effect on QoL. 
 
Reid, Johnstone, Westbury, Rawicki and Reddihough (2008) in their randomized 
trial of botulinum injections to reduce drooling in children, measured the impact 
of drooling at baseline and after treatment via questions to the primary caregivers. 
Besides the severity and frequency of drooling, and the number of bib/clothing 
change questions, the researchers wanted to know the following: 
· How offensive was the smell of saliva on your child? 
· How much skin irritation has your child had? 
· How embarrassed did your child seem to be about his/her drooling? 
· To what extent did the drooling affect your child’s life? 
· To what extent did the drooling affect you and your family’s life? 
 
The inclusion of these types of questions leads me to believe that drooling is being 
acknowledged as having a major detrimental effect on the quality of life of 
neurologically impaired children. 
 
                                                                                                                                                                                                                             
 
Table 2.11.1: The Effects of Drooling on Quality of Life, based on Van der Burg et al (2006b). 
 
Care Given to a Child/Economic Consequences Social Interaction Self-esteem 
Child told to swallow often. 
Mouth and chin wiped regularly. 
Bibs, shawls, terry cloth wristbands  
replaced regularly. 
Complete change of clothing needed. 
Multiple laundry loads in a week. 
Damage to clothes, toys, books, furniture, 
communication aids, electronic communication 
devices, computers and audio equipment. 
Curtailing of child’s play to prevent 
damage to objects. 
Limited play and social interaction with 
children and adults. 
Child often avoided by other children. 
Child often avoided by familiar and  
unfamiliar adults. 
Child assessed by outsiders as being mentally 
incapable due to unsightly look of drooling. 
Unhappiness with physical appearance. 
Feelings of incompetence. 
Lack of peer acceptance. 
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Clinically, I have witnessed the detrimental effect of drooling in schools, hospitals 
and in homes, over a period of more than 20 years. As such, questions regarding 
the effect any drooling has on a disabled/CP child’s life should be included in 
pediatric quality of life questionnaires for the neurologically impaired. Further, I 
believe that drooling has an effect on the QoL of South African 
neurologically impaired children and their parents/primary caregivers. For 
this reason parents/primary caregivers in the DTP were interviewed and given a 
QoL questionnaire (Appendices L & M).  
 
This chapter has dealt with the neurological impairments of the participants in the 
DTP, QoL in South Africa and the effects of disability on QoL. In the present 
study drooling is considered to have an influence on QoL. Saliva, drooling and 
treatments for drooling, including Botox® injections, therefore are discussed in 
the next chapter.  
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CHAPTER 3 
 
SALIVA, DROOLING AND BOTOX® 
 
In this chapter I consider saliva and its important functions, what constitutes 
drooling, the problems that drooling can cause, the variety of techniques to 
measure drooling and treatment strategies, including the use of Botox®. An 
overview of the history and pharmacology of Botox® is given, followed by the 
clinical uses of Botox®, with specific reference to the fields of Speech Pathology 
and Audiology. The chapter concludes with a critical review of previous studies 
that have used Botox® to reduce drooling in neurologically impaired children.    
 
3.1. Saliva  
 
Saliva is secreted by six major salivary glands: two parotid glands, two 
submandibular glands and two sublingual glands. In addition there are hundreds 
of minor glands located throughout the surface of the palate, tongue and oral 
mucosa (Hockstein et al, 2004). 
 
In adults, approximately 1 to 1,5 litres of saliva are produced by the major glands 
per day ( Lal & Hotaling, 2006; Hockstein et al, 2004). In healthy children aged 
between 6 and 11 years, approximately 677 millilitres of saliva are produced in a 
day (Rotteveel, Jongerius, van Limbeek & van den Hoogen, 2004). In an 
unstimulated state, the submandibular gland produces 70% of the saliva, with the 
parotid glands producing 20%, as a result of stimulations such as food or even just 
the smell of food. The remaining 10% is produced by the sublingual glands and 
the minor glands. When stimulated, salivary flow increases five times. (Stuchell & 
Mandell, 1988).  
 
As can be seen from Figure 3.1.1 the parotid glands are located deep in the soft 
tissue of the check and they produce a watery secretion. The submandibular and 
the sublingual glands drain into the floor of the mouth and the secretions are more 
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viscous. Generally, it is this thicker saliva that is troublesome in drooling 
(Brodsky, 2002). 
 
Figure 3.1.1: The Positions of the Salivary Glands (Johnson & Scott, 1993) 
 
A clear understanding of the neural pathways and control of salivation is needed 
to understand drooling. Therefore a brief description follows. 
 
Neurophysiology of Salivation 
 
The majority of secretory control lies with the parasympathetic nervous system, 
but the sympathetic nervous system does play a part. Stimulation of the 
parasympathetic nerves causes production of saliva, whereas sympathetic 
stimulation causes secretion of protein and glycoprotein (Ferguson, 1988). In 
addition, the flow of saliva is enhanced by sympathetic innervation, which 
promotes contraction of muscle fibers around the salivary glands (Hockstein et al, 
2004). 
 
The autonomic nervous system (ANS) supplies the involuntary muscles, the heart 
and the secreting glands. The parasympathetic and sympathetic nervous systems 
together form the peripheral ANS. As the name implies, most activities of the 
ANS are not under voluntary control, but are usually regulated by the reflex arc. 
The peripheral ANS is efferent, that is a motor system, but most of the nerves 
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containing ANS fibers also have afferent neurons. The efferent fibers convey the 
reflex response to afferent information. The ANS is a two neuron system. The 
place where the first neuron ends in a synapse with the second neuron is termed a 
ganglion. The nerve fiber before the synapse is the preganglionic fiber and after 
the synapse is the postganglionic fiber. The chemical transmitter in the 
parasympathetic system, at both the synapse and the postganglionic termination is 
acetylcholine.  
 
As can be seen from Figure 3.1.2, the sympathetic nerves leave the central 
nervous system between the first thoracic and the second lumbar segments of the 
spinal cord. The route of the sympathetic fibres from the superior cervical 
ganglion to the salivary glands is also shown. Figure 3.1.3 shows that the 
parasympathetic nerves leave the central nervous system in the spinal region only 
at the second, third and fourth sacral segments, but in addition there is an 
important outflow in some of the cranial nerves which arise from the brain itself 
(Green, 1976; Despopoulos, 2003). The parasympathetic fibers from the otic and 
submandibular ganglions to the salivary glands are also illustrated. 
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Figure 3.1.2: Fibers of the Sympathetic Nervous System (Greenstein, 2000) 
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Figure 3.1.3: Fibers of the Parasympathetic Nervous System 
                     (Greenstein, 2000) 
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Parasympathetic fibers are found in the cranial nerves III, VII, IX and X. The 
parasympathetic fibers in the VII, facial nerve, reach the submandibular and 
sublingual salivary glands by a complex pathway. These fibers arise in the 
superior salivary nucleus which lies in the reticular formation in the lower pons, in 
the brain stem. The fibers travel in the VII, facial nerve, until they leave in the 
chorda tympani nerve just above the stylomastoid foramen. The chorda tympani 
run across the ear drum to reach the lingual nerve. A branch from this nerve runs 
to the submandibular ganglion. Postganglionic fibers supply secretory function to 
the submandibular and sublingual glands (Green, 1976).  
  
The parasympathetic fibers in the IX, glossopharyngeal nerve, supply the parotid 
gland. They arise in the inferior salivary nucleus which lies just below the 
superior salivary nucleus. The fibers travel in the tympanic branch of the 
glossopharyngeal nerve to the lesser superficial petrosal nerve to reach the otic 
ganglion. The postganglionic fibers run in the auriculotemporal nerve to the 
parotid gland (Green, 1976).  
 
Sympathetic fibres pass from the superior cervical ganglion with blood vessels to 
the salivary glands (Ferguson, 1988). 
 
As already mentioned, activities of the ANS are regulated by a reflex arc. The 
salivary – taste reflex is a prime example of the reflex arc. When gustatory 
stimulus is placed on the anterior two thirds of the tongue, the salivary glands 
increase their saliva output. The afferent stimulus is carried by taste fibers in the 
facial nerve to the nucleus of the solitary tract. Connecting fibers from this 
nucleus go to parasympathetic neurons in the superior and inferior salivatory 
nuclei. The efferent stimulus is carried back to the salivary glands via the 
previously described routes. The reflex pathway for gustatory stimuli on the 
posterior one third of the tongue is similar to that of the anterior two thirds of the 
tongue, except the afferent stimulus is carried by the glossopharyngeal nerve 
(Gillman & Newman, 1992). Conditioned reflexes also have a role to play in the 
stimulation of saliva secretion. For example, the clattering of plates when 
preparing a meal can elicit a saliva response (Despopoulos, 2003).  
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Functions of Saliva 
 
Saliva has several functions: it keeps the vocal cords damp; it aids articulation by 
keeping the tongue, lips and palate lubricated; it protects the teeth and gums from 
bacteria, which can cause gingivitis and tooth decay; it helps to decrease bad 
smelling breath by cleaning the mouth; it is an essential component in 
swallowing, as it lubricates the oral mucosa and mixes with food in the mouth to 
form a bolus; it facilitates tasting, as food can only be tasted in solution; and it 
promotes digestion by breaking down proteins and carbohydrates with amylase 
(Brodsky, 2002; Hockstein et al, 2004; Lal & Hotaling, 2006; Mathur, Vaughn & 
Brown, 2006; Winstock, 2005).  
 
As saliva has many important functions, when considering the treatment of 
drooling, it is essential to preserve an adequate amount of saliva production. If the 
majority of saliva production is eliminated, which is often the case with radical 
surgical procedures, swallowing becomes difficult, tooth decay can occur, the lips 
and mouth can become encrusted with bits of dry food, and the smooth movement 
of the oral musculature, needed for the co-articulation of sounds, can be 
hampered. These were some of the reasons it was decided to inject only the 
submandibular glands with Botox® in the DTP, thus leaving the other major and 
minor salivary glands to continue producing saliva. 
 
Factors Affecting the Production of Saliva 
 
There are several factors which can affect the production of saliva. As can be seen 
from Table 3.1.1 different factors influence the amount of saliva produced, either 
causing an increase or a decrease in the amount of saliva produced. Although the 
participants in the DTP were a convenience sample, it is interesting to note that 
the majority were males.  
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Table 3.1.1: Factors that Influence the Production of Saliva  
                    (Based on Winstock, 2005)  
 
Factors that ↑ Saliva Production   Factors that ↓ Saliva Production 
Age: saliva production ↑ up to the age of 
15 years. 
Gender: males produce more saliva. 
Fluid intake: a ↑ in the amount of fluid 
drunk can ↑ the amount of saliva 
produced. 
Chewing: ↑ in frequency and amount of 
chewing can ↑ the amount of saliva 
produced. 
Taste: citric acid ↑ saliva production. 
Time: saliva production peaks during the 
afternoon. 
Visual imagination: good visual 
imagination ↑ saliva production. 
Illness: saliva production ↑ with nausea 
and vomiting. 
 
 
Age: saliva production decreases after 15 
years of age. 
Gender: females produce less saliva. 
Fluid intake: a ↓ in the amount of fluid drunk 
can ↓ the amount of saliva produced. 
Time: saliva production ↓ during sleep. 
Season: saliva production ↓ in summer. 
Emotions: fear and depression ↓ saliva 
production. 
Darkness/blindfold: saliva production ↓ in 
the dark or if blindfolded. 
Medication: certain medications ↓ saliva 
production. 
 
Key: ↑ - Increase; ↓ - Decrease. 
 
3.2. Drooling 
 
Definition of Drooling 
 
“Drooling is the unintentional, involuntary loss of saliva from the mouth due to a 
lack of control over oral secretions” (Lal & Hotaling, 2006, p. 381). The medical 
term for drooling is sialorrhea and the literature is full of authors who basically all 
give the same definition of drooling. (Bax, 1992; Blasco & Allaire, 1992; 
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Crysdale, 1989; Meningaud, Pitak-Arnnop, Chikhani & Bertrand, 2006; Nunn, 
2000; Suskind & Tilton, 2002; Wilkie, 1967). 
 
Development of Drooling 
 
Drooling is a physiological phenomenon, considered to be normal in children 
under the age of two years. Table 3.2.1 illustrates that the development of 
drooling occurs in stages. 
 
Table 3.2.1: Developmental Stages of Drooling (Alexander, Boehme & Cupps,  
                    1993; Boner & Perlin, 1994) 
 
Age Development 
1-2 months Little drooling in supine, but drooling ↑ in prone or supported sitting, as the 
jaw and tongue move in wider excursions. 
3-5 months Drooling ↓ in positions with greater stability, but does ↑ with teething. 
6 months Drooling is controlled in supine, prone and sitting. It does occur with 
babbling, reaching and teething, but is less during feeding. 
7-9 months Drooling rarely occurs, even with new gross motor activities. With new 
upper extremity activities drooling may occur, also when teething. 
10 to 12 
months 
Drooling rarely occurs, except when teething. 
15 months No drooling with new gross motor activities, but it does occur with new 
fine motor activities. 
18 months No drooling with early fine motor activities, but it does occur with feeding, 
random play and undressing. 
24 months No drooling with more advanced fine motor activities, drawing, self-
feeding, random play, undressing, or during two-word utterances. 
 
Key: ↑ - Increase; ↓ - Decrease. 
 
Occasionally children up to the ages of four to six may exhibit drooling, 
especially if they are teething. However, drooling resolves with the maturation of 
oro-facial movement and swallowing (Mathur et al, 2006). 
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Etiology of Drooling   
 
Drooling is rarely caused by an increase in the production of saliva, commonly 
known as hypersecretion or primary sialorrhea (Mathur et al, 2006; Senner, 
Logemann, Zecker, Gaebler-Spira, 2004). In fact, it has been shown that patients 
who produce less saliva can drool (Proulx, de Courval, Wiseman, & Panisset, 
2005). Primary sialorrhea is usually caused by: inflammation, such as during 
teething; dental caries; mouth infections; rabies; certain medications, as a side 
effect from the use of tranquilizers or anticonvulsants; toxin exposure (mercury 
vapour); and gastro esophageal reflux (Hockstein et al, 2004; Winstock, 2005). 
Before considering any treatment that reduces the amount of saliva produced, it is 
essential to consider and attend to any of the above mentioned causes. 
 
More commonly, drooling is caused by impaired neuromuscular control and/or 
sensory dysfunction. This impaired neurological control results in poor co-
ordination of the oral musculature and poor suction force, leading to an inadequate 
swallowing function. Swallowing studies of CP children point to three areas of 
difficulty: incomplete lip closure; low suction force; and a prolonged delay 
between suction and the backwards propelling of food stage (Lespargot, 
Langevin, Muller & Guillemont, 1993). Excessive pooling of saliva in the anterior 
portion of the mouth and the unintentional loss of saliva from the mouth are the 
results (Brodsky, 1999; Meningaud et al, 2006). This is known as secondary, 
anterior drooling. 
 
The list of disorders/deformities that can cause secondary drooling is extensive, as 
can be seen from Table 3.2.2 on the following page. 
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Table 3.2.2: The Etiology of Drooling (Based on Meinigaud et al, 2006) 
 
Neurological Deficits Anatomical Deformities 
Predominantly Adult Deficits 
Motor neuron disease (amyotrophic lateral sclerosis) 
Multiple sclerosis, Facial paralysis  
Parkinson’s disease 
Cerebrovascular accidents 
Macroglossia (enlarged tongue) 
Dental malocclusion 
Orthodontic problems 
Nasal obstruction 
Head and neck surgical defects  
(i.e. ‘Andy Gump’ deformity) Seizures, Traumatic brain injury 
Predominantly Childhood Deficits 
Cerebral palsy 
Congenital suprabulbar palsy 
Severe mental retardation, Down’s syndrome 
Worster Drought syndrome, Operculum syndrome 
Landau Kleffner syndrome, Angleman’s syndrome 
Freeman-Sheldon syndrome, Moebius syndrome 
Encephalitis, Hydrocephalus, Hypoxic encephalopathy 
Early sign of Sjogren’s syndrome 
 
 
It is important to distinguish between anterior and posterior drooling. Posterior 
drooling, in which saliva spills over the tongue through the faucial isthmus, can 
cause congested breathing, coughing, gagging, vomiting and occasionally 
aspiration into the trachea that results in recurrent pneumonia (Jongerius, van 
Hulst, van den Hoogen & Rotteveel, 2005). A diagnosis of posterior drooling 
warrants additional investigations, not just treatment for the drooling. Although 
Jongerius et al (2005) have treated children with posterior drooling with Botox® 
successfully, it was decided for reasons of safety that all participants in the DTP 
had to exhibit anterior drooling not posterior drooling. 
 
Impaired sensory awareness, hyposensitivity, on or within the mouth may be a 
primary causative factor in the ability to control saliva (Rosenfeld-Johnson, 2002). 
In fact, according to Allaire (1999, p. 107) “experts believe that the perception of 
sensation within and around the mouth of a child who drools is different from that 
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of other children.” The relationship between oral sensations and drooling was 
examined by Weiss-Lambrou, Tetreault and Dudley (1989). Their results 
suggested that CP children who drool may have an oral sensory problem, possibly 
associated with a perceptual deficit, as those children scored lower on tests of oral 
sensation compared to CP children who did not drool. Normal oral sensation 
activates the movement of the jaw, tongue and throat and provides the cue to 
swallow (Allaire, 1999). If sensation is impaired, “a wet chin may feel normal” 
(Winstock, 2005, p. 172).  
 
Although Morris and Klein (2000) acknowledge that some CP children may lack 
oral sensory awareness, they also argue that saliva accumulates in the mouth 
because of a reduced frequency of swallowing and this can cause drooling. 
Further, the constant drooling and wet face can reduce the sensory cues needed to 
trigger a proper swallow. The old saying ‘which comes first, the chicken or the 
egg’ comes to mind. Suffice it to say, if there is an indication of reduced oral 
sensation, treatment should include increasing the child’s awareness in and around 
the mouth.  
 
When drooling persists after the age of six years, it is usually as a result of 
neurological deficits or anatomical problems. Mathur et al (2006) contend that 
within the CP population more than 85% of patients with drooling are younger 
than 21 years. They attribute this to the shortened life span of persons with CP.  
 
3.3. Factors that Exacerbate Drooling 
 
Poor postural and head control, poor oral-motor control, a constantly open mouth, 
enlarged tonsils and adenoids, increased concentration during a task, and certain 
medications, such as clozapine and lithium, can all exacerbate drooling. These 
factors should be taken into consideration when planning therapy for drooling. In 
the study by Senner et al (2004) a positive correlation was found between severity 
of drooling and severity of dysarthria. This finding highlights the importance of 
oral-motor control in controlling saliva and producing clear speech. 
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Complications of Drooling 
 
Most authorities agree that the complications of drooling can range from mild and 
inconvenient to severe problems that negatively affect the quality of life.  
 
Complications are usually divided into three areas: 
 
a). The physical symptoms include: sore lips and chins; dehydration; the 
discomfort of a dry mouth; halitosis; gum and dental problems; wet clothes, which 
have to be changed frequently, leading to an increased work load for the 
parents/primary caregivers; wet furniture, toys, books and computer keyboards 
(Winstock, 2005). The severity of the drooling affects the severity of the physical 
symptoms.  
 
b). The psychosocial complications include: social unacceptability and 
embarrassment, leading to isolation; increased dependency and level of care; 
caretakers, family and friends may find it difficult to demonstrate affection; 
strangers or the uninformed may assume the child is severely mentally retarded 
(Banerjee, Glasson & O’Flaherty, 2006; Hockstein et al, 2004; Mathur et al, 2006; 
Winstock, 2005). 
 
c). The third area is barriers to participation: negative attitudes of teaching staff 
and other pupils often lead to exclusion from school activities (Mihaylov, Jarvis, 
Colver & Beresford, 2004; Hemmingson & Borell, 2002; Pivik, McComas & 
Laflamme, 2002). Castaneto and Willemsen (2007) found there was subtle 
prejudice against disabled children, while Nadeau and Tessier (2006) discovered 
that in a mainstream school, CP children particularly the females, suffered social 
isolation and victimization. These studies seem to imply that the education of the 
disabled child may not be as comprehensive as the non-disabled child. One study 
on higher education and employment of CP individuals indicated that only 29% of 
the participants, despite some of them having a main stream education, were 
employed in the open labour market (Michelsen, Uldall, Kejs & Madsen, 2005). 
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The authors postulate that one reason for the low employment rate is the fact that 
CP individuals have problems with social interaction. 
 
It would appear, based on extensive clinical experience, that drooling, amongst 
other symptoms, has a negative effect on the social interaction of a CP individual.     
 
3.4. Prevalence of Drooling 
 
The prevalence rate for drooling in children with operculum syndrome is 100%. A 
diagnosis of operculum syndrome can only be made if significant drooling is 
present (Christen et al, 2000). The actual prevalence rate for drooling in the CP 
population is unknown. Ten to 37% of CP persons world wide are reported to 
have difficulty with drooling. Ten percent of Swedish children, 37% of Belgian 
children, and 13% of Indian children with CP have severe drooling. However, 
drooling is not related to any particular ethnic background (Mathur et al, 2006). 
The variation in percentages of drooling therefore is due to the use of different 
measurement tools. At present there is no universal measurement of drooling. 
Severe drooling is estimated to be present in 10-15% of children born with CP 
(Brodsky, 2002). Meningaud et al (2006) consider drooling to be a relatively 
common clinical sign and provide evidence for this statement by quoting the 
Oxford Feeding Study (Sullivan, Lambert, Rose, Ford-Adams, Johnson & 
Griffiths, 2000) which estimates that 28% of children with neurological 
impairments suffer from continuous drooling. 
 
In 2003, Tahmassebi and Curzon investigated the prevalence of drooling in 
children with CP who attended special schools. Their results showed that 93 of the 
160 children (58%) had a drooling condition and of these 53 (33%) had severe 
drooling. They also looked at the prevalence rates in relation to the maturation of 
the child’s oral-musculature. In other words, they compared the prevalence of 
drooling in different dental age groups. They hypothesized there would be no 
difference in drooling prevalence between the CP children in different dental age 
groups. However, they found that drooling decreased as the child’s dental age 
increased. They concluded that any invasive treatment to reduce drooling should 
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be postponed until the child’s oral-musculature has matured. This conclusion has 
repercussions for the management of drooling in CP children. It must be 
mentioned, however, that the invasive treatment they were referring to was 
surgery. As the participants in the DTP were not going for surgery, but rather 
Botox® injections, it was decided to include some children whose oral-
musculature was not fully matured.   
 
Prevalence rates for drooling in South African CP children are unknown at this 
stage, but one would estimate them to be quite high, as large sections of the CP 
population live in rural areas or informal settlements, and do not have access to 
therapeutic or medical services. Based on clinical experience, in one LSEN school 
in Gauteng, 50% of the learners are diagnosed with CP and of those 20% drool.  
 
3.5. Techniques to Measure Drooling 
 
An accurate evaluation of drooling is difficult because of variations between 
individuals, but also because drooling fluctuates throughout the day and between 
activities. Several systems have been devised and used by authors, either in 
isolation or in combination. Measurement can be objective and quantitative or 
subjective and qualitative. 
 
a). Objective, Quantitative Measures 
 
Salivary duct cannulation is considered the gold standard for drool measurement 
(Suskind & Tilton, 2002). The drool quantification system developed by 
Sochaniwskyj (1982) consists of a head bonnet, a saliva collection cup, a 
collection chamber with calibrated test tubes and a vacuum pump. Technetium 
scanning has also been used to assess salivary flow (Lal & Hotaling, 2006). These 
methods are primarily used for research purposes and were considered unsuitable 
for use in the clinical setting of the DTP. 
 
Roll saturation and weighing dental rolls which have been placed in the oral 
cavity have also been used. These methods are considered non-invasive for 
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measuring drool and have been used in a number of studies (Jongerius, van den 
Hoogen et al, 2004; Hassin-Baer, Scheuer, Buchman, Jacobson & Ben-Zeev, 
2005). However, Suskind and Tilton (2002) found that their patients either 
continually gagged or tried to swallow the rolls. Some authors have used 
weighing the saliva collected on a dental bib (Banerjee et al, 2006). These 
methods were also considered impractical for use in the clinical setting of the 
DTP. 
 
The Drooling Quotient (DQ) is a validated, semi-quantitative direct observational 
method developed by Rapp (1980). Drooling is scored during two periods of 10 
minutes separated by a 60-minute break. Every 15 seconds (40 observations in 10 
minutes) the presence or absence of drooling is assessed. Drooling is defined as 
new saliva on the lip margin or dropping from the chin. The DQ is expressed as a 
ratio of the observed drooling episodes divided by the total number of 
observations. Although this is a validated method it was felt that it would be too 
disruptive to the children’s school day to use this method in the five different 
situations that were being investigated in the DTP. 
 
Counting the number of bibs changed in a day, despite being an objective 
quantitative measure, relies on teacher or parent observation and their judgements 
as to when a bib is sufficiently soaked to require changing. As only 4 children 
wore bibs or scarves at the time of the DTP, this method was only used as part of 
the descriptive analysis applied to the parental perceptions on drooling. 
 
b). Subjective, Qualitative Measures  
  
A variety of subjective scales have been developed. One of the initial scales was 
developed by Wilkie and Brody (1977) to classify the results of surgical drooling 
procedures: 
· Excellent – normal salivary control 
· Good – slight loss of saliva with or without dried froth on the lips 
· Fair – improved, but with significant residual saliva loss or with thickened, 
offensive, brown, gummy froth 
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· Poor – failure to control saliva or too dry 
 
The Visual Analogue scale (VAS), a semi-quantitative scale, is usually given to 
parents/primary caregivers. Scales of exactly 10 cm without visible subdivisions, 
on which the average degree of drooling is marked, are given. Ten means severe 
drooling and 0 means no drooling. An independent person then scores the VAS 
with a ruler in millimetres, resulting in a number ranging from 0 to 100 
(Jongerius, van den Hoogen et al, 2004).    
 
Jongerius, van den Hoogen et al (2004) used The Teacher Drooling Score (TDS), 
which is a subjective expression on an ordinal scale. As can be seen from Figure 
3.5.1 this scale does not separate severity and frequency of drooling and therefore 
was not considered sensitive enough for the purposes of the DTP. 
 
 
1--------------No drooling 
2--------------Infrequent drooling; small amount 
3--------------Occasional drooling; intermittent all day 
4--------------Frequent drooling but not profuse 
5--------------Constant drooling; always wet 
 
 
 
Figure 3.5.1: The Teacher Drooling Score (Jongerius, van den Hoogen et al, 2004) 
 
The Drooling Severity and Frequency rating scales are a qualitative, questionnaire 
based scoring system, originally developed by Thomas-Stonell and Greenberg 
(1988). They are a validated method of assessing drooling severity and frequency 
and have been used by a number of authors (Banerjee et al, 2006; Wong, Sun & 
Wong, 2001). In addition, they are presently used by The Saliva Control Clinic at 
The Royal Children’s Hospital, Melbourne, Australia (Saliva Control in Children, 
retrieved June 2007).  
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Although a subjective qualitative measure it allows one to separate severity and 
frequency scores, has descriptions as to what each score means, as can be seen 
from Figure 3.5.2, and is relatively quick to administer. This last factor was 
considered to be important in the clinical setting of the school, as each child in the 
DTP had to be assessed in five different situations at baseline, 8 weeks post 
treatment and 24-26 weeks post treatment. Parents/primary caregivers were also 
asked to assess their child’s drooling in the five different situations and at the 
same time intervals. It was felt that the severity and frequency rating scales would 
be easy and appropriate for them to use.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.2: Drooling Frequency and Severity Scales (Thomas-Stonell &  
                     Greenberg, 1988) 
 
 
Perhaps the most important factor in the choice of this measure was the fact that it 
is a qualitative measure and the aims of the DTP were to establish whether there 
would be a visible decrease in drooling in representative daily situations, not just a 
reduction in saliva production rate. In addition, if there was a visible decrease in 
drooling, would the children’s and the parents/primary caregivers’ qualities of life 
have improved.  
Frequency Scale: 
1------------------Never drools 
2------------------Occasionally (not every day) 
3------------------Frequently (part of every day) 
4------------------Constantly 
 
Severity Scale: 
1------------------Dry (never drools) 
2------------------Mild (only wet lips) 
3------------------Moderate (wet on lips and chin) 
4------------------Severe (drool extends to wet clothes) 
5------------------Profuse (drool extends to wet hands, tray and objects 
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An additional subjective measure is the Drooling Impact Scale. Although used 
previously in the Saliva Control Clinic at The Royal Children’s Hospital, 
Melbourne, Australia for parents/primary caregivers to assess their children’s 
drooling, in 2008 it was used in a randomized controlled study of children’s 
drooling. It consists of 10 questions that are rated between 1 and 10 on a semantic 
differential scale. The maximum possible total for the scale is 100 (Reid et al, 
2008). 
 
Reid et al (2008) comment that objective measures may be invasive, unsuitable 
and sometimes inaccurate and that the main aim of reducing drooling is to 
improve quality of life. 
 
3.6. Management Options 
 
In the last 20 years there have been many approaches to alleviate the problem of 
drooling in the neurologically impaired population. One aspect of treatment is 
agreed upon by everyone working in the field. A multi-disciplinary team approach 
must be used (Brodsky, 2002; Crysdale, McCann, Roske, Joseph, Semenuk & 
Chait, 2006; Faulconbridge, Tranter, Moffat & Green, 2001; Hockstein et al, 
2004; Lal & Hotaling, 2006; Meningaud et al, 2006). 
 
A team may comprise the following members: dentist/orthodontist who assesses 
and treats dental and oral diseases and malocclusion; otolaryngologist/ENT 
surgeon who medically evaluates the child, paying particular attention to the oral 
cavity and structural problems encountered in the upper aerodigestive tract and 
who may perform surgery; plastic surgeon who may also perform surgery; social 
worker who offers education and counselling; occupational therapist and/or 
speech, language and hearing therapist who assesses the oral-motor function and 
swallowing skills of the child.  
 
The speech, language and hearing therapist may obtain information regarding 
previous management and assess the attitudes of the parents/primary caregivers, 
teachers and child. In addition she/he assesses the frequency and severity of 
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drooling, the presence of odour, skin changes, body posture and head position 
(Brodsky, 2002; Crysdale et al, 2006). In South Africa, it has been my experience 
that the speech, language and hearing therapist provides information to the 
parents/primary caregivers regarding the possible options of treatment for 
drooling and then refers to the relevant specialist.  
 
Once all available information has been gathered, team recommendations should 
be made. Treatment should progress from least invasive to most invasive, and 
should be safe, cost-effective, side effects should be minimal and it should have 
no permanent adverse consequences, even if it is successful (Brodsky, 2002; Lal 
& Hotaling, 2006).  
 
3.7. Treatment Strategies  
 
a). The first strategy is no treatment. This is the treatment of choice if there is 
minimal drooling or parents/caregivers perceive drooling as a low priority, 
children are under the age of five to six years, or in adults with unstable 
neurological function, following an acquired neurological deficit, In addition, 
where aspiration is a significant concern or other airway problems exist, no 
treatment may be the wisest choice (Brodsky, 2002; Crysdale et al, 2006). 
 
b). Control of certain situational factors may lead to a reduction in drooling: 
improving head control, seating and/or positioning; correction of dental problems; 
improving oral hygiene and promoting healthy dentition; orthodontic care to 
permit closure of the mouth; removal of adenoids and tonsils that are enlarged; 
and the replacement or removal, if possible, of medication that increases drooling, 
can all help to reduce drooling (Brodsky, 2002; Crysdale et al, 2006; Winstock, 
2005). 
 
c). Behaviour modification strategies include activities designed to increase the 
child’s awareness of drooling. Verbal and/or gestured reminders to close the 
mouth and swallow, together with praise for the child’s efforts are often used. 
Building an awareness of the language concepts ‘wet’ and ‘dry’, ‘open’ and 
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‘closed’ can also be of help (Morris & Klein, 2000). Biofeedback and automatic 
cueing techniques use timed auditory stimuli to remind the client to swallow or 
wipe the saliva. Usually these techniques are applicable to a small number of 
clients, those who are highly motivated, have good cognition and only mild to 
moderate drooling (Brodsky, 2002; Lal & Hotaling, 2006; Meningaud et al, 2006; 
Winstock, 2005). Hockstein et al (2004) feel that patients eventually become used 
to the stimulus or forget to wear the cue-producing device.  
 
For South Africans automatic cueing devices are expensive as they must be 
imported from overseas. Therefore their use is limited. The participants in the 
DTP had all received training in behavioural modification strategies, prior to their 
inclusion in the project. However, success was minimal. This was most probably 
due to limited motivation, limited cognition and poor carry-over into the home 
situation. This last fact is a reality in South Africa. Most of the parents/primary 
caregivers of the children were in the low socio-economic sector, had to work 
long hours and often had to travel large distances to get to work and home. As 
Saloojee et al comment (2006, p. 234) “the sense of despair and hopelessness felt 
by caregivers of more severely disabled children was unmistakeable.” In these 
circumstances it is not surprising that parents/primary caregivers do not consider it 
a priority to remind their child to swallow, to keep his/her mouth closed, or to 
wipe the chin. 
 
Several orthodontic appliances have been used to treat drooling. Customized 
plates formed to fit the palate, used in conjunction with oral-motor treatment, can 
aid in better lip closure, developing jaw stability, increased oral awareness leading 
to increased oral-motor activity and increased frequency of swallowing. Palatal 
training appliances (PTA’s) have been described in the literature by Limbrock, 
Hayer & Scheying (1990). The plate has the advantage of lowering the hard palate 
thereby improving tongue-palate contact (Hockstein et al, 2004; Meningaud et al, 
2006; Winstock, 2005). PTA’s should not be used with children under the age of 
six, as their dentition is not usually mature enough to be able to wear a PTA 
(Faulconbridge et al, 2001).  
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One child in the DTP had an orthodontic appliance fitted to correct the alignment 
of her teeth, thereby improving lip closure. At the time of the DTP she had worn 
the appliance for nearly two years and little improvement in her drooling had been 
noticed. It must be mentioned that the specialist involved had donated his time 
and the appliance was paid for by donations, illustrating once again that for the 
majority of South Africans treatments for drooling are not within their budgets.  
 
A small prospective Chinese study, involving 10 children who drooled, found that 
the use of acupuncture subjectively improved drooling in seven of the children 
(Wong, Sun, & Wong, 2001). As far as I know acupuncture has not been used in 
South Africa to treat drooling.  
 
d). Compensatory strategies help those in the child’s environment cope better with 
the drooling, although they do not reduce the amount of saliva falling from the 
mouth. They may include providing information to the parent/primary caregiver 
on the use of bibs, scarves, specialized super-absorbent material from which 
clothes can be made, terrycloth wristbands for wiping, deodorant sprays to help 
reduce the odour from drooling, barrier creams applied to the chin to prevent the 
skin from chapping, specially designed pillows that prevent the child from 
sleeping in a pool of saliva, and the use of a slanted work surface to minimize the 
use of a head forward posture (Allaire, 1999; Crysdale et al, 2006). Most children 
who drool at the LSEN school in Gauteng now use bibs, scarves or wristbands to 
minimize the effects of their drooling, as well as using slanted work surfaces.  
 
e). Oral – motor therapy is the realm of the speech, language and hearing 
therapist, occupational therapist and physiotherapist. They often work together, 
using a NDT approach, to normalize muscle tone, improve sensory awareness on 
the face and within the mouth, improve positioning of the patient, improve 
biomechanical alignment of the body, and improve head and trunk control. 
(Allaire, 1999; Morris & Klein, 2000).  
 
Oral-motor therapy is intended to increase coordinated muscle function in the oral 
cavity and to improve swallowing and control of secretions. It is considered to be 
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the first line of action for persons who drool and is usually started at an early age 
(Brodsky, 2002). Lal and Hotaling (2006, p. 382) contend that “oral motor 
training is the keystone of non-surgical intervention and a minimum of a six 
month trial is indicated before other therapeutic options.”  
 
According to Rosenfeld-Johnson (2002), four variables in the oral-motor function 
form the basis for the control of drooling.  
· Body Posture: Stability in the body allows for mobility in the mouth. 
· Sensory Awareness: Hyposensitivity in the oral area is a primary cause of 
drooling. 
· Lip Closure: Lip closure is achieved when there is jaw stability and 
dissociation between lips and jaw. Nasal breathing is essential, as mouth 
breathing inhibits lip closure. 
· Saliva Retraction: Saliva must be retracted back over the tongue to 
position it for effective swallowing. A tongue thrust or reverse suckle 
swallow make it difficult for saliva to be retracted. 
 
Rosenfeld-Johnson (2002) advocates working on all four areas to improve 
drooling. Exercises using bite blocks, tongue depressors, horn blowing exercises, 
bubble blowing exercises, button-pull exercises, and straw drinking exercises all 
form part of her Drooling Remediation Programme (Rosenfeld-Johnson, 2002).  
 
This programme has been used with some success at the LSEN School in Gauteng 
to improve the oral-motor functioning of the children. However, sustained 
significant improvement in the children’s drooling has not been achieved. This 
finding corroborates with the following conclusions: Hockstein et al (2004) 
comment that a feeding programme, aimed at improving oral motor control, is 
rarely successful in treating drooling problems; Suskind and Tilton (2002) state 
that numerous therapies, including oral motor therapy, have been advocated to 
reduce drooling, but none has produced optimal results.  
 
f). Pharmacologic treatment has been used by several researchers to decrease 
drooling in the neurologically impaired population. As salivation is under 
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parasympathetic control, anti-cholinergic medications have an inhibitory effect on 
salivary flow (Tuchman & Walter, 1994). Camp-Bruno, Winsburg, Green-Parsons 
and Abrams (1989) used benztropine and found a significant reduction in 
drooling. However, there was only a short follow up time to assess any possible 
side effects of the drug.  
 
Transdermal scopolamine, applied as patches, has been shown to be of use in the 
short term (Siegel & Klingbeil, 1991; Jongerius, van den Hoogen et al, 2004). The 
side effects from the use of anti-cholinergic medications can be numerous and 
often cause non-compliance and cessation of treatment. Such side effects include: 
overly dry mouth; constipation; blurred vision; urinary retention; confusion; and 
even toxic psychosis (Brodsky, 2002; Lal & Hotaling, 2006).  
 
The use of drugs is often contraindicated, for example, when there is a history of 
cardiac problems. Drug interactions with other medications must also be 
considered. Despite the negative aspects of oral medications, Blasco (2003, p.845) 
feels it is “the best option at this point.” Several drugs are available in South 
Africa, but their use is limited by their expense.  
 
g). Surgery is the most invasive approach to drooling and is usually deferred until 
after six years of age. It is recommended for patients with profuse and constant 
drooling and those with severe cognitive impairment. It is also recommended for 
those who continue to have severe drooling despite appropriate non-surgical 
therapy (Crysdale et al, 2006; Lal & Hotaling, 2006). Since the 1960’s many 
procedures have been described as treatments for drooling. Table 3.7.1 describes 
the various surgical procedures but more importantly indicates the disadvantages 
of each procedure.  
 
Several procedures have been used in South Africa, but their use is limited. 
 
                                                                                                                                                                                                                                                                                                 
 
Table 3.7.1: Surgical Options for Drooling (Based on Brodsky, 2002; Meningaud et al, 2006) 
 
Procedure Reference Rationale Efficacy Advantages Disadvantages 
Parotid duct 
transposition 
Wilkie, 1967 Redirect saliva from parotid gland 
to posterior oral cavity 
80% Redirects flow in 
stimulated state 
Duct stenosis, potential for 
aspiration 
Tympanic neurectomy Friedman & Kaplan, 
1975 
Disrupts parasympathetic 
innervation to parotid gland 
47-100% 
short term 
Technically easy Possible caries, middle ear 
surgery, return of salivary 
function, possible hearing loss 
Chorda tympani 
section 
Parisier, Blitzer, 
Binder, Friedman & 
Marovitz, 1978 
Disrupts parasympathetic 
innervation to sublingual & 
submandibular glands 
47-100% 
short term 
Technically easy Loss of taste, possible caries, 
middle ear surgery 
Parotid duct ligation Dundas & Peterson, 
1979 
Eliminate salivary flow from 
parotid gland 
80% Simple procedure, 
successful 
Loss of saliva with possible 
caries, risk of sialocele 
Submandibular 
(Wharton’s) duct 
relocation 
Crysdale & White, 
1989 
Redirect saliva to posterior oral 
cavity for swallowing by reflex 
control 
80-100% Highly successful, 
technically easy, 
physiologically acceptable 
Possible ranula, intra-oral 
dissection 
Submandibular gland 
excision 
Rosen, Komisar, 
Ophir & Marshak, 
1990 
Almost always done in 
conjunction with parotid duct 
ligation/transposition 
86% Eliminates 50% of total 
salivary secretion 
External incisions, loss of saliva 
with possible caries 
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h). Meningaud et al (2006) reported on a study that used laser photocoagulation to 
partially destroy the parotid glands and occlude the parotid ducts. Significant 
improvement in drooling severity and frequency was measured in the majority of 
cases. However, transient facial swelling was noted in all patients (Chang & 
Wong, 2001, in Meningaud et al, 2006).   
 
i). The use of botulinum toxin to reduce drooling has been the subject of 
numerous studies since 1999. Although still in the early stages of use, and studies 
to date have included relatively small groups of participants, the outcomes have 
been favourable, with rare reports of serious complications (Meningaud et al, 
2006). The use of Botox® to control drooling appears to fit in the scale of 
treatment options between pharmacotherapy and surgery. This is especially true 
when used with children, as at this stage general anaesthetic seems warranted in 
the administration of Botox® with children. The history of Botox®, together with 
a description of the pharmacology of botulinum toxins follows. A detailed critique 
of the studies using Botox® to control drooling in children is also given. 
 
3.8. Botulinum Toxin Type A: Botox® 
 
Historical Perspective 
 
Botulinum toxin, the most potent poison known, is a neurotoxin, which has often 
been feared as a possible biological weapon (Arnon, 2001, in Jankovic, 2004).  In 
1817 Justinus Kerner, a German poet and physician, provided the first account of 
food borne botulism. From this outbreak, he recognized the potential of the toxin 
as a therapeutic agent. He noticed that the toxin paralyzed skeletal muscles and 
parasympathetic function. Kerner hypothesized that the toxic substance causing 
botulism could be helpful in treating hypersalivation, as severe dry mouth was one 
of the first manifestations of botulism (Erbguth, 2004).  
 
It was not until 1949 that Burgen, Dickens and Zatman (in Jankovic & Brin, 2002) 
discovered that botulinum toxin blocks neuromuscular transmission. This 
discovery laid the foundation for the development of the toxin into a therapeutic 
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tool. According to Jankovic and Brin (2002, p. 100) the use of botulinum toxin 
“represents one of the most dramatic role reversals in modern medicine: a 
potential evil transformed into a health benefit.” 
 
In 1973 Dr Alan Scott used botulinum toxin type A to treat strabismus in non-
human primates. By 1980 he reported on its use to treat strabismus in humans 
(Scott, 1980). Since then botulinum toxin has been used to treat a large number of 
neurological and non-neurological disorders.  
 
In 1989, after extensive laboratory and clinical testing of botulinum toxin type A 
(Botox®, Allergan Inc, Irvine, California, USA) the Food and Drug 
Administration (FDA) approved it as a therapeutic agent in patients with 
strabismus, blepharospasm and other facial nerve disorders, including hemifacial 
spasm. In 2000 the FDA approved Botox® and botulinum type B (Myobloc, Elan 
Pharmaceuticals Inc, Morristown, New Jersey, USA) as treatments for cervical 
dystonia and Botox® cosmetic for the treatment of glabellar (frown) lines 
(Jankovic, 2004).  
 
Pharmacology of Botulinum Toxins 
 
The botulinum toxins work by inhibiting the release of the neurotransmitter, 
acetylcholine, at the neuromuscular junction thus causing muscle relaxation. 
Acetylcholine is also the neurotransmitter in postganglionic fibres of the 
parasympathetic division of the autonomic nervous system. These fibres innervate 
various glands, such as the salivary glands (Aoki & Guyer, 2001; Jankovic & 
Brin, 2002). By inhibiting the release of acetylcholine at the neuroglandular 
junction, a temporary salivary flow rate reduction can be achieved (Jongerius, 
Rotteveel, van Limbeek, Gabreëls, van Hulst, & van den Hoogen, 2004).  
  
Strains of Clostridium botulinum produce seven immunologically distinct toxins 
designated A – G. All these neurotoxins are proteins of similar molecular structure 
and weight. Most types are bound by enzymes and form potent di-chain molecules 
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which consist of a heavy chain joined to a light chain by a disulphide bond. The 
action of botulinum toxin involves a four step process: 
1. serotype specific binding by the heavy chains to acceptors on the 
presynaptic membrane of cholinergic nerve endings; 
2. the toxin complex is internalised by endocytosis; 
3. once internalised and within a vesicle, the light chain translocates across the 
vesicle membrane and is released into the neuronal cytoplasm; 
4. the light chain cleaves various components of SNARE, including SNAP-25, 
and thus prevents the fusion of the acetylcholine synaptic vesicle with the 
plasma membrane. This blocks the release of the neurotransmitter, 
acetylcholine, into the synaptic cleft, causing local chemodenervation 
(Glickman and Deaney, 2001; Jankovic, 2004). 
 
SNARE, (soluble NSF, N-ethyl maleimide-sensitive factor, attachment receptors, 
and proteins essential for regulated exocytosis) is the complex of proteins that is 
involved in the regulated fusion of the synaptic vesicle with the plasma 
membrane. The complex consists of the following proteins; synaptobrevin, 
syntaxin and SNAP-25. The light chains of botulinum toxin A and E cleave 
SNAP-25, but at different sites; the light chains of botulinum toxin B, D and F 
cleave synaptobrevin and type C cleaves both SNAP-25 and syntaxin (Glickman 
and Deaney, 2001; Jankovic, 2004; Lim, Mace, Reza Nouraei, & Sandhu, 2006). 
So far, types A and B have been studied and used the most.  
 
Different commercial preparations have unique properties that account for 
different potencies and clinical effects. Potency of a product is determined 
through in vivo mouse essays. One unit (U) of botulinum toxin is defined as the 
amount of toxin, administered intraperitoneally, needed to kill 50% of a group of 
18-20 gram female Swiss-Webster mice. This unit is referred to as a mouse unit or 
a Unit. As numerous factors influence the clinical potency of a preparation, units 
are neither clinically equivalent nor interchangeable between products. Different 
preparations require different doses to achieve similar clinical effects. Therefore it 
is of vital importance that the specific product used is noted (Jankovic, 2004; 
Jankovic & Brin, 2002).  
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In a small cohort of patients who received repeat botulinum toxin treatments for 
various movement disorders, there was a lack of response to subsequent 
treatments. This is thought to be as a result of the development of blocking 
antibodies. The presence of these antibodies means that the patient will no longer 
respond to the serotype that induced the antibodies (Jankovic, 2004). To minimize 
immunoresistance, preparations of botulinum toxin with the lowest antigenicity 
should be used, such as the current Botox®; the smallest possible effective dose 
should be used; the interval between treatments should be extended as long as 
possible; and the use of booster injections should be avoided (Jankovic, 2004; 
Jankovic & Brin, 2002). Barnes, Best, Kidd, Roberts, Stark, Weeks and Whitaker 
(2005) investigated using botulinum toxin type B on patients with cervical 
dystonia who had become unresponsive to botulinum toxin type A. The overall 
responses to botulinum toxin type B were disappointing. Jankovic’s comment 
(2004, p. 955) that “because of epitope homology between various serotypes, the 
cross reactivity may result in immuno-resistance to the alternate serotype” may 
explain the disappointing results.  
 
There has been only one case study reporting on the failed response to repeated 
botulinum toxin type B injections to control drooling (Berweck, Schroeder, Lee, 
Bigalke & Heinen, 2007). After three successful treatments, no clinical response 
was shown to subsequent treatments. It was postulated that this secondary non-
response was associated with the formation of neutralizing antibodies against 
botulinum toxin type B.  
 
Several authors have hypothesized that atrophy of the injected salivary glands 
may be induced due to long lasting denervation of the salivary glands, (Jongerius, 
van Hulst, van den Hoogen, & Rotteveel, 2005; Kim, Lee, Weiner, Kaye, Cahill 
& Yudkoff, 2006). Although atrophy of the prostate gland in rats has been shown 
to occur following Botox® injections (Doggweiler, Zermann, Ishigooka & 
Schmidt, 1998) this result has not been found with Botox® injections to the rat 
submandibular gland. Moreover it was observed that the Botox® injection did not 
have a direct effect on the cells in the submandibular gland, but it did cause a 
homogenic shrinking in gland size without atrophy and no change in 
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vascularization (Coskun, Savk, Cicek, Basak, Basak & Dadas, 2007). This finding 
is of interest in relation to the theory that locally injected Botox® has a central 
effect (Currà, Trompetto, Abbruzzese & Berardelli, 2004). Perhaps as there is no 
change in the blood supply to the submandibular gland, Botox® is transported to 
the brain via the blood supply.    
 
3.9. Clinical Use of Botox® with Specific Reference to the Fields of Speech 
Pathology and Audiology 
 
The use of Botox® as a therapeutic agent has dramatically increased over the last 
two decades. Few therapeutic agents have been better understood in terms of how 
they work or have had a greater beneficial impact on patients’ functioning than 
Botox®. As can be seen from Table 3.9.1, Botox® has been most widely used in 
the treatment of disorders manifested by abnormal, excessive or inappropriate 
muscle contractions, but its use has rapidly expanded to include the treatment of a 
variety of ophthalmologic, gastrointestinal, urological, orthopaedic, 
dermatological, secretory, pain management and cosmetic disorders (Brin, Hallett 
& Jankovic, 2002). Expansion of the use of Botox® as a therapeutic agent within 
the speech pathology and audiology areas has also occurred. These areas have 
been highlighted in Table 3.9.1 by the use of a bold font.  
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Table 3.9.1:  Clinical Applications of Botulinum Toxin (Brin et al, 2002). 
 
Dystonia 
Blepharospasm and lid apraxia 
Oromandibular-facial-lingual dystonia 
Cervical dystonia (torticollis) 
Laryngeal dystonia (spasmodic dysphonia) 
Limb dystonia 
Task specific dystonia (eg. writer’s or other occupational cramps) 
Other focal/segmental dystonias (primary, secondary) 
 
Other Involuntary Movements 
Hemifacial spasm 
Limb, head, voice, chin tremor 
Palatal myoclonus 
Motor and phonic tics (including coprolalia) 
Nystagmus and oscillopsia 
Myokymia 
 
Inappropriate Muscle Contractions 
Spasticity (stroke, cerebral palsy, head injury, multiple sclerosis) 
Painful rigidity 
Strabismus 
Bruxism and tempero-mandibular joint disorders (tinnitus) 
Stuttering 
Chronic tension (muscle contraction) headaches 
Lumbosacral strain and back spasm 
Myofascial pain syndromes 
Achalasia (lower oesophageal sphincter spasm) 
Spasm of the inferior constrictor of the pharynx 
Spasm of the sphincter of Oddi 
Spastic bladder, detrusor sphincter dyssynergia 
Anismus 
Vaginismus 
 
Other Applications 
Protective ptosis,  
Hyperlachrymation 
Drooling (sialorrhoea) anterior and posterior  
Hyperhidrosis, 
Gustatory sweating 
Anal fissure,  
Constipation,  
Obesity (distal stomach) 
Cosmetic (wrinkles, brow furrows, frown lines, “crow’s feet”, platysma lines, facial 
asymmetry). 
Tennis elbow and other sports injuries. 
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Oromandibular dystonia is manifested by involuntary jaw closure, jaw opening 
or jaw deviation. It rarely improves with drug treatment and there are no surgical 
treatments. An injection of Botox® into the masseter and temporalis for jaw 
closure or into the submental muscle complex and lateral pterygoid muscles for 
jaw opening can often improve the symptoms. In addition, temporomandibular 
joint disorders, such as tinnitus, dysarthria and chewing difficulties can be 
helped (Jankovic, 2004). 
 
Laryngeal dystonia or spasmodic dysphonia is a neurological voice disorder 
characterized by involuntary adductor or abductor vocal fold spasms during 
phonation, which result in phonatory breaks. The degree of difficulty in speaking 
can be variable, but if severe the disease can cause emotional, functional and 
social effects that significantly reduce the patient’s quality of life. A local 
injection of Botox® into the laryngeal muscles is currently the gold standard of 
treatment and can produce clinical improvements in speech (Watts, Nye & Whurr, 
2006) and measurable improvements in the quality of life (Jankovic, 2004).  
 
Less consistent improvements have been reported with the laryngeal injections for 
the treatment of stuttering and voice tremor (Brin, Stewart & Blitzer, 1994). 
Palatal tremor is a rare hyperkinetic disorder, characterized by high frequency, 
rhythmic jerks of the soft palate and ear clicks. Botox® injected into the levator 
veli palatine muscle is an effective treatment for distressing ear clicks (Deuschl, 
Lohle, Heinen & Lucking, 1991). 
 
Hemifacial spasm is characterized by chronic involuntary and unilateral 
contractions, involving lower and upper facial muscles. It is usually caused by 
compression or irritation of the facial nerve by vascular loops at the level of the 
brain stem. Treatment with Botox® is currently considered the treatment of 
choice (Jankovic, 2004; Ward, Molenaers, Colosimo & Berardelli, 2006).  
 
Disorders such as dysphagia caused by spasm of the cricopharyngeal component 
of the inferior constrictor of the pharynx, and achalasia which is a rare idiopathic 
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motility disorder of the esophagus, have also been treated successfully with local 
injections of Botox® (Jankovic, 2004). 
 
3.10. Botox® to Control Drooling 
 
The idea to use botulinum toxin to treat drooling was first suggested by Justinus 
Kerner, as already discussed. In experimental animals botulinum toxin produced 
significant reductions in salivary secretion without direct toxicity to the acinar 
cells (Shaari , Bei-Lian, Biller, Chuang & Sanders, 1998). In the last six to seven 
years, botulinum toxin has been used to treat drooling in human subjects.  
 
The first study on humans was published by Pal, Calne, Calne and Tsui in 2000. 
Nine adults with Parkinson’s disease were injected with 15-22,5 units of 
botulinum toxin A (Botox®) into the parotid glands. Approximately 66% of the 
patients had subjective improvement in drooling. A second report using Botox® 
was published by Giess, Naumann, Werner, Riemann, Beck, Puls, Reiners and 
Toyka in 2000. They injected five patients who had amyotrophic lateral sclerosis 
(ALS) and drooling. 6-20 units of Botox® were injected into each parotid gland. 
If no clinical response was noted within two weeks, injections were repeated. 
Submandibular glands were only injected if parotid gland injections were not 
effective. After four weeks there was a pronounced reduction in the number of 
handkerchiefs used per day. Porta, Gamba, Bertacchi and Vaj (2001) 
demonstrated that the efficacy of Botox® was increased if the submandibular 
gland was also injected and the site of injection was guided by ultrasound. 
 
In these early open-label studies, the amount of Botox® used varied and the exact 
site of injection was chosen by individual preference. Since 2001, there have been 
numerous published studies which provided corroborative evidence supporting 
observations in the early studies (Lal and Hotaling, 2006; Tan, 2006).  
 
More robust evidence came from controlled studies. In a double-blind, placebo-
controlled study, Mancini and colleagues (2003) injected into the submandibular 
and the parotid glands of 20 patients diagnosed with Parkinson’s disease, either 
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with 450 units of Dysport® or 2ml of placebo. No anaesthetic was given, but 
ultrasound was used. The average secretion of saliva in the Dysport® group was 
significantly lower than in the placebo group.  
 
In a double-blind, placebo-controlled dose-finding study, Lipp, Trottenberg, 
Schink, Kupsch and Arnold (2003) injected into the parotid glands of 32 patients, 
age unspecified, and diagnosed with a variety of neuromuscular disorders. No 
anaesthetic was given and ultrasound guidance was not used. Patients were 
randomized into 4 groups, placebo, 18.75 units, 37.5 units or 75 units of 
Dysport®. Although 12 out 18 Dysport® treated patients reported less drooling, 
only patients treated with the highest dose showed statistically significant 
improvement over placebo treated patients. 
 
Researchers also tested the efficacy of using Botox® in neurologically impaired 
children. Suskind and Tilton (2002) injected 22 subjects, diagnosed with cerebral 
palsy and significant drooling, aged between 8-21 years. Subjects were divided 
into two groups. Group 1 received injections of 10, 20 or 30 units in escalating 
doses into the submandibular glands. Group 2 received injections of 30 units into 
the submandibular glands and 20, 30 or 40 units into the parotid glands. Although 
this was a dose escalation study, there was no comment on the optimum dosage 
within the groups.  
 
Jongerius, van den Hoogen et al (2004) conducted a controlled clinical trial with 
single injections of Botox® into the submandibular glands and compared it with 
scopolamine treatment in 45 school-aged children diagnosed with cerebral palsy. 
The injections were performed under general anaesthetic with ultrasound guidance 
and dosages were based on the child’s weight. The mean decrease in salivary flow 
was 25% during scopolamine and 42% following the Botox® injection. In 
addition, fewer and less serious side effects were noted with the Botox® injection.  
 
Some researchers feel that the use of botulinum toxin type A is a “minimally 
invasive, effective and potentially safe treatment for drooling and has the potential 
to become the treatment of choice for sialorrhoea” (Lim, Mace, Reza Nouraei, and 
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Sandhu, 2006, p. 272.). Tan (2006, p. 63.) feels that botulinum toxin holds “great 
promise for the treatment of patients suffering from sialorrhea.” Table 3.10.1, 
based on Lim et al (2006), Meningaud et al (2006) and Tan (2006), illustrates the 
studies that have used botulinum toxin type A to treat drooling in cerebral palsied 
children. As can be seen in this table, a variety of outcomes measures have been 
used. As discussed in the previous section on measurement techniques for 
drooling, there is no universally accepted measurement of drooling. Consequently 
we are unable to compare results between the different studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3.10.1:  Studies that have Used Botulinum Toxin Type A to Treat Drooling in Children. 
 
Study Design No. of 
Subjects 
Age 
Range 
(years) 
BTX/A 
Dose 
(mouse 
unit -U) in 
each 
gland 
Glands 
Injected 
Outcomes 
Measures 
Results of Outcome 
Measures 
Side Effects 
Jongerius,Rotteveel, van den 
Hoogen, Joosten, van Hulst & 
Gabreels (2001) 
Case 
series 
3 11,13,13 15,20 & 
25  
Submandibular Salivary flow rate.  
Q of L 
questionnaire 
↓ salivary flow rate at 2 
to 16 weeks. All parents 
expressed satisfaction 
with ↓ in drooling.  
 
Mild transient 
thickening of 
saliva in 1 
subject 
Suskind & Tilton (2002)  Open 
labelled 
study 
22 8-21 20-40 
10-30 
Parotid 
Submandibular 
DQ 
Qof L 
questionnaire 
 
↓ drooling in 8 subjects 
at 2 weeks 
None 
Bothwell, Clarke, Dooley, 
Gordon, Anderson, Wood,  
Camfield, & Camfield, 
(2002) 
 
Open 
labelled 
study 
9 4-17 5 Parotid Weight of saliva. 
Freq. of drooling 
↓ in drooling freq. at 
week 4. 8 subjects had ↓ 
in saliva weight. 
No serious side  
effects 
Ellies, Rohrbach-Volland, 
Arglebe, Wilken, Laskawi & 
Hanefeld, (2002) 
Case 
series 
5 None 
given 
50-65 U in 
total on 
both sides 
Parotid 
and 
Submandibular 
 Clinical 
impression of 
drooling sev. 
Saliva flow rate 
Distinct improvement in 
drooling. Reduced flow 
rate of saliva 
None 
 
Key: No.- Number; BTX/A- Botox®; QoL- Quality of Life; ↓- Decrease; DQ- Drooling Quotient; Freq.- Frequency; Sev.- Severity.  
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Table 3.10.1 continued:  Studies that have Used Botulinum Toxin Type A to Treat Drooling in Children. 
 
Study Design No. of 
Subjects 
Age 
Range 
(years) 
BTX/A 
Dose 
(mouse unit 
-U) in each 
gland 
Glands 
Injected 
Outcomes Measures Results of Outcome 
Measures 
Side Effects 
Jongerius, van den 
Hoogen et al (2004) 
Control
led 
clinical 
trial 
45 3-18 15,20 & 25 Submandibular DQ,VAS,TDS Statistical ↓ drooling at 2 
to 24 weeks 
Temp. difficulty 
in swallowing for 
2 subjects 
Savarese, Diamond, 
Elovic & Millis 
(2004) 
 
Open 
labelled 
study 
21 5-18 15 Parotid VAS, bibs/scarves used, 
saliva production 
 
Statistical ↓ drooling at 4 
to 8 weeks 
None 
Hassin-Baer et al 
(2005) 
Open 
labelled 
study 
9 6-18 10-25 Parotid Roll saturation 
Drooling sev. & freq. 
rating scales 
Statistical ↓ in saliva 
prod. in 7 subjects. 
Subjective ↓ drooling in 
3 subjects. 
None 
Jongerius, van Hulst 
et al (2005) 
Case 
report 
1 9 25 Submandibular Roll saturation, 
DQ,VAS, TDS 
For posterior and 
anterior drooling 
↓ saliva prod. ↓ posterior 
drooling, ↓ pneumonia, 
gagging, coughing. ↓ 
anterior drooling. 
None 
 
Key: No- Number; BTX/A- Botox®; ↓- Decrease; DQ.- Drooling Quotient; VAS- Visual Analogue Scale; TDS- Teacher Drooling Score.                                                                                                                   
        Temp.- Temperary; Sev.- Severity; Freq.- Frequency. 
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Table 3.10.1 continued:  Studies that have Used Botulinum Toxin Type A to Treat Drooling in Children. 
 
Study Design No. of 
Subjects 
Age 
Range 
(years) 
BTX/A Dose 
(mouse unit 
-U) in each 
gland 
Glands 
Injected 
Outcomes Measures Results of Outcome Measures Side Effects 
Banerjee et al 
(2006) 
Open 
labelled 
study 
20 6-16 1.4U/kg 
weight 
0.6U/kg 
weight 
Parotid 
and 
Submandibular 
Drooling sev. & freq.   
DQ. Weight of saliva on 
dental bib. Bibs/scarves 
used. 
Qof L scores. 
 
Statistical ↓ in no.of bibs. 
Statistical ↓ drooling sev. & 
freq. Statistical improvement in 
Q of L scores, 4-12 weeks. 
None 
Kim et al (2006) Case series 2 3 
6 
1U/kg weight 
1U/kg weight 
Submandibular 
Submandibular 
Suctioning of saliva 
Pneumonia episodes 
↓ in no. of times of suctioning. 
↓ in no. of episodes of 
pneumonia 
None 
Reid et al 
(2008) 
Randomized 
controlled 
trial 
48 6-18 25 or 4U/kg 
if child 
weighed less 
than 25kg. 
Parotid 
And  
Submandibular 
Comparison of drooling 
impact scale, consisting 
of 10 questions, rated on 
a scale of 1-10 by 
parent/primary caregiver. 
Shortened version, 3 
questions-frequency, 
severity of drooling and 
no. of bibs given to 
treatment group only. 
 
Comparison between treatment 
and control group scores. ↑ in 
the difference of scores 
between control and treatment 
groups. ↓ in drooling impact 
scale score of treatment group.  
Thicker, more 
viscous saliva 
in 4 children. ↑ 
difficulty with 
swallowing 
food, 
reluctance to 
eat dry or hard 
food, in some 
families. 
 
Key: No- Number; kg- Kilogram; BTX/A- Botox®; ↓- Decrease; ↑- Increase; DQ- Drooling Quotient; QoL- Quality of Life;                                                                                   
        Sev.- Severity; Freq.- Frequency. 
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As can be seen from Table 3.10.1, comparisons between studies are difficult. 
Some studies frequently involved small numbers of participants, and thus may 
have lacked statistical power for meaningful analysis (Bothwell, Clarke, Dooley, 
Gordon, Anderson, Wood,  Camfield, & Camfield, 2002; Ellies, Rohrbach-
Volland, Arglebe, Wilken, Laskawi & Hanefeld, 2002; Jongerius, Rotteveel, van 
den Hoogen, Joosten, van Hulst & Gabreels, 2001; Hassin-Baer et al, 2005).  
 
The amount of Botox® used varied and the exact site of injection was often 
chosen by individual preference. The relative superiority of injecting the parotid 
glands and the submandibular glands over injecting just one pair of glands has not 
been clarified. Different outcomes measures, ranging from visual analogue scales 
to counting of dental rolls, bibs, to clinical rating scales, such as the one used in 
the DTP have all been used. As already stated, the use of different outcomes 
measures makes it difficult to compare the results of drooling reductions between 
different studies. Whether the use of ultra-sound is worthwhile is still unclear as 
well. 
 
Some studies did not comment on the reliability of their subjective measures 
results (Banerjee et al, 2006; Ellies, Rohrbach-Volland, Arglebe, Wilken, Laskawi 
& Hanefeld, 2002; Hassin-Baer et al, 2005; Savarese, Diamond, Elovic & Millis, 
2004). Suskind & Tilton (2002, p. 80) did not explain what they meant by their 
“best clinical results.”  
 
These studies looked at drooling as a whole and did not separate frequency and 
severity, even though frequency and severity rating scales were used (Banerjee et 
al, 2006; Hassin-Baer et al, 2005). In a study investigating the severity and 
frequency of drooling in patients with Parkinson’s disease, 52% of patients did 
not present with an improvement in the frequency of drooling, despite an 
improvement in severity of drooling. The authors postulated that the lack of 
improvement in the frequency of drooling could be attributed to a swallowing 
dysfunction, whereas the improvement in severity of drooling could be attributed 
to a decrease in the production of saliva (Nobrega, Rodrigues, Torres, Enzo & 
Melo, 2007).  
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More importantly none of these studies looked at whether there was an 
improvement in drooling, following botulinum toxin injection, in different 
contexts. Banerjee et al (2006), despite injecting the parotid glands, as well as the 
submandibular glands, did not assess drooling during an eating or drinking 
activity. This omission seems to me to be a lost opportunity to assess any 
reduction in drooling that may have occurred during eating and drinking. The 
same can be said for the Suskind & Tilton (2002) study.  
 
In the study by Jongerius, van den Hoogen et al (2004) drooling assessments were 
made while the child watched television and during one other activity chosen by 
the child, which required a higher level of concentration or physical effort. 
However, they did not separate these results nor compared them to establish if 
there was a difference in drooling rate during the two activities.  
 
Despite being a randomized controlled trial, with a sufficient number of 
participants, and a pilot study having been conducted previously, using data on the 
Drooling Impact Scale from the Saliva Control Clinic, drooling was not assessed 
during different activities in the study by Reid et al (2008). In fact the scores from 
the Drooling Impact Scale, provided by the parents/caregivers, were totalled to 
give an overall numerical rating of the degree and impact of drooling over the 
course of a week. 
 
3.11. Concluding Remarks 
 
In the previous 3 chapters I have produced a review of the literature on the topic 
of Botox® to control drooling in neurologically impaired South African children.  
I have highlighted some methodological challenges in the published literature and  
have considered treatment options particularly within the South African context. 
At this stage little is known about the use of Botox® to control drooling in the 
South African pediatric population. The present study attempts to resolve some of 
the issues by analyzing the effects of Botox® on drooling within five different 
daily situations. In addition, the study examines whether Botox® has a different 
effect on drooling frequency as opposed to drooling severity. The study also 
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compares the effects of Botox® on drooling in the CP and operculum syndrome 
participants, as well as comparing the effects on drooling within different types of 
CP. As mentioned throughout chapter 3, there is no universal measure of drooling, 
which makes comparisons between studies difficult. I chose the severity and 
frequency of drooling scale (Thomas-Stonell & Greenberg, 1988) as it was 
appropriate for use in the clinical setting of the DTP. This study intends to 
illustrate that this scale is a reliable, quick and relevant scale for South African 
speech, language and hearing therapists to routinely use in their assessments of 
neurologically impaired children. I have also discussed in the introductory 
chapters that drooling has the potential to significantly affect QoL in the pediatric 
neurologically impaired population. Little is known about this phenomenon in 
South Africa. Some understanding of the QoL of the participants and their 
parents/primary caregivers and the effect drooling has on their QoL is obtained 
from the interview form and the parent/primary caregiver questionnaire. Finally it 
is hoped that this study provides speech, language and hearing therapists with 
information that will allow them to make informed decisions when considering 
the use of Botox® injections to control drooling.  Chapter 4 explains the 
methodology of the present study. 
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CHAPTER 4 
 
METHODOLOGY 
 
This chapter outlines the aims of the study, provides background information as to 
where the DTP of 2006 took place and describes the DTP. The research design, 
data collection methods and data analyses are explained.  
 
4.1. Aims of the Study 
 
This study comprised of an analysis of the clinical data collected during a 
Drooling Treatment Project (DTP) conducted at a cerebral palsy school in 
Gauteng. The study’s main aim was to determine if Botox®, injected bilaterally 
into the submandibular salivary glands, had an effect on drooling in nine 
neurologically impaired children in a number of situations.  
 
Within this main aim, several sub-aims were developed. These sub-aims were to: 
1. Ascertain if there was a reduction of drooling in participants in the following 
situations: 
· General appearance of the child 
· Child participating in a table top activity 
· Child eating 
· Child drinking 
· Child communicating 
 
2. Compare the effects of Botox® on drooling in the participants with CP and         
    operculum syndrome; 
3. Compare the effects of Botox® on drooling within different types of cerebral 
palsy;  
4. Explore relationships between severity of drooling and efficiency of the 
Botox® injection; 
5. Explore the duration of effect of Botox®; 
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6. To ascertain parents’/primary caregivers’ perceptions and feelings towards their 
children’s drooling, before and after the injection, and their perceptions towards 
the Botox® injection. 
 
4.2. The Drooling Treatment Project (DTP) 
 
Context of the DTP and the Present Study 
 
The school where I work is 60 years old this year. It was started by a group of 
parents who wanted to provide education for their CP children. At present the 
school caters for 340 learners between the ages of 3 and 18 years. Types of 
disabilities range from CP, a variety of syndromes, children with Attention 
Deficit/Hyperactivity Disorder (ADD/ADHD) and severe learning difficulties, 
epilepsy, partially hearing and sighted children and children with low cognitive 
development. We even have a child with a cochlear implant. Learners come from 
a 60km radius around greater Johannesburg, Gauteng, using the school’s own 
transport system, local taxis, and parental transport.  
 
Services offered by the school, besides education by qualified teachers, include: 
speech, language and hearing therapy; occupational therapy; physiotherapy, - 
most of the therapists are NDT trained; social work and psychological 
intervention; skills training and a work experience programme. We also have a 
qualified nurse who dispenses medication and emergency care, if needed.  
 
Specialized clinics are regularly run and we have the generous, donated services 
of a neurologist, pediatric neurologist, orthopaedic surgeon, plastic surgeon and an 
ENT specialist. The Wits dental school also provides dental care for our children. 
 
The Physiotherapy Department runs a very successful Botox® clinic for the lower 
limb and the Occupational Therapy Department runs the Botox® clinic for the 
upper limb and hands. The Speech Therapy Department is in the process of 
establishing a Botox® clinic for drooling. We are exceedingly grateful to all 
specialists who donate their time and especially to Genop South Africa, 
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distributers of Botox® for Allergan Ltd, who donate the Botox®. As Botox® is 
unavailable at governmental hospitals, children who are indigent and not on a 
medical aid are given the chance to receive Botox®. This school is the only 
organization to offer this service in South Africa. In addition, the therapy 
departments provide wheelchairs, specialized seating inserts, low and high 
technology AAC devices, as well as regular therapy. 
 
The Umsebe Welanga Sunbeam Caregiver training programme is also run at the 
school. Caregivers from historically disadvantaged centres in rural, semi-urban 
and urban areas throughout Gauteng come for training provided by the staff of the 
school.  
 
The DTP of 2006  
 
This project was carried out as a treatment regime, under the supervision of an 
Ear, Nose and Throat (ENT) Specialist, competent with the procedure of injecting 
Botox®. Botox® was injected bilaterally into the submandibular glands of the 
participants, under general anaesthetic, by the ENT Specialist. The submandibular 
salivary glands were chosen for the site of injection as they produce the majority 
of saliva, and the production of saliva is not stimulus related, as with the parotid 
glands (Faulconbridge et al, 2001). In addition, the submandibular secretions are 
more viscous and it is this thicker saliva that is usually troublesome in drooling 
(Brodsky, 2002). The ENT Specialist calculated the required dosage, 15 – 25 units 
per gland, dependent on each child’s body weight and guidelines from the 
Pharmaceutical Company. Ultrasound guidance was not used. According to Lim 
et al (2006) no added advantage is demonstrated in using ultrasound guidance.  
 
Individual speech, language and hearing therapists working at the above-
mentioned school, were asked to provide a list of children who drooled. 
Parents/primary caregivers were initially contacted telephonically to briefly 
explain and outline the procedure and to discover if they were interested in their 
children taking part in the DTP. Any parent/primary caregiver who was interested 
was then invited to a meeting, held at the school. Present at this meeting were the 
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children’s individual speech, language and hearing therapists, the school nurse, 
who provided translation into a home language when necessary, any interested 
parents/primary caregivers and myself. Each parent/primary caregiver was given: 
an information sheet; detailed verbal explanations, as to what would happen in the 
treatment procedure; the telephone number of the ENT Specialist who would 
perform the injections, in case they wanted more information; and an informed 
consent form, which invited them to be participants. An assent form, specifically 
for the children to sign, was also given to the parents. As a general anaesthetic 
was used during the procedure, a consent to anaesthetic form was also given to the 
parents/primary caregivers.  
 
Parents/primary caregivers were encouraged to discuss the treatment project with 
their children, before giving their consent. Parents/primary caregivers and children 
who were willing to be participants returned all the relevant forms. From these 
parents/primary caregivers and children, the final selection of participants was 
made. Written consent was obtained for the children to be photographed at 
different stages of the treatment project, from the parents/primary caregivers and 
children. This consent also entailed allowing their child’s drooling to be rated in a 
face to face setting by each parent/primary caregiver and three fully qualified 
neurodevelopmental speech, language and hearing therapists.   
 
A description of what is entailed in neurodevelopmental therapy has been given in 
chapter 2. 
 
Participants in the DTP were selected from the initial list of children who drooled, 
using the following criteria: 
· Participants of the project were between the ages of 5-17 years, with a mean 
age of 9,3 years. Drooling has been defined as an abnormality in a child more 
than four years of age in the awake state (Crysdale, 1989). Crysdale et al 
(2006) in their report on 30 years of experience in team management of 
drooling state that treatment of children with cerebral palsy is frequently 
delayed until the ages of five to six years. The reason for this delay is that 
drooling can improve spontaneously due to maturation of oral-motor 
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function. In the operculum syndrome, dysarthria and excessive drooling are 
part of the distinct clinical picture of suprabulbar (pseudobulbar) palsy. In 
this condition, an improvement in drooling is not dependent upon oral-motor 
maturation (Christen et al, 2000). Therefore it was feasible to include the 
operculum syndrome participant who was five years old.  
· Participants had all been diagnosed with neurological impairment by 
neurologists with special expertise in childhood neurological impairments. 
Seven participants were diagnosed with different types of cerebral palsy; two 
participants were diagnosed with operculum syndrome. 
· All participants were diagnosed by the three fully qualified 
neurodevelopmental speech, language and hearing therapists with anterior 
drooling. The difference between anterior and posterior drooling and any 
relevance to the present study has been discussed in chapter 3. 
· Drooling was present, varying in severity and frequency from mild and 
occasionally drools to profuse and constantly drools, in all participants 
(Thomas-Stonell & Greenberg, 1988).  
· All participants had to have undergone at least six months of oral-motor 
therapy (Lal & Hotaling, 2006).  
· Prior to the DTP, submandibular salivary glands had to be present in all 
participants, although one participant had undergone a tympanic neurectomy, 
five years previously. Drooling had returned to severe and constant in that 
child.  
· Participants had not received Botox® for another indication in the previous 
six months.  
· None of them had a known hypersensitivity to Botox®.  
· None of them suffered from systemic diseases such as bronchial asthma or 
congenital heart failure, or diseases of the neuromuscular junction such as 
myasthenia gravis. Patients with these types of diseases are extremely 
sensitive to botulinum toxin and adverse reactions have been recorded 
(Gioltzoglou, Cordivari, Lee, Hanna & Lees, 2005). 
· Participants had variable cognitive abilities, as determined by an educational 
psychologist.  
· No participants were on drugs which control drooling. 
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4.3. Research Design 
 
The research consisted of two phases.  
 
Phase One 
 
In this phase, a retrospective, explanatory, multiple case study design was used to 
review the findings of the DTP. According to Schiavetti and Metz (2006, p. 69), 
the danger in retrospective research can be the lack of validity and reliability of 
the data. Although not involved specifically with the ratings of the children’s 
drooling, I did have administrative control over the collection of the data in the 
DTP. This control ensured uniformity of measurement and drooling rating by the 
three speech, language and hearing therapists (Schiavetti & Metz, 2006, p. 69).  
 
The small number of participants in the DTP allowed each one to be treated as a 
case study. Case studies are an ideal methodology when a holistic, in-depth 
investigation is needed. They are designed to bring out the details from the 
viewpoint of the participants by using multiple sources of data (Tellis, 1997). 
Baker (1994) contends that effective case studies are used as classic examples of 
how social research can be performed. Yin (1993) has identified three specific 
types of case studies: exploratory, explanatory and descriptive. Explanatory case 
studies can be used in causal investigations, which the DTP could be considered.  
 
Case study is also known as a triangulated research strategy. Denzin (1984, in 
Tellis, 1997) identified four types of triangulation: data source; theory; 
methodological triangulation; and investigator triangulation. Investigator 
triangulation is when several investigators examine the same phenomenon. In the 
DTP, observations and ratings of the same phenomena were made by 
parents/primary caregivers and three speech, language and hearing therapists. In 
the second phase of the study a ‘blind’ independent rater also examined the same 
phenomena.  
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Finally, support for the use of a case study design comes from Blasco (2003, p. 
846). He contends that “in the final analysis, the best comparison will be a study, 
probably single subject design, directly comparing these various treatments.” The 
treatments he was referring to were intraglandular botulinum toxin injections and 
the intra-oral appliance to reduce drooling in the neurologically impaired 
population.  
 
Phase Two 
 
In phase two of the study, further management and expansion of the clinical data 
by a ‘blind’ independent rater were conducted. Cohen’s Kappa coefficients 
(Cohen, 1988) were calculated to assess the reliability/agreement of the data 
obtained from the three speech, language and hearing therapists in the DTP 
compared with the data obtained from the ‘blind’ independent rater. 
 
4.4. Participants 
 
Demographic Information 
 
The participants in the DTP were nine neurologically impaired children, their 
parents/primary caregivers and the three neurodevelopmentally trained speech, 
language and hearing therapists. These therapists had many years of experience 
working with neurologically impaired children. The ‘blind’ independent rater was 
also a qualified neurodevelopmental speech, language and hearing therapist, who 
had previously worked with cerebral palsied children.  
 
In this study the parents were predominantly single mothers. As can be seen from 
Table 4.4.1, only three participants had fathers actively involved. This aspect of 
gender in care giving has been referred to in chapter 2 with a discussion of 
Barratt’s study (2007). The primary caregiver in the present study was the 
grandmother. Some of the single mothers did have support from their mothers, i.e. 
the child’s grandmother.  It was also mentioned in chapter 2, that older, black 
South Africans are often the primary caregivers for their families. This heavy 
  
83
burden results in a decreased QoL for them and their dependents. It is therefore 
incumbent on South African health personnel to consider parental/primary 
caregiver demographics when planning treatment. 
 
All children were classified according to the Gross Motor Functional 
Classification system, which has been described in chapter 2. The diagnoses, ages, 
case history and therapy notes are given. Parental/primary caregiver socio-
economic statuses and race have been included in the demographics as this 
information provides support for the comments, discussed in chapter 2, that in 
South Africa the majority of disabled people are in the lower socio-economic 
sector and that most are African. Six of the participants were black and all of them 
were in the low or low to medium bracket. Six participants were males. This fact 
would appear to correlate with the finding that males produce more saliva than 
females (Winstock, 2005), implying that in the neurologically impaired 
population males drool more than females.  
 
 
 
 
  
Table 4.4.1:  Participant Demographics. 
 
Child Gen. P/CG Age 
(years) 
Diagnosis GMFC Case History & Therapy Notes S-
E.Status 
Race 
1 M Mom/ 
Dad 
11 Spastic 
quadriplegic 
CP 
Level 5 Non-verbal. Oral hypersensitivity, open mouth posture, forward tongue 
placement, little lateral tongue movement, tongue thrust during swallowing, 
poor oral sensory awareness. 
Medium White 
2 F Mom 6 Spastic 
hemiplegic CP 
Level 1 Severe dysarthria. Open mouth posture, forward tongue placement, no lateral 
tongue movements, high tone in lips, poor oral sensory awareness.   
Low to 
medium 
Black 
3 M Mom 17 Athetoid CP Level 1 Mild dysarthria. Open mouth posture, some lateral tongue movement, adequate 
oral sensory awareness. 
Low Black 
4 M Mom/ 
Dad 
6 Athetoid CP Level 4 Non-verbal. Gastro-esophageal reflux in 2002. Low oral tone, tone increases 
with activity, open mouth posture, forward tongue placement, little lateral 
tongue movement, poor oral sensory awareness. 
Low to 
medium 
Black 
5 M Mom/ 
Dad 
10 Athetoid CP Level 5  Non-verbal. Mouth breather, enlarged adenoids, previous bout of pneumonia. 
Fluctuating oral tone, forward tongue placement, no lateral tongue movement, 
very poor sensory awareness. Poor head control. Low motivational levels. 
Medium Indian 
6 M Mom 5 Ataxic CP Level 2 Severe dysarthria. Open mouth posture, forward tongue placement, tongue 
thrust during swallowing, little lateral tongue movement, poor oral sensory 
awareness. Choked on food when a baby. Low cognitive abilities. 
Low Black 
7 F Mom 16 Ataxic CP Level 1 Moderate dysarthria. Open mouth posture, some lateral tongue movement, 
some oral sensory awareness. Tympanic neurectomy 5 years previously. 
Drooling returned to severe and constant. 
Low Black 
8 F Mom 5 Operculum 
syndrome 
Walker Severe drooling and dysarthria. Open mouth posture, forward tongue 
placement, no lateral tongue movement, poor oral sensory awareness. 
Low White 
9 M Granny 8 Operculum 
syndrome 
Walker Severe drooling and dysarthria. Open mouth posture, forward tongue 
placement, no lateral tongue movement, poor oral sensory awareness. 
Low Black 
  
Key: Gen – Gender; M – Male; F – Female; P – Parent; CG – Caregiver; CP – Cerebral Palsy; S-E Status – Socio-Economic status;     
        GMFC – Gross Motor Functional Classification (Palisano et al. 1997).
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Sampling Strategy 
 
The children and the parents/primary caregivers could be considered to be a non-
probability convenience sample. Dooley (1995) states that convenience sampling 
is a common non-probability method, which depends on the convenient 
availability of participants. Generalisations to the wider population cannot be 
made as information regarding how or if the chosen sample matches the wider 
population is unavailable. However, it was not possible to use random sampling, 
due to the nature of the DTP. A matched control group was not used, as selection 
of a matched control group in the CP population is difficult due to the wide 
variations in the degree of deficit. Rather each child acted as her/his own control 
by comparing the data from the pre- and post intervention states (Franklin, Allison 
and Gorman, 1996; Schiavetti and Metz, 2006, p. 93).  
 
4.5. Ethical Considerations 
 
Ethical clearance to undertake the study was granted by the University Committee 
for Research using Human Subjects (Appendix A). Permission from the Gauteng 
Department of Education (GDE) to conduct the study at a GDE school was given 
(Appendix B). Written permission from the ENT Specialist concerned was also 
given for me to use all data related to the DTP (Appendix C). Permissions from 
the Principal of the school (Appendix D), the parents/primary caregivers and the 
participants (Appendices E & F) were given to allow me to use any or all data 
from the DTP, including photographs, case history information and rating results. 
All participants were assured that they could withdraw from the study at any time 
if they wished to, and feedback was given to parents/primary caregivers by me 
when this was requested. 
 
4.6. Data Collection 
 
The following data from the DTP was used in the present study. It was collected 
from the Speech Therapy Department of the school, where it had been kept safely. 
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Case history information from the children’s school files. Factors analyzed 
included the diagnosis, age and relevant medical histories of the participants. 
Speech therapy notes made by the three speech, language and hearing therapists at 
baseline, 8 weeks and 24-26 weeks post Botox® injection were obtained. This 
information allowed me to consider the causes of drooling in the study 
participants. It also allowed me to investigate any influence Botox® may have had 
on oral motor skills and oral sensory processing. 
 
A saliva control assessment form, based on the form used at the Saliva Control 
Clinic at The Royal Children’s Hospital, Melbourne (Saliva Control in Children, 
2007), was completed by the parents/primary caregivers before the DTP began 
(Appendix G). This form required information pertaining to how the 
parents/primary caregivers viewed their children’s communication skills, walking 
ability, head position, oral motor skills, dental health, general health, and whether 
there had been any bouts of pneumonia. I was able to compare the information 
obtained from this form with the information obtained from the speech therapy 
notes.  
 
Drooling rating scales: The three neurodevelopmental speech, language and 
hearing therapists used a severity rating scale and a frequency rating scale to 
assess the participants’ drooling (Thomas-Stonell & Greenberg, 1988). The 
therapists completed the ratings independently, but at the same time. Any 
discrepancies in ratings were discussed by the therapists and a consensus was 
reached. I was not involved in the rating of the participants’ drooling, thus 
minimising the problem of experimenter bias or the Rosenthal Effect (Schiavetti 
& Metz, 2006, p. 151). Table 4.6.1 explains the different rating scores for drooling 
severity and drooling frequency used in the DTP. 
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Table 4.6.1: Rating Scores for Severity and Frequency of Drooling (Thomas- 
                    Stonell & Greenberg, 1988) 
 
Severity Rating Scale Frequency Rating Scale 
Dry – Never drools 1 Never drools 1 
Mild – Wet lips only 2 Occasionally drools – not every day 2 
Moderate – Wet lips and chin 3 Frequently drools – part of every day 3 
Severe – Clothing becomes damp 4 Constantly drools 4 
Profuse – Clothing, hands, tray, 
                Table, objects are wet 
5   
  
 
These drooling rating scales are a subjective outcome measure and have been used 
by researchers in random controlled trials (Ondo, Hunter & Moore, 2004; Senner 
et al, 2004; Banerjee et al, 2006) and currently are in use by The Saliva Control 
Clinic at The Royal Children’s Hospital, Melbourne (Saliva Control in Children, 
2007). As discussed in chapter 3, these ratings scales were chosen as they 
provided an unobtrusive means of measuring the participants’ drooling. Objective, 
quantitative measures, such as the weighing of dental rolls soaked in a child’s 
saliva, calculating the drooling quotient, or the cannulation of the salivary ducts, 
were deemed to be inappropriate for the DTP and impractical in a time-
constrained clinical setting. Van der Burg, Jongerius, van Limbeek, van Hulst and 
Rotteveel (2006a, p. 179) contend that “a statistically significant change in 
salivary flow rate does not always necessarily imply a change in drooling 
severity.” As the aim of the DTP was to establish if any changes in drooling 
severity or frequency occurred and not changes in salivary flow rates, the drooling 
rating scales were thought to be appropriate.  
 
The speech, language and hearing therapists made notes as to the body/head 
posture, tongue placement, jaw stability, lip position and sensory awareness of 
each child in each situation (Appendix H). The parents/primary caregivers used 
the same severity and frequency rating scales, but without making any notes 
(Appendix I). 
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 The rating scales were completed at baseline, 8 weeks and 24-26 weeks post 
Botox® injection, in the following five different situations and in a face to face 
setting: 
 
1. General appearance of the child 
2. Child participating in a table top activity 
3. Child eating 
4. Child drinking 
5. Child communicating  
    
The intervals of 8 and 24-26 weeks were chosen as according to Tan (2006) in his 
review of different studies, the maximum effect for botulinum toxin injections is 
between 2 to 8 weeks. By 24-26 weeks the effects of the Botox® should be 
wearing off. As discussed in chapter 3, previous studies have not looked at the 
effect Botox® may have on drooling in different contexts. In the DTP we wanted 
to establish if Botox® would have an effect on drooling in different situations. 
The five different situations were chosen as they represented a cross section of 
activities that occur throughout a normal day.  
 
Drooling is known to increase during concentrated activity, therefore the table 
top activity was included (Brodsky, 2002). In a stimulated state, such as during 
eating and drinking, drooling increases because the parotid glands and other 
salivary glands produce saliva, therefore the eating and drinking activities were 
included (Mathur et al, 2006). The DTP aimed to establish if injecting only the 
submandibular glands with Botox® would decrease drooling noticeably during 
eating and drinking, despite the production of saliva by the parotid and other 
glands. Although saliva is needed when we speak, all the children in the DTP 
drooled significantly when they spoke, therefore the communicating activity was 
included. Moreover, as speech, language and hearing therapists we are concerned 
with improving all aspects of communication. 
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Procedures for Rating Severity and Frequency of Drooling 
  
The procedures for rating the severity and frequency of drooling in the DTP were 
standardized for each participant. The time of day each participant was assessed 
and the positioning of each participant in each different situation, across all three 
time periods were the same. The same routine was used to eliminate extraneous 
variables. Assessments were completed in the morning, just before and during the 
tea break, 10am. to 10.30am. In situations 2 to 5, the children were seated at a 
desk or in their wheelchairs with a lap tray attached. In situation 1, the children 
were quietly standing or sitting, but not engaged in any activity or talking. 
Activities in situation 2 included colouring or drawing a picture, for those who 
had sufficient hand control, and fitting shapes into a post box, using hand over 
hand manipulation, for those who did not have adequate fine motor control. Oral 
motor control was used for cup drinking for two participants across the three time 
periods, as they were unable to drink from a cup independently. Communication 
was elicited by asking the participants what they had done over the weekend. As 
accuracy of speech/articulation was not being investigated in the DTP, any 
vocalization was accepted as communication. Three participants could be 
considered predominantly non-verbal communicators. They used gestures and 
picture communication symbols on their communication boards to communicate.   
 
Interview form: Parents/primary caregivers were interviewed, in a face to face 
setting, at the end of the DTP. The interview aimed to establish parents/primary 
caregivers’ perceptions and feelings towards their children’s drooling and the 
Botox® injection. The social consequences of drooling were also discussed with 
the parents/primary caregivers. Parents/primary caregivers entered their responses 
on the interview form (Appendix J).  
 
Questionnaire: A quality of life questionnaire, based on the questionnaire used by 
Van der Burg et al (2006a) was given to parents/primary caregivers at the 
beginning and again at the end of the DTP. These questionnaires aimed to 
establish during which time of day parents/primary caregivers thought their 
children drooled the most and during which activities drooling occurred the most. 
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Parents/primary caregivers were asked to rate the severity of drooling on the five 
point severity rating scale. In addition bib use, the number of laundry loads 
completed in a week, and overall quality of life were investigated (Appendix K).  
  
Digital photographs were taken at every stage of the DTP and during every 
situation. Photographs were taken of the participants’ mouths and were taken in 
such a way as to prevent identification and were numbered for identification 
purposes. The amount of drool present was not altered in any way. In other words, 
participants did not have their mouths wiped, nor were they told to swallow, 
before a photograph was taken. In many instances the participants were unaware 
of the exact moment a photograph was taken. These photographs provided a 
record of treatment effects. In addition they allowed a ‘blind’ independent rater to 
rate the treatment effects and thus the reliability of the rating scales could be 
investigated. Figure 4.6.1 illustrates the edited photographs and the different 
situations used in the DTP. 
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Before: Table Top Activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After: Table Top Activity 
Before: Eating After: Eating 
Before: General After: General 
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Figure 4.6.1: Edited Photographs of Participants During Different Activities 
Before and 8 Weeks After the Botox® Injection 
 
Pilot study: A pilot study was conducted, where nine different photographs of one 
child’s mouth and any drooling were rated by two independent raters. These raters 
were qualified speech, language and hearing therapists, employed by the 
University of the Witwatersrand as senior lecturers. Three photographs from each 
Before: Talking  After: Talking 
Before: Drinking After: Drinking 
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time point, baseline, 8 weeks and 24-26 weeks and in the different situations were 
used. Results indicated the following: 
· The independent raters could rate using only the severity scale and not 
the frequency scale. As frequency of drooling is measured over time, 
they were unable to gauge the frequency of drooling from one instant in 
time, as captured by a photograph. 
· Explanations of what exactly was included in each point rating were 
needed to avoid confusion. For example, if a droplet of saliva was on 
the outer edge of the lip and clearly was about to fall onto the table, then 
a severity rating of five was indicated.   
· Participant confidentiality was maintained by the editing of the 
photographs and the assignment of a number to the photographs for 
identification purposes. 
· Cohen’s kappa coefficients were calculated and showed fair agreement 
of measurement, 0.5432, between the independent raters’ scores and the 
three speech, language and hearing therapists’ scores for each time point 
and each situation.  
· Use of digital photography provided clear pictures, but did not allow for 
sequences of events to be recorded.  
 
Data Collection in Phases One and Two of the Study 
 
Phase One: When all consents had been obtained, all relevant records from the 
DTP were collected from the speech therapy department of the participants’ 
school, where they had been safely kept. The review and analyses of the DTP 
records were then conducted by me. At the time the parents/primary caregivers 
gave their consent, approximately ten months after the Botox® injection, they 
were asked two additional open-ended questions: “how long do you think the 
treatment effect of Botox® lasted?” and “would you consider Botox® treatment 
again?” These questions aimed to find out if parents/primary caregivers thought 
the Botox® was still having an effect on their children’s drooling and their 
feelings towards a further injection of Botox®.  
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Phase Two: The ‘blind’ independent rater was given access to 296 digital 
photographs, presented in random order and asked to rate the severity of drooling 
for each photograph (Appendix L). The presentation of photographs in random 
order prevented the ‘blind’ independent rater from knowing whether the 
photograph she was rating came from the baseline, 8 weeks post injection or 24-
26 weeks post injection time frame. In this way, treatment, halo and expectancy 
biases had little effect on her ratings (Schiavetti & Metz, 2006, p. 191). She rated 
the photographs on the severity drooling scale only. As frequency of drooling is 
measured over time, she was unable to gauge the frequency of drooling from one 
instance in time, as captured by a photograph. Her rating scores for each 
photograph were also collected by me. Table 4.6.2 indicates the records that were 
analysed in the study and who completed each record. 
 
Table 4.6.2: Records of Data Analysed. 
 
 
 PARENTS THERAPISTS BLIND RATER 
CASE HISTORY/ 
THERAPISTS’ NOTES 
X X  
SALIVA CONTROL 
ASSESSMENT FORM 
X   
RATING-FREQUENCY X X  
RATING-SEVERITY X X X 
QUESTIONNAIRES X   
INTERVIEW X   
DIGITAL PHOTOS OF 
PARTICIPANTS’ MOUTHS 
  X 
 
 
 
4.7. Data Analyses 
 
The analyses of the results were handled in two ways. Some aspects, such as the 
demographic information, the information from the saliva control assessment 
form, and the results from the parental/primary caregiver interview and 
questionnaires, were handled using descriptive analyses. The small sample size 
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necessitated a case study design and the use of descriptive analyses in places. 
Other areas, such as the severity and frequency drooling rating scores, were 
handled using statistical analyses. It is important to acknowledge that although the 
rating scores are considered to be ordinal, I have used a parametric measure. This 
type of analysis is required when comparing 3 points in time, which the results 
from the baseline, 8 weeks and 24-26 weeks severity and frequency rating scores 
were. However, a small possibility exists that by using this method a false positive 
result may have been given.   
 
Case history information and therapy notes were tabulated to provide expanded 
demographic information at baseline.  
 
Information from the saliva control assessment form was tabulated to provide a 
qualitative, baseline assessment of the participants’ communicative skills, walking 
ability, head position, oral motor skills, dental health and general health, as 
perceived by the parents. 
 
Results from the severity and frequency rating scales from the three speech, 
language and hearing therapists were tabulated on spread sheets (Microsoft Excel) 
and mean scores and standard deviations were calculated. Parents/primary 
caregivers’ ratings were also tabulated on spread sheets. The ‘blind’ independent 
rater’s ratings were cross-referenced to the situation and the time frame which the 
photographs depicted and were also tabulated on spread sheets. Thereafter, grids 
were made to compare parents/primary caregivers’ versus therapists’ ratings for 
severity and frequency. Further grids were made to compare therapists’ ratings 
and the ‘blind’ independent rater’s ratings for severity only.  
 
Reliability measures: Some form of inter-rater reliability was deemed necessary, 
as rating of the children’s drooling relied on clinical or parental/primary caregiver 
judgement, as opposed to already validated test scores. Treatment, halo and 
expectancy biases can affect behavioural observations (Michelson, Mannarino, 
Marchione, Kazdin & Costello, 1985). In addition, therapeutic misestimations and 
unrealistic optimism can also affect the judgements made by parents/primary 
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caregivers and research participants (Appelbaum, Roth, Lidz, Benson & Windale, 
1987; Horng & Grady, 2003; Jansen, 2006).  
 
Inter-rater reliabilities/agreements were calculated, for parental/primary 
caregivers’ versus therapists’ ratings and therapists’ versus ‘blind’ independent 
rater’s ratings, using Cohen’s Kappa (Cohen, 1988), which is defined as follows:             
     
               K = Σfo – Σfe 
                       N – Σfe 
                                                                                                                                                                         
Where Σfo = the sum of the observed values of the diagonals 
           Σfe  = the sum of the expected values of the diagonals 
             N  = the total number of ratings. 
 
This measure of agreement is more stringent than a simple percentage agreement 
measure, as it corrects for chance agreements by subtracting the potential number 
of chance agreements from the numerator and the denominator of the kappa 
formula and then forming a ratio of the two chance-corrected values (Cohen, 
1988; Howell, 1992). 
 
Statistical analyses: 
 
All statistical analyses were carried out using the speech, language and hearing 
therapists’ ratings. Bar graphs were made to illustrate the following: 
· Any effect the Botox® injection had on drooling severity and frequency 
across all participants and all situations; 
· Comparisons of drooling for severity and frequency between cerebral 
palsied participants and operculum syndrome participants in all situations 
and across the three time periods; 
· Any effect the Botox® injection had on drooling severity and frequency in 
each situation, across all participants; 
· Response to the Botox® injection by different types of cerebral palsied 
participants, to be used in a descriptive analysis. 
  
97
Mean scores and standard deviations for severity ratings and frequency ratings for 
each time period were calculated. One-way analyses of variances (ANOVA’s) 
were computed, followed by Bonferroni post tests. The Bonferroni post test is a 
modified t test, which accounts for multiple comparisons, repeated measures, as 
well as for the fact that the comparisons are interrelated. It adjusts the t test 
analysis to account for the additional probability of rejecting a true null 
hypothesis, Type 1 error (Schiavetti & Metz, 2006, p. 351). The statistical 
analyses were carried out using the Statistical Package for the Social Sciences 
(SPSS Inc, Chicago, IL). 
 
Cohen’s d was calculated to estimate effect size between each time period. 
Cohen’s d is generally defined as the difference between two group means, M1- 
M2 divided by the standard deviation, s, of either group (Cohen, 1988). 
d = M1 – M2  
                    s 
Cohen (1988) suggests that the interpretation of d is as follows: 
· 0.20 < d < 0.50, small effect size;  
· 0.50 < d < 0.80, medium effect size;  
· d > 0.80, large effect size.  
 
The American Psychological Association (2001, p. 25) advises “for the reader to 
fully understand the importance of your findings, it is almost always necessary to 
include some index of effect size.” Huck (2004) asserts that researchers are 
increasingly reporting the effect size of their results, as well as the statistical 
significance of their results. Effect sizes give some indication as to the practical 
significance of the data. A statistician was consulted to assist with the relevant 
data analyses. 
 
Descriptive Analyses: 
 
Demographic information together with drooling severity rating scores were used 
to investigate whether different types of cerebral palsy responded differently to 
the Botox® injection and whether severity of drooling at baseline, across all 
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situations, influenced any reduction of drooling post Botox® injection. A total 
severity rating score for each child was calculated by adding the severity rating 
scores from each situation together. For example, a score of 5 for each situation 
gives a total severity rating score of 25. The responses of individual participants to 
the Botox® injection were also analysed.  
 
The results from the parental/primary caregiver interview and questionnaires were 
analyzed and tabulated to provide a qualitative review on the following: 
parental/primary caregiver perceptions of their children’s drooling; social 
consequences of drooling; at what time of day and during which activities 
drooling occurred the most; any effects on drooling the Botox® may have had and 
how long that effect lasted; finally whether they would consider further treatment 
with Botox® injections for drooling. 
 
This chapter has provided an overview of the DTP, the results from that project 
and how they were analyzed. The analyses and discussion of the results follows in 
chapter 5.  
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CHAPTER 5 
 
RESULTS AND DISCUSSION 
 
The results from the two phases of this study provide findings which are 
particularly relevant to the speech, language and hearing therapist working with 
neurologically impaired children who drool. Although results cannot be 
generalized to the wider population, they are consistent with other published 
studies. Unique aspects of the present study are that it has compared the drooling 
response to Botox® in the CP children and the operculum syndrome children, as 
well as the response to Botox® of different types of CP. More importantly it has 
compared the drooling response to Botox® in five different contexts.  
 
The results are presented in line with the aims of the study and according to 
whether the information came from phase one or phase two of the study. 
 
5.1. Phase One  
 
Case history information and therapy notes were tabulated to form expanded 
demographic information which was presented in chapter 4, page 84.  
 
The Saliva Control Assessment Form 
 
The results obtained from the saliva control assessment, completed by the 
parents/primary caregivers at baseline, are summarized in Table 5.1.1 and are 
discussed under the following, separate headings: 
· Communication 
· Mobility 
· Illness 
· Head control 
· Oral motor control 
· Oral sensory awareness/sensitivity 
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It can be seen from Table 5.1.1 that most parents/primary caregivers felt that poor 
oral motor skills, as exemplified by mouth position, lip position, ability to pucker 
lips and presence of a tongue thrust, were a significant factor in their child’s 
drooling. In addition, most parents/primary caregivers felt that their children had 
poor oral sensitivity, as shown by notices saliva on lips/chin. 
 
Table 5.1.1: Number of Participants Rated by the Parents/Primary Caregivers on  
                    Different Components of the Saliva Control Assessment Form 
 
Skill No. Skill Description 
Communication 4 
2 
1 
1 
1 
Some functional speech 
Uses speech but with difficulty 
Difficulty making some sounds in words 
No speech 
No problems 
Walking 4 
2 
3 
No difficulty 
Some difficulty, but walks independently  
Wheelchair most/all of the time 
Head Position 8 
1 
Head held up with no difficulty 
Sits with head down mostly 
Mouth Position 7 
2 
Mouth always open 
Mouth usually closed 
Lip Position 4 
3 
1 
1 
Bring lips together only briefly 
Hold lips together with effort for limited time 
Unable to bring lips together 
Lips together easily and for long time  
Pucker Lips 6 
3 
Unable to do 
Can do 
Tongue Thrust 5 
2 
2 
No 
Yes 
Sometimes 
Straw Use 5 
2 
2 
Difficulty using straw 
Cannot use straw 
Easily uses straw 
Eating/Drinking 6 
2 
1 
7 
Food needs to be cut into small pieces 
Eats a wide range of food 
Eats foods that are difficult to chew 
Can use a cup independently 
Messy Eater 9 Yes 
Swallows Saliva when Asked 6 
3 
Yes 
Attempts to swallow saliva 
Notices Saliva on Lips/Chin 7 
2 
No 
Yes 
Frequently Blocked or Runny Nose 5 
4 
No 
Yes 
Bouts of Pneumonia 8 
1 
No 
Yes 
Recent Dental Check-up 5 
4 
Yes 
No 
 
Key:  No. – Number 
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a). Communication. 
 
According to the parents/primary caregivers, only one participant was non-verbal. 
This result was not supported by the speech therapy notes, which indicated that 
three participants were non-verbal, four participants displayed severe dysarthria 
resulting in speech being mostly unintelligible, one participant displayed moderate 
dysarthria and only one participant could be classified with mild dysarthria. In the 
study by Van der Burg, Jongerius, van Limbeek, van Hulst and Rotteveel (2006b) 
51% of the children could not speak. This percentage of non-verbal participants is 
consistent with the percentage of non-verbal participants indicated by the speech 
therapy notes.  
 
In my clinical experience, parents/primary caregivers tend to over-estimate their 
children’s ability to use speech and no doubt this accounts for the fact that only 
one child was considered to be non-verbal by the parents/primary caregivers. Lack 
of ability to speak does not appear to be a factor in the cause of drooling, nor in 
the reduction of drooling for the participants in this study.  
 
b). Mobility. 
 
Six participants (67%) could walk. This number of walkers was supported by the 
speech therapy notes. Four participants were classified as being at Level 1 or 2 on 
the Gross Motor Functional Classification system (Palisano et al, 1997) and both 
operculum syndrome participants could walk. In the study by Thomas-Stonell and 
Greenberg (1988), which investigated “Three Treatment Approaches and Clinical 
Factors in the Reduction of Drooling,” mobility was one of the variables 
associated with successful treatment. It must be mentioned that Botox® injection 
was not one of the treatment strategies. However, in the study by Van der Burg et 
al (2006,b) only 19% of participants could walk. It is therefore doubtful that 
degree of mobility has an effect neither on drooling nor on the reduction of 
drooling with the use of Botox® injections. 
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c). Illness. 
 
Four participants had a frequently runny/blocked nose and one participant had had 
a previous bout of pneumonia. Banerjee et al (2006) assert that illness, particularly 
oropharyngeal, increases drooling. This has certainly been the case in my 
experience. This view is supported by the fact that when one of the operculum 
syndrome participants, who had marked reduction of drooling following the 
Botox® injection, had a cold, drooling increased considerably whilst she had the 
cold.  
 
d). Head Control. 
 
Most participants (8) had good head control and displayed a good head position. 
This was confirmed by the speech therapy notes. This result was pleasing, as all of 
the participants had received neurodevelopmental therapy, which emphasizes the 
importance of body and head positioning and alignment (Bobath, 1980). In 
Thomas-Stonell and Greenberg’s study (1988) good head control was found to be 
positively associated with decreased drooling. However, in the present study six 
participants were classified with severe drooling at baseline, despite having good 
head control. It would seem that other factors influenced the drooling experienced 
in the present study participants.  
 
e). Oral Motor Control.  
 
Poor oral motor control is a major factor negatively influencing drooling, as 
already discussed in chapter 3 (Morris and Klein, 2000; Brodsky, 2002; Winstock, 
2005; Lal and Hotaling, 2006). Although all of the participants had received oral 
motor therapy previously, including being taught correct feeding patterns, the 
majority of the participants still had poor oral motor skills. This result was 
indicated by: difficulty bringing lips together, 8 participants; an inability to purse 
the lips, 6 participants; an open mouth posture, 7 participants; and a forward 
tongue position or tongue thrusting, 4 participants. Poor oral motor skills were 
confirmed by the speech therapy notes, but these indicated that the majority of 
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participants, 7 participants, had a forward tongue position, had poor stability of 
the jaw and poor grading of opening and 3 participants had minimal or no lateral 
tongue movements. Two of these participants were the children with operculum 
syndrome. Lack of lateral tongue movement and even very little tongue 
movement in any plane, is characteristic of the child with operculum syndrome. 
This lack of lingual movement is due to the paresis/paralysis of the tongue 
(Christen et al, 2000), as discussed in chapter 2.  
 
Banerjee et al (2006) contend that drooling is exacerbated by constant tongue 
thrusting. Lespargot et al, (1993) felt that adequate suction of saliva from the front 
of the mouth to the pharynx during swallowing was hampered by poor lip closure, 
thus drooling is the result. With such poor oral motor skills, it is not surprising 
that all of the participants were considered messy eaters and exhibited drooling. 
 
f). Oral Sensory Awarenes 
 
The majority of participants were unaware of saliva on their lips or chin, 7 
participants. This was supported by the speech therapy notes. Banerjee et al 
(2006) state that drooling can be exacerbated by diminished intra-oral tactile 
sensitivity. Hyposensitivity is defined as an inability or reduced ability to respond 
to sensory input (Rosenfeld-Johnson, 2002). Rosenfeld-Johnson (2002) feels 
chronic drooling can be attributed to the inability or reduced ability to feel saliva 
build up on or within the mouth. The majority of the participants in this study 
would seem to support these statements.  
 
Morris and Klein (2000) contend that drooling can also be caused by the 
accumulation of saliva in the mouth, as a result of reduced frequency of 
swallowing and/or inadequate oral movement and control during the swallow. As 
a result, a constantly wet face from drooling can reduce the sensory cues needed 
to trigger a proper swallow. One participant in the study exhibited oral 
hypersensitivity.  It is unclear from the case history notes what caused the 
hypersensitivity or when it was first noticed. This child illustrates that drooling 
can occur with increased oral-tactile sensitivity. It is possible that the act of 
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swallowing causes this child unpleasant sensations. Thus he swallows during 
feeding and drinking, but not to rid his mouth of saliva. Only 2 participants had 
some oral sensory awareness, as observed by their efforts to occasionally remove 
saliva from their lips/chins.  
 
The etiology of drooling in cerebral palsy and operculum syndrome has been 
discussed in detail in chapter 3, as has the relationship between oral sensation and 
drooling.  
 
It would appear that poor oral motor skills, diminished oral sensory awareness and 
oral hypersensitivity were the main factors that influenced the participants’ 
drooling. In most areas of the saliva control assessment, the parent/primary 
caregivers were in agreement with the speech therapy notes. 
 
5.2. Reliability Measures in Phase One 
 
The results of the reliability measures in phase one, between the parents/primary 
caregivers and the three speech, language and hearing therapists are shown in 
Table 5.2.1. As can be seen, there was poor agreement for severity and frequency 
ratings for all children across all situations (Cohen, 1988). 
  
Table 5.2.1:  Cohen’s Kappa Coefficients for Parents and Therapists (Cohen,  
                     1988) 
 
Ratings Cohen’s Kappa Agreement 
Severity Ratings 
All Situations 
0.2458 Poor 
Frequency Ratings 
All Situations 
0.1398 Poor 
 
 
These results could be due to the fact that parents/primary caregivers do not have 
the clinical skill or experience to objectively rate the severity and frequency of 
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their children’s drooling. Another reason may be that the parents/primary 
caregivers, some of whom were English second language speakers, did not fully 
understand the definitions of each level of the rating scales, despite the fact that 
home language interpreters were used.  
 
An analysis of the parental/primary caregiver ratings indicated that they tended to 
rate their child’s drooling, particularly after the Botox® injection, more 
favourably than the speech, language and hearing therapists. This could be due to 
the ‘treatment’ bias – I know my child’s drooling has improved because he/she 
has received the treatment (Michelson et al, 1985). In fact, Michelson et al (1985) 
contend that treatment, halo and expectancy biases can affect behavioural 
observations, even among well-trained and reliable raters. 
 
The concepts of the therapeutic misestimation and unrealistic optimism 
correspond to treatment and expectancy biases. In misestimations a person 
underestimates the risk of treatment and/or overestimates the benefits of 
treatment. Unrealistic optimism is a kind of bias where a person believes that the 
outcome of her/his treatment is more likely to be positive, as compared to others 
who are in a similar situation (Appelbaum et al, 1987; Horng & Grady, 2003; 
Jansen, 2006).  
 
The results of the reliability measures in phase one confirmed the decision to use a 
‘blind’ independent rater to ensure that ratings were not influenced by biased 
perceptions or therapeutic misestimations (Cicchetti,  & Sparrow, 1981; Horng & 
Grady, 2003). The results of the reliability measures from phase two are discussed 
later in this chapter. 
 
5.3. Quantitative Results 
 
Reduction of Drooling in Neurologically Impaired Participants 
 
The main research aim to determine if Botox® had an effect on the drooling of 
nine neurologically impaired children was positively answered. As can be seen 
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from Figures 5.3.1 and 5.3.2, drooling severity and frequency rating scores 
decreased at 8 weeks and increased at 24-26 weeks post Botox® injection. The 
increase was not, however, back to baseline levels.  
   
 
Figure 5.3.1:  Severity Rating Totals of Drooling for All Children across All Five   
                      Situations in the Study 
 
 
 
Figure 5.3.2:  Frequency Rating Totals of Drooling for All Children across All  
                      Five Situations in the Study  
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From the raw totals, mean scores and standard deviations for severity and 
frequency ratings for each time period were calculated. Table 5.3.1 illustrates 
these values. 
 
Table 5.3.1: Overall Mean Scores and Standard Deviations for Severity and  
                    Frequency Ratings of Drooling 
 
 
 
 
 
 
 
 
 
 
 
 
Key:  Std. Dev. – Standard Deviation; No. of Obs. – Number of Observations;  
         Wks – Weeks. 
 
One-way ANOVAS were computed to assess whether there were statistically 
significant reductions of drooling severity and frequency rating scores. The 
Bonferroni t tests established between which time periods there were significant 
reductions of drooling severity and frequency rating scores. An alpha level of .05 
was used for all statistical tests. 
 
Cohen’s d’s were calculated to estimate the effect sizes between each time period 
for severity and frequency ratings. Table 5.3.2 indicates the significant values and 
effect sizes for severity and frequency ratings at the three time periods, for all 
children across all five situations.  
 
 
Time Mean Std. Dev. No. of Obs. 
Severity    
Baseline 3.8888889 1.1720654 45 
8 Wks 2.7777778 .90173794 45 
24-26 Wks 3.1111111 1.1525115 45 
Total 3.2592593 1.1715722 135 
Frequency    
Baseline 3.2888889 .84267491 45 
8 Wks 2.5333333 .69413124 45 
24-26 Wks 2.7333333 .78044276 45 
Total 2.8518519 .83325041 135 
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The interpretation of d was as follows (Cohen, 1988):  
· 0.20 < d < 0.50 – small effect size 
· 0.50 < d < 0.80 – medium effect size 
· d > 0.80 – large effect size 
 
Table 5.3.2:  Significant Values and Effect Sizes for Severity and Frequency  
                     Ratings of Drooling 
 
 Significance Effect Size 
Severity F (2,132) = 12.49, p < 0.0001  
Baseline - 8 Weeks p < 0.001 Large 
Baseline – 24-26 Weeks p = 0.003 Moderate 
8 Weeks – 24-26 Weeks No significance:  p = 0.439 Small 
Frequency F (2,132) = 11.49, p < 0.0001  
Baseline - 8 Weeks p < 0.001 Large 
Baseline – 24-26 Weeks p = 0.003 Moderate 
8 Weeks – 24-26 Weeks No significance: p = 0.669 Small 
  
Key:  Bold Font indicates Significant Results 
 
As can be seen from Table 5.3.2, the statistical analyses indicated that Botox® 
injected bilaterally into the submandibular glands reduced the judged severity and 
frequency of drooling rating scores across all situations and for all children with a 
significant, large effect from baseline up to 8 weeks. In addition, the reduction in 
drooling severity and frequency rating scores was statistically significant, but with 
a moderate effect, from baseline to 24-26 weeks. This result suggests that at 24-26 
weeks the effect of Botox® was on-going, although reduced. The small effect 
sizes and lack of statistically significant differences between 8 weeks and 24-26 
weeks supports the idea that at 24-26 weeks the effect of the Botox® injection 
was still in place. The probability of these results occurring by chance is p < 0.001 
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at 8 weeks and p = 0.003 at 24-26 weeks and the results are significant at the 5% 
level.  
 
The results from this study are consistent with results obtained in other published 
studies. Jongerius, van den Hoogen et al (2004) found the greatest reduction in 
drooling at 2 weeks post Botox® injection. At the end of their study, 24 weeks 
post Botox® injection, there was still a statistically significant reduction of 
drooling in some participants. It must be mentioned that in Jongerius, van den 
Hoogen et al’s study (2004), the drooling quotient (DQ) and the visual analogue 
scales (VAS) were used to assess the amount of drooling. As mentioned in chapter 
3, they did not differentiate between severity and frequency of drooling, as has 
been done in this study. Despite the different methods of quantifying drooling, a 
significant reduction in drooling was seen in their study and the present study.  
 
Bannerjee et al (2006) used the DQ, weighing the saliva collected on dental bibs, 
the number of bibs/scarves changed per day to assess drooling and they looked at 
the severity and frequency of drooling as assessed by the parent/primary 
caregiver, using the same scales as in this study. However, they injected the 
parotid glands as well as the submandibular glands and their study only lasted 12 
weeks. Nevertheless, there were statistically significant reductions of severity and 
frequency drooling scores at 4 weeks and 12 weeks. 
 
Reduction of Drooling in Different Situations 
 
As discussed in chapter 3, very little research has been done in investigating the 
reduction of drooling in different contexts. The present study looked at whether 
there were any reductions of drooling severity and frequency rating scores across 
all participants in five different situations. The results indicated that the context in 
which drooling occurs is a significant factor. As such, the results suggest the value 
of considering the situational context when making drooling judgements. This 
viewpoint is supported by Banerjee et al (2006), even though they did not 
investigate drooling in different contexts.  
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As part of their study on the impact of drooling on daily life, social interaction and 
self-esteem, Van der Burg et al (2006,a & b) investigated parental perceptions of 
decreased drooling in different situations. The results from this particular study 
are discussed later in the chapter and comparisons are made between the 
perceptions of South African parents/primary caregivers in the present study and 
parental perceptions from Van der Burg’s study. 
 
It can be seen from Figure 5.3.3 that the severity drooling rate at baseline was the 
highest in the table top situation. As all participants were considered to be messy 
eaters and saliva production is increased during stimulated states, one would have 
expected the eating and drinking situations to provide the highest severity 
drooling rates. However, it is known that drooling increases with concentration 
(Brodsky, 2002). This factor probably accounted for the high rate of drooling in 
the table top activity. The severity drooling rate in the table top situation did not 
increase at 24-26 weeks. In the other situations, severity drooling rates did 
increase, but not back to baseline levels.  
 
 
 
Key:   Baseline         ; 8 Weeks          ; 24-26 Weeks         
 
Figure 5.3.3:  Severity Drooling Rates of All Children in Different Situations 
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Figure 5.3.4 shows that the frequency of drooling rate was the highest in the 
general appearance and the communicating situations. Again, one would have 
expected the frequency of drooling rate to be the highest in the eating and 
drinking situations. In the table top and drinking situations the reductions of 
drooling frequency rates were continuing to decrease at 24-26 weeks. These 
reductions in frequency were not statistically significant. However, in the table 
top situation the effect size was large.  
 
 
 
 
Key:   Baseline          ; 8 Weeks          ; 24-26 Weeks 
            
Figure 5.3.4:  Frequency Drooling Rates of All Children in Different Situations 
                    
Statistical analyses were computed for each different situation for severity of 
drooling rates and frequency of drooling rates across all children. Effect sizes, 
Cohen’s d, were also calculated (Cohen, 1988).  
 
As can be seen from Table 5.3.3, statistically significant reductions were found in 
the ratings of drooling severity in the general appearance of the child: F (2, 24) 
= 4.11, p = 0.0291; and in the communicating situation: F (2, 24) = 5.43, p = 
0.0114. In the table top activity, eating and drinking situations, reductions of 
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drooling severity ratings were not statistically significant. Bonferroni t tests 
established that for the general appearance of the child and the communicating 
situation, statistically significant reductions in drooling severity ratings occurred 
between the baseline and 8 week time periods only. Significant values are 
highlighted in bold font. 
 
Table 5.3.3:  Effect Sizes and Significant Reductions in Drooling Severity for  
                     Each Situation 
 
 
Key: Base-Baseline; Wks-Weeks; Signif-Significance; Gen.Appear.-General 
Appearance; Comm.-Communication; ↓ - Decrease;  ↑ - Increase 
 
Table 5.3.4 illustrates that as with the severity ratings, statistically significant 
reductions were found in the ratings of drooling frequency in the general 
appearance of the child: F (2, 24) = 4.78, p = 0.0178; and in the communicating 
situation: F (2, 24) = 4.67, p = 0.0194. In the table top activity, eating and 
drinking situations, reductions of drooling frequency ratings were not 
statistically significant. Bonferroni t tests established that for the general 
appearance of the child and the communicating situations, statistically 
significant reductions in drooling frequency ratings occurred between the baseline 
and 8 week time periods only.  
 
 
 
Situation 
Base - 8 Wks Base - 24 to 26 Wks 8 Wks - 24 to 26 Wks 
Effect 
Size 
d 
Inter- 
pretation 
Signif 
↓ 
 
Effect 
 Size 
d 
Inter – 
pretation 
Signif 
↓ 
Effect 
Size 
d 
Inter- 
pretation 
Signif. 
↑ 
Gen.Appear. 1.333 Large Yes 0.647 Mod. No -0.46 Small No 
Table Top 0.853 Large No 0.853 Large No 0 Small No 
Eating 0.503 Mod. No 0.168 Small No -0.38 Small No 
Drinking 0.832 Large No 0.588 Mod. No -0.16 Small No 
Comm. 1.37 Large Yes 0.948 Large No -0.42 Small No 
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The effect sizes were large for drooling severity and frequency ratings in the 
general appearance and the communicating situations at the baseline to 8 week 
time periods. Once again, significant results are highlighted in bold font.  
 
Table 5.3.4: Effect Sizes and Significant Reductions in Drooling Frequency for  
                    Each Situation 
 
 
 
 
Situation 
Base - 8 Wks Base - 24 to 26 Wks 8 Wks - 24 to 26 Wks 
Effect 
Size 
d 
Inter – 
pretation 
Signif. 
↓ 
Effect 
 Size 
d 
Inter – 
pretation 
Signif. 
↓ 
Effect 
Size 
d 
Inter – 
pretation 
Signif. 
↑ 
Gen.Appear. 1.376 Large Yes 0.710 Mod. No -0.56 Small No 
Table Top 0.769 Mod. No 0.898 Large No 0.153 Small No 
Eating 0.777 Mod. No 0.333 Small No -0.53 Small No 
Drinking 0.343 Small No 0.406 Small No 0.101 Small No 
Comm. 1.376 Large Yes 0.917 Large No -0.45 Small No 
 
 
Key: Base-Baseline; Wks-Weeks; Signif-Significance; Gen.Appear.-General 
Appearance; Comm.-Communication; ↓ - Decrease;  ↑ - Increase. 
  
In the general and communicating situations, from 8 weeks to 24-26 weeks, 
drooling severity and frequency rates started to increase. The effect sizes for 
drooling severity and frequency rate increases were small between 8 weeks and 
24-26 weeks and were not statistically significant. Together these results provide 
support for the conclusion that at 24-26 weeks the Botox® was still exerting an 
effect on saliva production. In the communicating situation, the effect sizes for 
severity and frequency rates between baseline and 24-26 weeks were large. These 
large effect sizes are surprising, as the differences in drooling severity and 
frequency ratings in the communicating situation from baseline to 24-26 weeks 
were not statistically significant. However, the large effect sizes provide added 
support to the notion that at 24-26 weeks Botox® was still in effect.  
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The lack of statistically significant reductions in drooling severity and frequency 
ratings in the table top activity could be accounted for by the fact that the head 
was in a downward position, thus gravity would have exerted an effect, causing 
saliva to drop more often from the mouth or lips onto the table. In addition, the 
child’s level of concentration would have been higher, thus increasing the amount 
of saliva produced (Brodsky, 2002).  
 
The lack of statistically significant results during the eating and drinking 
situations could be as a result of increased saliva production, as the parotid glands 
produce saliva when stimulated by food or drink. Poor oral motor skills, causing 
an inability to deal effectively with food and drink mixed with increased amounts 
of saliva, could be another possibility (Brodsky, 2002; Winstock, 2005).  
 
Contrary to the results in the present study, Suskind & Tilton (2002) felt there was 
a significant decrease in drooling during eating. This discrepancy can probably be 
accounted for by the fact that they injected the parotid glands as well as the 
submandibular glands. 
 
It is interesting to note, that despite the lack of statistically significant reductions 
in the drooling severity rating scores for the table top and drinking activities, 
the effect sizes of the treatment were large, from baseline to 8 weeks and baseline 
to 24-26 weeks for the table top activity and from baseline to 8 weeks for the 
drinking activity. These large effect sizes correlate with the positive 
parental/primary caregiver perceptions of improved drooling during their 
children’s drinking activities and activities that required concentration. 
 
5.4. Descriptive Analyses 
 
Reductions in Drooling in the Cerebral Palsied Participants versus the Operculum 
Syndrome Participants 
 
The results demonstrated that there was a reduction of drooling in the participants 
with cerebral palsy and the participants with operculum syndrome. Figures 5.4.1 
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and 5.4.2 respectively show the comparison of drooling reduction rates for 
severity and frequency between the cerebral palsied participants and the 
operculum syndrome participants in all situations and across the three time 
periods. It is clear that the patterns of reduction for severity and frequency rates 
are different between the two diagnostic groups.  
 
 
 
 
Key:   Baseline          ; 8 Weeks          ; 24-26 Weeks         
            
Figure 5.4.1:  Comparison of Drooling Reduction for Severity between the CP and  
                       the Operculum Syndrome Participants 
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Key:   Baseline          ; 8 Weeks          ; 24-26 Weeks         
            
Figure 5.4.2: Comparison of Drooling Reduction for Frequency between the CP  
                      and the Operculum Syndrome Participants 
            
It was not possible to calculate statistical differences with such small groups, but 
percentage reductions were calculated from the raw rating scores. 
 
A reduction in drooling of 25 – 50% seems to be considered a successful outcome 
to therapy (Hassin-Baer, Scheuer, Buchman, Jacobson & Ben-Zeev, 2005; 
Jongerius, Van den Hoogen, et al, 2004). As can be seen from Table 5.4.1, 
successful outcomes were evident for all participants. However, it is noteworthy 
that the reductions in drooling severity and frequency rates for the participants 
with operculum syndrome were continuing to decrease at 24-26 weeks, as 
opposed to most of the participants with cerebral palsy, whose drooling severity 
and frequency rates were increasing, although not back to baseline levels. 
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Table 5.4.1:  Percentage Values of Drooling Reduction According to Diagnosis 
 
 
 
 
 
 
 
 
 
 
 
Key: Wks – Weeks; ↓ - Decrease; ↑ - Increase; % - Percentage 
 
This finding implies that the effect of Botox® injections lasted longer with the 
operculum syndrome participants. According to Suskind & Tilton (2002) the basis 
for the difference in duration of action is uncertain at this stage. One explanation 
for this result could be provided by the fact that damage to the brain is restricted 
to the operculum area.  
 
The neurophysiology of saliva production and swallowing involves pathways that 
eventually reach the cerebral cortex, as discussed in chapter 3. The possibility of 
Botox® affecting a central nervous system structure, for example the operculum, 
either directly or indirectly, is at this stage without proof.  However, Currà, 
Trompetto, Abbruzzese and Berardelli (2004, p. S60) present various 
experimental and clinical studies that provide information on the theory that 
“locally injected BT-A could produce central effects directly, by being transported 
into central structures, or indirectly, by altering central sensorimotor integration 
through a peripheral mechanism.”  
 
 
 
 
Time Line Cerebral Palsied Children Operculum Syndrome Children 
Severity     
Baseline – 8 Wks  26%  ↓ 36% ↓ 
Baseline – 24-26 
Wks 
14% ↓ 40% ↓ 
Frequency   
Baseline – 8 Wks 24% ↓ 21% ↓ 
Baseline – 24-26 
Wks 
12% ↓ 32% ↓ 
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Individual Severity and Frequency Scores of Drooling by Diagnosis 
 
As can be seen from Figures 5.4.3 and 5.4.4, participants 1 to 7 are CP individuals 
and participants 8 and 9 are the operculum syndrome participants. The severity 
and frequency drooling scores for individual participants are for all five situations. 
Totals scores were arrived at by adding together each drooling severity or 
frequency score from each situation for each individual at each time point. 
 
  
 
Key:   Baseline          ; 8 Weeks          ; 24-26 Weeks      
           Spast. Quad. – Spastic Quadriplegic; Spast. Hemi. – Spastic Hemiplegic;   
           Athet. – Athetoid;  Oper. Synd. – Operculum Syndrome 
                  
Figure 5.4.3:  Total Individual Severity Drooling Responses to Botox® Organized    
                       by Diagnosis 
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Key:   Baseline          ; 8 Weeks          ; 24-26 Weeks 
           Spast. Quad. – Spastic Quadriplegic; Spast. Hemi. – Spastic Hemiplegic;   
           Athet. – Athetoid;  Oper. Synd. – Operculum Syndrome 
 
Figure 5.4.4:  Total Individual Frequency Drooling Responses to Botox®  
                       Organized by Diagnosis 
            
As illustrated in Table 4.4.1: Participant Demographics in chapter 4, page 84, 
participant 3 was a 17 year old male. From the above figures, it can be seen that 
despite a reduction in drooling severity, he did not show a reduction in drooling 
frequency. This could be accounted for by the fact that his drooling was 
considered to be mild and occasional at baseline. Mild drooling (severity score 2) 
by definition states that only the lips are wet and occasional drooling (frequency 
score 2) is only on some days, not every day (Thomas-Stonell & Greenberg, 
1988). For this participant, a reduction in drooling frequency would have meant 
that he would have been rated as never drooling (frequency score 1). A rating of 
never drooling (1) would have been false; therefore he had to remain rated as 
occasionally drooling (2).  
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Participant 6 was a 5 year old male. Although diagnosed with cerebral palsy, he 
showed a continuing decrease in drooling severity at 24-26 weeks. However, the 
initial reduction in drooling severity at 8 weeks was less than in the other cerebral 
palsied participants. The frequency of his drooling did not show any decrease at 8 
weeks. However, by 24-26 weeks a reduction in drooling frequency was noted. 
This participant was considered to have an overall developmental delay and it is 
possible that this contributed to a delayed reaction of reduced drooling severity 
and frequency. In addition, it is possible that the continuing decreases in drooling 
severity and frequency rates can be attributed to the fact that drooling improves 
with the maturation of oro-facial movement and swallowing (Mathur et al, 2006).  
 
As already discussed, the 2 paticipants with operculum syndrome showed a 
continuing decrease in drooling severity and frequency rates at 24-26 weeks post 
Botox® injection. 
 
From the present study, it seems clear that the response to Botox® is variable 
between individuals. It is also possible that Botox® has a different effect on 
drooling severity as opposed to drooling frequency in some individuals. This 
possibility has been referred to in chapter 3 with a description of the study by 
Nobrega et al, (2007).  
 
These factors should be taken into account when deciding to use Botox® as a 
treatment in the neurologically impaired population. A ‘one size fits all’ approach 
cannot be advocated. Previous studies on the use of Botox® to reduce drooling in 
neurologically impaired children have not differentiated between the responses of 
different diagnostic categories. Nor has there been a separation between severity 
and frequency of drooling. The results described in this section have provided 
further areas for research.  
 
Response of Different Types of Cerebral Palsy to Botox® 
 
Although the demographic information of the participants has been given in the 
methodology section, Table 5.4.2 illustrates the baseline drooling severity ratings 
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and the 8 weeks post Botox® injection drooling severity ratings across all five 
situations for each participant. These ratings were conducted by the three speech, 
language and hearing therapists in the DTP. From these ratings a simple 
percentage analysis was conducted to answer the question of whether different 
types of cerebral palsy responded differently to the Botox® injection. 
 
Table 5.4.2:  Participant Demographics, Baseline and 8 Weeks’ Severity Ratings   
                     for Each Participant, Across All Situations 
 
Child Diagnosis Baseline 
Severity 
Ratings 
8 Weeks Post Botox® 
Severity 
Ratings 
Percentage 
↓ 
1 Spastic quadriplegic 
CP 
25 19  
 
26,5% 2 Spastic hemiplegic 
CP 
24 17 
3 Athetoid CP 9 7  
26,9% 4 Athetoid CP 22 13 
5 Athetoid CP 21 18 
6 Ataxic CP 14 13  
25% 7 Ataxic CP 18 11 
   8 Weeks 24-26 Weeks  
8 Operculum syndrome 21 13 12 35,7% 
40% 9 Operculum syndrome 21 14 13 
  
Key: CP – Cerebral Palsy; ↓ - Decrease; % - Percentage 
 
As can be seen from Table 5.4.2, the spastic cerebral palsied participants had a 
26,5% decrease in drooling rates, the athetoid participants had a 26,9% decrease 
in drooling rates and the ataxic participants had a 25% decrease in drooling rates. 
These results seem to imply that different types of cerebral palsy did not respond 
very differently to the Botox® injection. Again, it is interesting to note that the 
operculum syndrome participants had a 35,7% decrease in drooling severity rates 
at eight weeks. This had improved to a 40% decrease in drooling severity rates by 
24-26 weeks. Individual variations in response to the Botox® injections were 
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found, however the results seem to imply that there is very little difference in 
response between participants with different types of CP. Tahmassebi and Curzon 
(2003) in their study on the prevalence of drooling in children with CP found that 
the children diagnosed with spastic quadriplegia displayed the most drooling. 
While this result was confirmed in the present study, the participant with spastic 
quadriplegia did not show the most reduction in drooling following the Botox® 
injection.  
 
Previous studies to determine the effect of Botox® injections on drooling have not 
looked at different responses to Botox® according to different types of CP or 
neurological impairment in children (Banerjee et al, 2006; Jongerius, van den 
Hoogen et al, 2004; Hassin-Baer et al, 2004; Suskind & Tilton, 2002.) Banerjee et 
al (2006) listed the number of children in each diagnostic CP category, but did not 
correlate their results to the different types of CP participants. Hassin-Baer et al 
(2004) also listed only the different diagnostic categories of the participants, 
including one participant with operculum syndrome, but with no correlation to the 
results of their study.  
 
Interestingly, the study by Lipp et al (2003) compared the response of drooling to 
Botox® injections of various participants with a wide range of neurological 
disorders. It must be mentioned, however, that the participants were adults and not 
CP. In addition, the study did not include participants with operculum syndrome. 
Nevertheless, they found that the response to Botox® was similar between 
participants with Parkinson’s disease, amyotrophic lateral sclerosis, multiple 
system atrophy and corticobasal degeneration. These results correspond to the 
overall lack of difference in response found in the present study, between different 
types of CP participants. Certainly within each CP diagnostic group, there were 
slight variations in individual responses to the Botox® injection. Furthermore, 
there appeared to be a very different response to the Botox® injection by the 
participants with operculum syndrome. Banerjee et al (2006) feel that variations in 
responses are at present unexplained.  
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Influence of Baseline Severity of Drooling 
 
According to the severity rating scales (Thomas-Stonell & Greenberg, 1988),  
A total drooling severity score, S, across all situations can be interpreted thus: 
· 5 < S < 15 indicates mild drooling  
· 15 < S < 20 indicates moderate drooling                 . 
· S > 20 indicates severe to profuse drooling  
         
Using the information in Table 5.4.2, the relationship between severity of drooling 
and efficiency of the Botox® injection was investigated. 
 
The participants with severe to profuse drooling, participants 1, 2, 4, and 5, had a 
27% decrease in drooling severity rate at 8 weeks. If the operculum syndrome 
participants, 8 and 9, are included in the calculation, there was a 29,9% decrease 
in drooling severity rate at 8 weeks; the participant with moderate drooling, 7, had 
a 38,8% decrease in drooling severity rate; and the participants with mild 
drooling, 3 and 6, had a 13% decrease in drooling severity rate at 8 weeks.  
 
From these results it would seem that severity of drooling at baseline had some 
influence on the amount of drooling reduction post injection. In other words, the 
participant with moderate drooling showed a greater reduction in drooling than 
those with severe or mild drooling at baseline. As most other studies included 
participants with severe drooling only, it is difficult to assess the validity of these 
results. Suskind and Tilton (2002, p. 81) observed “the best clinical results” in 
those with the least drooling. However, they did not quantify the level of “least 
drooling” nor did they explain what their “best clinical results” were.  
 
Duration of Effect. 
 
The question of how long the effect of the Botox® injection lasted appears to be 
related to the participants’ diagnoses. At 24-26 weeks post injection, the severity 
and frequency ratings for the CP participants had increased, implying that 
although the effect of Botox® was still apparent, it was wearing off. However, the 
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ratings for the operculum syndrome participants were still decreasing at 24 – 26 
weeks. This seems to imply that the effect of Botox® would have lasted longer in 
the participants with operculum syndrome. Site and extent of brain damage may 
be a factor in determining how long Botox® lasts.  
 
Previous studies indicate that the duration of effect of Botox® on drooling is 
variable, anywhere between 3 and 24 weeks (Banerjee et al, 2006; Bothwell et al, 
2002; Ellies et al, 2002; Jongerius, van den Hoogen et al, 2004; Hassin-Baer et al, 
2004; Kim et al, 2006; Lipp et al, 2003; Ondo et al, 2004; Savarese et al, 2004; 
Suskind & Tilton, 2002 ).  
 
Ellies et al (2002) feel that the individual duration of effect with Botox® is more 
variable with intra-glandular injections as opposed to intra-muscular injections. 
Suskind and Tilton (2002) postulate that the effect lasts longer at the glandular 
level.  
 
At ten months post injection, when parents/primary caregivers gave their 
permission for the DTP data to be used in this study, most felt that the effect of 
the Botox® injection had worn off. However, the parent/primary caregiver of 
participant 4, a 6 year old male athetoid CP child, felt that the drooling had not 
returned to baseline levels. From the speech therapy notes it was clear that he had 
received oral motor therapy on a regular basis following the Botox® injections.   
 
There is emerging evidence that functional outcomes last beyond the 
pharmacologically effective period of Botox® when combined with therapy. This 
evidence comes from studies involving the use of Botox® to improve upper limb 
function (Lowe, Novak & Cusick, 2006). Theodoros, Scudamore, Baldock, 
Coman and Hancock (2007) present a case study where improvements in voice 
production were maintained longer following Botox® injection and additional 
voice therapy. There is reason to believe, therefore, that reductions in drooling can 
last longer when Botox® injections are combined with oral motor therapy. This 
combination of treatments would have the positive aspect of decreasing the 
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number of injections needed in the long term and reducing the likelihood of 
antibody formation. 
 
Parental/primary Caregivers’ Perceptions. 
 
Parental/primary caregivers’ perceptions and feelings towards their children’s 
drooling, before and after the Botox® injections and their perceptions towards the 
Botox® injection itself were analyzed using the following areas: 
 
a). Time of Day Drooling Peaked 
 
Parents/primary caregivers were asked to indicate during which time of day 
drooling occurred the most, before and after the Botox® injections. As can be 
seen from Figure 5.4.5, 7 parents/primary caregivers agreed that drooling occurred 
the most during the afternoon, before and after treatment. This result corresponds 
with the literature that states saliva production peaks during the afternoon 
(Winstock, 2005). Although the same percentage of parents/primary caregivers 
thought that drooling still occurred more often in the afternoon, they thought the 
severity of drooling was less after the treatment.  
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            p/pgs – parents/primary caregivers 
 
Figure 5.4.5:  Parental/primary caregivers’ Perceptions of the Time of Day  
                      Drooling Peaked, Before and After Botox® Treatment 
 
b). Severity during Activities/Feelings 
 
Parents/primary caregivers rated the severity of their children’s drooling during 
certain activities and feelings, before and after treatment, using the five point 
severity rating scale (Thomas-Stonell & Greenberg, 1988). Table 5.4.3 indicates 
the activities rated from ‘severe’ to ‘mild’.  As can be seen, activities that required 
concentration were placed on the ‘severe’ end of the scale, whereas sleeping and 
walking were on the ‘mild’ end of the scale. These results correspond with the 
literature, which states that drooling increases with concentration and is usually 
less during sleep (Winstock, 2005).  
 
 
 
 
 
1 p/pg 
7 p/pgs
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 Morning   Afternoon   Evening Key: 
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Table 5.4.3: Parental/Primary Caregiver Severity Ratings of Drooling during  
                    Activities/Feelings from the Quality of Life Questionnaire (based on  
                    Van der Burg et al, 2006, a) 
 
 Before Botox® Treatment After Botox® Treatment  
   Severe 
 
 
 
 
 
 
 
 
 
 
    Mild 
Brushing Teeth Concentrating 
Concentrating; sick; anxious; Upset/crying Brushing teeth; upset/crying 
Drinking Sick 
Eating Anxious 
Watching TV; happy Happy; drinking 
Tired Watching TV; eating 
Communicating Tired 
Smelling food Communicating; smelling food 
Sitting unsupported Sitting unsupported 
Sitting supported Sitting supported 
Walking Walking 
Sleeping Sleeping 
 
 
The parental/primary caregivers’ ratings of drooling severity before the Botox® 
correspond to the results of the three speech, language and hearing therapists. As 
mentioned previously, the table top situation, involving an activity requiring 
concentration, was the situation with the worst drooling. After treatment the 
parents/primary caregivers felt the mildest drooling was when the child was 
communicating, excluding sitting, walking and sleeping. This result also 
corresponds to the speech, language and hearing therapists’ evaluations, where the 
reductions in drooling during the communicating situation were found to be 
statistically significant. In this instance it seems reasonable to assume that 
statistical significance corresponds to clinical significance (Goldstein, 1990).    
 
c). Reduction/Improvement in Drooling during Activities 
 
Parents/primary caregivers were then asked to indicate, again using the five point 
severity rating scale (Thomas-Stonell & Greenberg, 1988), during which activities 
or feelings they thought the most reduction in drooling had occurred. As can be 
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seen from Table 5.4.4, parents/primary caregivers thought the most improvement 
in drooling occurred during the eating and drinking activities. The least amount 
of improvement was thought to occur during sleeping.  
 
Table 5.4.4: Parental/Primary Caregivers’ Perceptions of Drooling Improvement  
                    in Activities/Feelings following Botox® Treatment (based on  
                    Van der Burg et al, 2006, a) 
 
Improvement Activities/Feelings 
      Most  
 
 
 
 
 
     Least  
Eating 
Drinking; anxious 
Brushing teeth; tired; sick; watching TV; communicating 
Concentrating. 
Upset/crying; supported sitting 
Walking 
Unsupported sitting; smelling food; happy 
Sleeping 
 
 
These results do not coincide with the therapists’ ratings. From their results, there 
was a significant reduction in drooling severity and frequency in the general and 
communicating situations. The parents/primary caregivers perceived the most 
reduction or improvement in drooling to have occurred during eating and 
drinking. In this instance, there is very little/no correlation between statistical 
significance and clinical significance (Goldstein, 1990). Does this mean we 
should ignore the perceptions of parents/primary caregivers? In my view if 
treatment results do not make a difference in the lives of those we treat and the 
lives of their families, we have not done our job. To improve the quality of life of 
our clients we need to listen to them and understand what will make a difference 
to them. Watson, Abbott and Townsley (2006) argue convincingly for the voices 
of children with complex health care needs to be heard, not only in decisions 
about treatments, but also in research. 
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In chapter 2, I discussed the aspects of quality of life, with particular reference to 
the South African context. As a speech, language and hearing therapist, in other 
words a communication therapist, it was pleasing that the reduction in drooling 
ratings was significant for the communicating situation. However, in the South 
African context that the parents/primary caregivers of this study live, the 
improvement in drooling during eating and drinking was the most important. 
 
d). Bib Use 
 
In the present study, only 4 children used a bib. Before the Botox® injection 17 
bibs were used in a day, giving an average of 4.25 bibs per day. After the 
treatment, only 10 bibs were used in a day, giving an average of 2.5 bibs a day, 
thus giving a 41% reduction in bibs used. This result correlates with results found 
in other studies. Banerjee et al (2006) found the reduction in the number of bibs 
worn in a day to be statistically significant, p < 0.001. As discussed in chapter 3, 
counting the number of bibs used in a day, before and after treatment, has been 
used to quantify the reduction in drooling.  
 
Van der Burg et al (2006 a) used the wearing of bibs to investigate the impact 
drooling has on daily care and the economic consequences thereof. In their study, 
84% of the participants wore bibs, almost twice the number of participants 
wearing bibs in the present study. This difference could be accounted for by the 
fact that 74% of the participants in Van der Burg et al’s study (2006 a) had a 
developmental level of below six years and therefore could be expected to wear 
bibs. The bibs had to be replaced on average six to seven times a day. Participants 
also had to have several changes of clothing in a day because of their drooling.  
 
e). Laundry Loads in a Week 
 
In the study of Van der Burg et al (2006 a ) on average 9 laundry loads per family 
were done in a week. In the present study, 3 parents/primary caregivers indicated 
that they ran three to four laundry loads a week before the treatment and the same 
parents/primary caregivers ran two to three loads after the treatment, giving a 30-
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50% reduction in laundry loads. Three parents/primary caregivers indicated there 
was no difference in the number of laundry loads run, before and after the 
treatment. These results would seem to indicate that the parents/primary 
caregivers ran less laundry loads overall as compared to overseas studies.  
 
This factor could be due to the participants requiring fewer bib/clothing changes 
in a day. In addition, some of the parents/primary caregivers were not in a position 
to run laundry loads every day, due to economic circumstances. It is highly likely 
that the majority of parents/primary caregivers in the present study do not ‘run 
laundry loads’. As indicated in the participant demographics, most of the 
parents/primary caregivers fall in the low socio-economic bracket, and probably 
do their washing by hand. The measure of ‘laundry loads run’ has little relevance 
in the context of poverty and hand-washing. A more appropriate question would 
be to ask how the treatment had affected the amount of washing done. In a hand 
washing scenario, a 30-50% reduction in the amount of washing would provide 
considerable relief to parents/primary caregivers. 
 
f). The Impact of Drooling on Social Interaction 
 
Parents/primary caregivers were asked to indicate whether they thought drooling 
influenced: 
· The amount of contact the children had with other children or adults;  
· The amount of hugs and kisses given to the children; 
· The estimation of mental ability by strangers. 
 
As can be seen from Table 5.4.5, parents/primary caregivers felt their children’s 
social interaction improved following the treatment. Comparisons are made to the 
results obtained in the Van der Burg et al study (2006 b). 
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Table 5.4.5: Parental/Primary Caregivers’ Perceptions of their Children’s Social  
                    Interaction 
 
 No. & (%) of P/PCGs Who Felt Drooling Influenced Social Interaction 
Social 
Interaction 
Present Study Van der Burg et al’s Study (2006b) 
 Before Trt. Aft. Trt. 
Improvement 
Before Trt. Aft. Trt. 
Improvement 
Avoided by 
other Children 
3 (33%)- child 
was avoided 
1 (11%)- child 
teased 
6 (67%)- contact 
increased 
35% - child was 
avoided 
75% - contact 
increased 
 
Avoided by 
Adults 
4(44%) - child 
was avoided 
4(44%) - contact 
increased 
30% - child was 
avoided 
No sign. change 
Hugs and Kisses 
Received from 
Parents/primary 
caregivers 
8 (89%) -  gave 
hugs & kisses 
4(44%) - no. of 
hugs 
& kisses 
increased 
85% gave hugs 
& kisses. 
15% of parents 
avoided child 
No sign. change 
Underestimation 
of Mental Ability 
by Strangers 
 
6 (67%) -
strangers 
underestimated 
ability 
4 (44%) - 
underestimation 
by strangers was 
less 
17% felt 
strangers 
underestimated 
ability 
No sign. change 
 
Key:  No. – Number; % - Percentage; P/PCG - Parents/primary caregivers;  
         Trt - Treatment; Aft.- After; Sign. – Significant. 
 
It is interesting to note that only 17% of parents in Van der Burg et al’s study 
(2006 b) felt their children’s mental ability was underestimated. This was 
probably due to the fact that 74% of the participants had a developmental level 
below six years. Van der Burg et al (2006 b) considered the effect of drooling on 
social interaction to be considerable. In support, they cite the fact that eight 
parents in their study avoided their own children. Although results from the 
present study did not include avoidance by parents, it was clear that the 
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parents/primary caregivers felt that drooling has a considerable effect on their 
children’s social interaction.  
 
g). General Quality of Life 
 
Parents/primary caregivers were asked how they felt about their children’s 
drooling. Five parents/primary caregivers felt it was a big problem and would do 
anything to reduce the drooling. Two parents/primary caregivers felt it was a 
problem, but would like non-invasive help. One parent/primary caregiver felt it 
was somewhat of a problem and might like non-invasive help. Only one 
parent/primary caregiver felt the drooling was not a problem.  
 
The impression created from these results contradicts the clinical impression I 
have formed from talking to parents/primary caregivers. Most are not interested in 
the invasive procedure of surgery. I have no doubt that drooling is a big problem 
for the parents/primary caregivers of the present study, but it is possible that they 
felt they had to indicate that they would do anything to improve the drooling, to 
be considered for inclusion in another round of Botox® injections.  
 
Eight parents/primary caregivers felt their children’s quality of life had improved 
after the Botox® injections. They also felt the injection was worthwhile and 
would repeat the treatment. One parent/primary caregiver felt there had been little 
change in his child’s quality of life, but the child’s awareness of drooling had 
improved. One parent/primary caregiver did not respond to the general quality of 
life questions. This was the same parent/primary caregiver who indicated that 
drooling was not a problem and would not repeat the treatment.  
Parental/primary caregiver comments included: 
· Child is better behaved generally 
· Child is more confident 
· There is less teasing 
· People in the African community are more willing to take an interest in the 
child 
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· Child is more aware of the drooling and makes an effort to wipe or 
swallow the drool. 
 
The comment that people in the African community were more willing to interact 
with the child is particularly significant. As mentioned in chapter 2, Barratt (2007) 
found that parents/primary caregivers of disabled children often felt a sense of 
abandonment and isolation from their communities. It is possible that a reduction 
in drooling would foster better integration into the community for disabled 
children and their parents/primary caregivers.    
 
h). Speech Therapy Notes Post Treatment 
 
According to the therapy notes, there were no adverse reactions by any of the 
participants, following the Botox® injection. This result is consistent with 
published studies (Banerjee et al, 2006; Hassin-Baer et al, 2005; Jongerius, van 
den Hoogen et al, 2004; Kim et al, 2006). 
 
It was felt that oral sensory awareness improved in 7 children post treatment. The 
grading of jaw opening appeared to have improved in all participants. Tongue 
placement appeared to have improved, as slightly less tongue thrusting was 
observed. However, 3 participants, including the 2 with operculum syndrome, still 
had little or no lateral tongue movement. Lip closure appeared to have improved, 
particularly in the operculum syndrome participants. An interesting observation 
commented on by not only the therapists but also by the parents/primary 
caregivers of the operculum syndrome participants, was that articulation in this 
group appeared to be clearer.  
 
These findings seem to imply that with a decrease in the amount of saliva 
produced, oral motor skills and oral sensory processing improve. By extension, 
one could argue that Botox® injections into the salivary glands improve oral 
motor skills and oral sensory processing.  
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5.5. Phase Two 
 
Reliability Measures in Phase Two 
 
The results of the reliability measure in phase two, between the three speech, 
language and hearing therapists and the ‘blind’ independent rater are shown in 
Table 5.5.1. Reliability measures were calculated, using severity ratings only, not 
only for all children across all situations, but also for all children in each different 
situation. As can be seen from Table 5.5.1, they showed a fair to good agreement, 
except in the drinking situation (Cohen, 1988).  
 
Table 5.5.1:  Cohen’s Kappa Coefficients for Therapists and ‘Blind’ Independent   
                     Rater (Cohen, 1988) 
 
 
 
 
 
 
 
 
 
These values suggest that different speech, language and hearing therapists can 
rate drooling on the severity rating scale with some degree of reliability, 
particularly in the areas of table top activities and communication situation.  
 
The severity of drooling rating scale itself (Thomas-Stonell & Greenberg, 1988) 
has good inter-rater reliability, as this scale, together with the frequency scale, has 
been used in other studies of drooling and shown good reliability (Ondo, Hunter 
& Moore, 2004; Senner, Logemann, Zecker & Gaebler-Spira, 2004). In addition, 
they are currently used in The Saliva Control Clinic at The Royal Children’s 
Hospital, Melbourne with good reliability (Saliva Control in Children, 2007). It 
seems reasonable to assume therefore that the drinking situation, rather than the 
 Cohen’s Kappa Agreement 
Severity -  All Situations 0.50648 Fair 
Severity - General Situation 0.4540 Fair 
Severity- Table Top Activity 0.608699 Good 
Severity - Drinking 0.2931 Poor 
Severity - Eating 0.5027 Fair 
Severity - Communicating 0.73937 Good 
  
135
scale, produced the poor reliability result. The independent rater was rating 
drooling from photographs, which show one instance in time, and not in a face to 
face setting. The three speech, language and hearing therapists were rating in a 
face to face setting. In addition, in some photographs it may have been difficult to 
distinguish between juice and drool, unless the colour of the juice could be seen. 
The use of a digital video camera, capturing the whole sequence of drinking and 
resultant drooling may have produced better inter-rater reliability/agreement.  
 
In summary, the drooling severity rating scale (Thomas-Stonell & Greenberg, 
1988) appeared to provide a reliable measure of drooling. It was an appropriate 
measure for use with the South African neurologically impaired children, in the 
clinical setting of the DTP. It was unfortunate, however, that the ‘blind’ 
independent rater could not use the frequency rating scale.  
 
5.6. An Additional Consequence from the Use of Botox®?  
 
The children in the DTP, who were diagnosed with anterior operculum syndrome, 
following the Botox® injection, displayed not only decreased drooling but also 
improved articulation. This was noticed by their mothers and the speech therapist 
working with them. What could account for this seemingly improved articulation?  
 
In their article “The motor theory of speech perception reviewed” Galantucci, 
Fowler and Turvey (2006) discuss the concept of “mirror neurons” found in the 
premotor cortex of primates and humans. “Individuals recognize actions made by 
others because the neural pattern elicited in their premotor areas during action 
observation is similar to that internally generated to produce that action” 
(Rizzolatti & Arbib, 1998, in Galantucci, Fowler & Turvey, 2006, p. 190). There 
is now evidence that perceiving speech involves neural activity of the motor 
system.  
 
Galantucci et al (2006) cite two recent studies involving the use of transcranial 
magnetic stimulation of the motor cortex, which demonstrate activation of speech 
related muscles during the perception of speech. In addition, Wilson, Saygin, 
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Sereno and Iacoboni (2004, in Galantucci, Fowler & Turvey, 2006) demonstrated 
that there is an overlap between the cortical areas active during speech production 
and those active during passive listening to speech. Does this mean that because 
there was less saliva produced in the child’s mouth following the Botox® 
injection, she perceived her own speech as being clearer, which in turn affected 
her articulation of the speech sounds?  
 
Another possible explanation is that there was diffusion of the Botox® from the 
salivary glands to the tongue (D.Giampaulo, Neurologist, Personal 
Communication, 9 September, 2007). Studies of Botox® have shown its ability to 
disseminate beyond fascial planes (Suskind & Tilton, 2002). Botox® exerts its 
effect at the neuromusculature junction by inhibiting the release of acetylcholine, 
thus producing muscle relaxation (Brin & Aoki, 2002). Acetycholine is the 
neurotransmitter in the nerves of the tongue. If, as according to Gordon (2002), 
operculum syndrome presents with weakness and spasticity of the oral 
musculature, a reduction in spasticity, following diffusion of Botox®, should 
facilitate easier articulation.  
 
As mentioned previously in this chapter, it is possible that Botox® affects a 
“central nervous system structure either directly, by being transported into central 
structures, or indirectly by altering central sensorimotor integration through a 
peripheral mechanism (Currà et al, 2004, p. 60).” Articulation would be improved 
in both scenarios. 
 
At this stage it is unclear what the reason for the improvement in articulation was 
or even if other children with anterior operculum syndrome treated with Botox® 
injections to the salivary glands would show improved, clearer articulation. If this 
is so, however, the use of Botox® would provide a potent therapeutic tool to 
improve articulation in a disorder that has a poor prognosis for improved clarity of 
speech. Further research into this area is warranted.   
 
The results presented in this chapter have shown that Botox® injected into the 
submandibular salivary glands, is a safe option to reduce drooling in South 
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African neurologically impaired children. This result is consistent with previously 
published studies. Significant reductions in drooling rating scores were achieved 
in two contexts, the general appearance of the child and the communicating 
situation. These results are unique to this study, as drooling reductions in 
different daily situations following Botox® injections, as assessed by qualified, 
healthcare professionals, have not been considered before. The present study also 
showed that there was a difference in the pattern of response to the Botox® 
injection between the CP participants and the operculum syndrome participants. 
This result seems to imply that etiology is a factor in the response to Botox®. The 
South African parents/primary caregivers in the present study felt that the Botox® 
injections reduced their children’s drooling and consequently improved the QoL 
of the children and themselves. Moreover, they felt it was a worthwhile procedure 
and would repeat it. As stated previously, the apparent improvement in the 
articulation of the operculum syndrome participants warrants further investigation. 
 
In conclusion, there are many factors that need to be taken into account when 
deciding to use Botox® as a treatment for drooling. Although Lim et al (2006, p. 
272) contend that Botox® “has the potential to become the treatment of choice for 
sialorrhea,” the results from this study indicate that each neurologically impaired 
child’s drooling needs to be assessed on an individual basis and the most 
appropriate treatment offered based on those needs. Therefore I believe that 
Botox® at the moment is not automatically the treatment of choice for drooling 
for every child. 
 
Chapter 6 discusses the clinical implications of this study. The reliability of the 
measure of drooling used in the present study is discussed and suggestions are 
made regarding its use. As I feel that Botox® is not the automatic treatment of 
choice at the moment, an assessment model to determine eligibility for Botox® 
injections to reduce drooling is presented. The improved QoL of the participants 
and their parents/primary caregivers is considered in relation to theories of QoL. 
Limitations of the present study are discussed and improvements for future studies 
are suggested. The results from the present study have indicated several areas 
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where further research is needed. Thus implications for research are presented. 
Finally, the relevance of using Botox® in the South African context is considered. 
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CHAPTER 6 
 
CONCLUSIONS 
 
The results of the present study indicate that severity and frequency of drooling 
can be reduced in South African neurologically impaired children with the use of 
Botox® injections into the submandibular glands. While these results are 
consistent with previously published studies, a difference in the pattern of 
drooling reductions between the CP group and the operculum syndrome group 
was shown in this study. The reductions in drooling severity and frequency for the 
participants with operculum syndrome were continuing to decrease at 24-26 
weeks post Botox® injection, as opposed to most of the participants with CP, 
whose drooling severity and frequency rates were reverting back to baseline 
levels.  
 
I also considered drooling in different contexts and a significant reduction in 
drooling rating scores and large effect sizes were obtained, following the Botox® 
injection in 2 situations – the general appearance of the child and the 
communicating situation. These results have implications for the speech, 
language and hearing therapist who works with neurologically impaired children 
who drool. 
 
6.1: Clinical Implications 
 
As most speech, language and hearing therapists know who work with severely 
drooling children, a significant reduction in drooling using non-invasive means is 
hard to achieve. Although Botox® cannot be considered non-invasive, it is less 
invasive than surgery and has none to few side effects, which most pharmacologic 
treatments have. As mentioned above, significant reductions in drooling severity 
and frequency rating scores, particularly during communication, can be achieved 
safely with Botox®. Thus speech, language and hearing therapists should consider 
using Botox® as a treatment option. However, a word of caution is needed. 
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A recent article in the Saturday Star (February 16 2008) reported on information 
that the US Food and Drug Administration (FDA) had received concerning 
systemic adverse reactions, including ‘respiratory compromise and death,’ 
following the use of botulinum toxins (botox). The article goes on to explain that 
the use of botox has increased tremendously in South Africa, not only for use in 
neurological conditions but predominantly for a variety of cosmetic uses. Concern 
was expressed as to who was injecting botox, citing dentists, GP’s, and 
physiotherapists.  
 
One of the recommendations arising from the present study is that Botox® should 
only be administered by qualified medical personnel. I believe that while it is 
essential for speech, language and hearing therapists to be knowledgeable 
regarding Botox® and its uses, allowing us to be able to offer sound advice to 
parents/primary caregivers, we are not qualified to administer the toxin.  
 
It is hoped that the results contained in this study provide South African speech, 
language and hearing therapists with information and guidelines regarding the use 
of Botox® to reduce drooling in pediatric clients.  
 
My results have indicated in which situations a significant reduction in drooling 
rates can be expected to occur. Further, they inform speech, language and hearing 
therapists that individual variations in response to Botox® injections can be 
expected. The different pattern of response to the Botox® injection between the 
CP participants and the operculum syndrome participants seems to imply that the 
duration of effect of Botox® may be related to etiology. However, within the CP 
participants, there was little variation in response to Botox® between the different 
types of CP.  
 
What does seem to influence the efficiency of Botox® is the severity of drooling 
at baseline. The CP participant with moderate drooling at baseline showed a 
greater reduction in drooling at 8 weeks, 38,8% than those with severe or mild 
drooling at baseline. It must be noted that even though the participants with 
operculum syndrome were rated with severe drooling at baseline, they responded 
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optimally with a 40% reduction in drooling at 24-26 weeks post injection. It is 
possible that severity of drooling at baseline may also affect the efficiency of 
Botox® in the CP population.  
 
In chapter 3, I reviewed the various measures used to quantify drooling and 
justified the choice of the severity and frequency drooling rating scales (Thomas-
Stonell & Greenberg, 1988) in the DTP. This study has shown that in the clinical 
setting of the DTP, these rating scales proved to be a reliable and appropriate 
measure of drooling for South African neurologically impaired children. It is 
suggested therefore that they should be used by speech, language and hearing 
therapists when assessing the drooling of neurologically impaired individuals. 
With the emphasis on evidence based treatment, initial ratings of drooling using 
these scales could be compared to ratings after treatment, thus providing evidence 
as to the efficacy of treatment.  
 
Ideally drooling should be assessed at different times of the day, as drooling 
fluctuates throughout the day. In a clinical setting, assessments at different times 
of the day are often impossible to perform. It is then essential to rely on the 
parental/primary caregiver judgements of their child’s drooling. In this study good 
reliability between the speech, language and hearing therapists’ ratings and the 
parental/primary caregiver ratings was not shown. A possible method to improve 
this reliability is suggested later in this chapter.  
 
What can and should be achieved in a clinical setting is the assessment of drooling 
in different contexts. The present study has shown that not only does drooling 
differ during different situations before treatment, but that the response to a 
treatment such as Botox®, is variable in different situations. As mentioned at the 
beginning of this chapter, there was a significant reduction in drooling severity 
and frequency rates in the general and communicating situations, while there was 
a moderate reduction of drooling severity and frequency rates in the table top 
activity, and the eating and drinking situations.     
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Perhaps a more important conclusion from the present study is that the use of 
Botox® for drooling must be based on individual needs and detailed assessments. 
For example, individuals with neuromuscular disorders such as myasthenia gravis, 
or significant pulmonary problems, should not use Botox®, as discussed in 
chapters 3 and 4 (Banerjee et al, 2006; Gioltzoglou et al, 2005; Tan, 2006).  
 
The etiology of drooling needs to be carefully considered by the speech, language 
and hearing therapist before a recommendation to treat drooling with Botox® is 
made. Primary drooling is caused by an increase in saliva production, usually 
associated with inflammation, enlarged adenoids and tonsils, dental caries, mouth 
infections, certain medications, and esophageal reflux. Often drooling of this 
nature can be ameliorated by attending to the cause of the drooling.  
 
Secondary drooling is due to impaired neuromuscular control and/or sensory 
dysfunction. Whether drooling is anterior or posterior also warrants close 
examination, as posterior drooling can lead to congested breathing, coughing, 
gagging, vomiting and occasionally aspiration into the trachea leading to 
pneumonia. Additional investigations, therefore, must be carried out if posterior 
drooling is suspected, not just treatment for drooling.  
 
Factors that can exacerbate drooling, such as poor body and head positioning, 
poor oral-motor control, and a constantly open mouth need to be considered. 
Treatment should focus on these areas first before Botox® is recommended. In 
addition, the age of the child should be looked at as drooling can improve with 
oro-facial maturation. These issues have been explained in detail in chapter 3. It 
seems important to formalize an assessment model to determine eligibility for 
Botox® injections to reduce drooling. Figure 6.1.1 is an example of a possible 
model. 
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Communication skills; Mobility; 
Previous illnesses eg. 
Pneumonia; Head control; Oral 
motor control, eg. Mouth & lip 
position, ability to pucker lips, 
presence of a tongue thrust; Oral 
sensory awareness, eg. Notices 
saliva on lips/chin. Eating & 
drinking skills.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.1: Proposed Assessment Model to Determine Eligibility for the Use of  
                     Botox® to Reduce Drooling in Neurologically Impaired Children 
CASE HISTORY/ FILE INFORMATION SALIVA CONTROL 
ASSESSMENT BY 
PARENTS 
Diagnosis;Age; 
Developmental level; 
Medical, dental & 
health history; 
Educational level; 
Socio-economic 
status of the family; 
 
Previous drooling 
treatments & out- 
comes. 
ETIOLOGY 
ASSESSMENT 
by THERAPIST 
INITIAL PARENTAL 
INTERVIEW by 
THERAPIST 
 
Baseline severity & 
frequency of drooling 
in different contexts; 
OSME; Anterior versus 
posterior drooling; 
Dysphagia; Factors that 
exacerbate drooling; 
speech & language 
skills; use of AAC 
device. 
Perception of drooling in 
different contexts & at 
different times of the day;  
Activity limitations attributed 
to drooling; QoL; Attitudes to 
various drooling treatments. 
DECISION 
BOTOX® APPROPRIATE 
REFERRAL 
ALTERNATIV E 
TREATMENT 
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As can be seen from Figure 6.1.1, information from the case history, provided by 
numerous professional personnel, as well as the parents/primary caregivers, is 
needed. Assessments of factors that contribute to drooling and the situations in 
which drooling occurs are essential and should be obtained not only from the 
parents/primary caregivers but also from a speech, language and hearing therapist. 
An assessment of baseline drooling in the various contexts needs to be considered. 
Most importantly the effect of drooling on the child’s and the parents/primary 
caregivers’ lives must be considered. These factors point to the etiology and the 
impact of drooling. I suggest the use of this model is considered by healthcare 
professionals before making a recommendation as to the treatment of drooling, 
particularly when deciding to use Botox® to reduce drooling. 
 
Returning to the article in The Star newspaper, the FDA also suggested that 
adverse reactions to Botox® could be related to overdosing and not from any 
defect in the product. This suggestion has major implications for the long term use 
of Botox®. It is imperative that the minimum dose necessary to produce a 
satisfactory response is used. As repeat injections of Botox® are needed, it is also 
essential to extend the duration of effect. In chapter 5, I discussed that it appears 
by combining intensive oral motor therapy with Botox®, the duration of effect 
can be prolonged and the functional outcome enhanced. Prolonging the duration 
of effect would also have a positive impact on the cost effectiveness of using 
Botox® to reduce drooling.  
 
At present the use of Botox® is not covered by medical aid schemes in South 
Africa and it is certainly not used at government hospitals (K. Hofmeyr, 2007. 
Genop SA. Distributors of Botox® for Allergan Ltd. Personal Communication. 22 
April 2007). Several studies have investigated the cost effectiveness of using 
Botox® for dystonia or spasticity. The conclusions are that the financial expense 
involved with Botox® is more than justified when compared to the cost of drugs, 
physiotherapy or surgery (Esquenazi, 2006; Jankovic, 2004). Cost effectiveness 
studies related to the use of Botox® for drooling need to be performed. As can be 
seen from figure 6.1.2 the use of Botox® to reduce drooling can possibly provide 
numerous benefits, one of which could be reduced overall costs. 
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Figure 6.1.2: Possible Benefits from the Use of Botox® to Decrease Drooling 
 
The possible benefits and reduced costs from the use of Botox® accrue not only 
to the parents/primary caregivers but also to the individuals who drool, as can be 
seen from the above figure. In addition, by increasing the independence and 
improving the job opportunities of the individuals who drool, the costs to the 
government could conceivably be reduced as well. As mentioned later in this 
chapter, costs analyses involved in the treatment of drooling by a variety of 
methods and comparisons between treatments, including Botox® need to be 
performed. 
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of Care 
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Participation in 
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6.2: Quality of Life Revisited 
 
One of the aims of reducing drooling is to improve the quality of life of the child 
and the parent/primary caregiver. Although at this stage very little is known about 
the relationship between drooling and the quality of life for South Africans, as 
discussed in chapter 2, I believe that drooling has a negative impact on the lives of 
South African neurologically impaired children and their parents/primary 
caregivers. The results from the present study seem to support my belief.  
 
In chapter 2, I also discussed three theories of QoL – The Lindstrom and Eriksson 
model (1993), the discrepancy model (Eisner et al, 2000) and the utility model 
(Feeny et al, 1998). Although Davis et al (2006) argue that none of the models are 
appropriate for pediatric QoL, the descriptive analysis of the parents/primary 
caregivers’ answers and views in the present study, as well as the views of 
caregivers expressed in Barratt’s study (2007) and Salojee et al’s study (2006) 
seem to me to lend support for Lindstom and Eriksson’s model (1993).   
 
In the global sphere, if the politics of a country do not allow for equal 
opportunities for disabled individuals and the community wherein the disabled 
individual and the parent/primary caregiver live isolates them (Barratt, 2007), then 
their quality of life is likely to be poor. The comments from the parents/primary 
caregivers in the present study indicate that they and their children had 
experienced isolation, but following the reduction in drooling, the isolation had 
lessened – “people in the African community are more willing to take an interest 
in the child.” Although South Africa supports the philosophy of equal opportunity 
for disabled individuals, and has an Integrated National Disability Strategy (1997) 
the practical implementation has yet to filter through to all people (Saloojee et al, 
2006).  
 
In the external sphere, the lack of educational and employment opportunities can 
impact negatively on QoL. Saloojee et al (2006) reported that 13% of the 
parents/primary caregivers interviewed had experienced difficulty in finding a 
school to accept their disabled children.  
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In the interpersonal sphere, disabled individuals often have difficulties with 
forming relationships (Nadeau & Tessier, 2006). Lack of friends can lead to 
feelings of isolation and consequently a negative QoL. Comments from the 
parents/primary caregivers following the reduction in drooling, such as “there is 
less teasing, more children will play with him, my child is better behaved” support 
the notion that the children had experienced difficulty in making friends with 
other children.  
 
In the personal sphere, self-esteem and self-concept may be negatively affected in 
the disabled individual, particularly if the individual drools (Van der Burg et al, 
2006 a). The comment “my child is more confident” supports the view that 
following a drooling reduction, the child’s self esteem had improved and thus her 
QoL. 
 
It is interesting to note that the parents/primary caregivers perceived the most 
improvement in drooling following the Botox® treatment, to have occurred 
during eating and drinking, whereas the speech, language and hearing therapists 
involved in the DTP judged the most improvement to be in the general and 
communicating situations. Reliability of the parental/primary caregivers’ 
judgments may have been lacking, as determined by Cohen’s Kappa coefficients 
(1988), but parents/primary caregivers are vital members of the team involved 
with the treatment of their disabled children and their views and the views of the 
disabled children should be paramount.   
 
Parental/primary caregiver perceptions and the social consequences of drooling in 
the present study were found to be similar to views expressed by parents/primary 
caregivers in other studies (Van der Burg et al, 2006 b). It was clear that the South 
African parents/primary caregivers felt that their children’s drooling had a 
considerable effect on their social interaction and quality of life and that these 
both improved after treatment with Botox®. These results support the belief of 
Tuna, Ünalan, Tuna and Kokina (2004, p. 648): 
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 ‘It is a well known fact that quality of life is subjective, and it should be 
considered that it may show important differences between countries or 
cultures. However, we believe that having a child with CP may well be 
deemed a universal problem which has profound shared characteristics 
experienced by all mothers…..’ 
 
An important footnote to this statement must be added. The parents/primary 
caregivers in the present study came from urban and semi-urban areas. If the 
statement by Tuna et al (2004) is true, then rural parents/primary caregivers 
should experience/perceive drooling in the same way. At this stage the accuracy 
of this statement is unknown. It is essential that the rural disabled population be 
consulted. A quality of life instrument that: includes considering the effects of 
drooling; is relevant to the unique South African rural disabled population, many 
of whom are illiterate; and considers the opinions of disabled children, needs to be 
formulated. Equally important, speech, language and hearing therapists must 
consider the QoL of the children they assess/treat and their parents/primary 
caregivers. 
 
6.3: Research Implications 
 
The results of this study have highlighted several areas for further research. 
 
A replication of this study with larger numbers of participants in each category of 
CP would help to confirm the result that there is very little difference in response 
to Botox® within the different types of CP.  
 
Likewise a replication of the study with larger numbers of participants categorized 
according to baseline ratings of drooling would confirm the hypothesis that there 
is a relationship between efficiency of response to Botox® and severity of 
drooling. 
 
The difference in the pattern of response to Botox® between the CP participants 
and the operculum syndrome participants seems to imply that the duration of 
  
149
Botox® effect is related to site or sites of lesions. Further research to validate this 
hypothesis is warranted.  
 
As poor reliability was shown between the therapists’ ratings and the 
parents/primary caregivers’ ratings, it is suggested that further research is carried 
out to establish if providing the parents/primary caregivers with visual examples 
of drooling at each level of rating, would improve inter-rater reliability in this 
area.  A universal clinical measure of drooling would then be available. 
 
Previous studies on the use of Botox® to reduce drooling in neurologically 
impaired children have not differentiated between the response of the severity and 
the frequency of drooling to Botox®. The results of this study seem to indicate 
that there is a difference. Further research would confirm or refute this.  
 
As mentioned in chapter 2, Rosenbaum et al (2007) feel there is a high priority to 
develop a scale for speech and laryngeal activity limitation in CP. Such a scale 
could include how much influence oral-motor functioning, oral sensitivity and 
awareness, and drooling have on activity limitations. 
 
Senner et al (2004) found a positive relationship between severity of drooling and 
severity of dysarthria. They were, however, unable to explain the relationship. The 
results from the present study seem to indicate that articulation improves with a 
decrease in saliva production in the operculum syndrome participants.  
 
The possibility that Botox® has an effect on oral motor skills, particularly 
articulation, provides another opportunity for research. The next step would be to 
investigate the effects of Botox® on drooling and oral motor skills, with an 
emphasis on articulation, within the operculum syndrome population versus a 
cerebral palsied population that is matched for age, gender, developmental level 
and severity and frequency of drooling. These criteria for sampling would 
necessitate a much larger sample size than the one in this study. Generalizations to 
the operculum syndrome population would then be possible. 
 
  
150
Cost effectiveness studies in relation to the use of Botox® to improve drooling are 
needed. 
 
The influence of drooling on quality of life, particularly in the rural population, 
should be considered together with the compilation of a pediatric quality of life 
instrument for the neurologically impaired. This measure should be relevant to the 
diverse population in South Africa and include a child self-report section. With 
such an instrument we would be able to compare the judged quality of life of 
South African neurologically impaired children and their parents/primary 
caregivers between an urban population and a rural population. 
 
6.4: Limitations of the Study 
 
Retrospective studies, as outlined in chapter 4, can lack validity and reliability of 
data. The fact that I had administrative control over the collection of the data in 
the DTP and the use of a ‘blind’ independent rater did control for validity and 
reliability to a certain extent. 
 
The use of a convenience, small sample precludes generalization to the wider 
population. However, as already stated, the use of Botox® to control drooling 
should be based on individual assessments and needs. 
 
The use of a still digital camera did not allow the ‘blind’ independent rater to 
assess drooling on the frequency rating scale. This could have been overcome by 
the use of a video digital camera. Unfortunately at the time of the DTP, one was 
not available. 
 
Although drooling measurements were made during five different contexts, only 
one measurement was made for each context at each time period. As drooling is 
known to be variable, in the interests of scientific research it would have been 
appropriate to have taken several drooling measurements for each situation and 
each time period. An average could then have been calculated. 
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When comparing the repeated measurements over time, parametric analysis was 
used. However, as the drooling measurements can be considered ordinal, there is a 
slight possibility that a false positive result was given.  
 
6.5: Concluding Remarks 
 
There is every indication to suggest that the treatment of Botox® injections into 
the submandibular glands to reduce drooling in neurologically impaired South 
African children has worked. Further, the treatment worked for a period of time 
and across a number of dimensions. The treatment also provided an improved 
quality of life, not only for the participants, but also for their parents/primary 
caregivers. In addition, there is a compelling emerging suggestion that etiology 
may be important and that children diagnosed with operculum syndrome may be 
demonstrating a different overall response to this treatment, as opposed to the 
children with CP. This suggestion has potential implications in relation to 
proposed models of explanation with regard to neural pathways and their 
physiological structures. 
 
If the judicious use of Botox® is to be extended, all stakeholders, from 
pharmaceutical companies, provincial hospitals, medical aids and government, 
need to be on board. We cannot allow only the wealthy to have access to the 
possible benefits. Botox® to reduce drooling must be available to all who would 
benefit. While I am cognizant of the expense and the tremendous hurdles needed 
to make this happen, and of other pressing issues, such as HIV/AIDS, alleviation 
of poverty, houses, electricity and sanitation for all, to name but a few, I am 
reminded of Martin Luther King’s famous words: 
 
‘I have a dream…..’ 
 
I, too, have a dream and this research has provided me with the impetus to 
continue to work towards that dream. As a clinician I have come a long way. 
Perhaps now I can call myself a clinician-researcher.
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APPENDIX D 
 
PRINCIPAL CONSENT FORM 
 
I hereby consent to the use of all data, relating to the children in my school, 
obtained from the drooling treatment procedure last year. Furthermore, I give the 
researcher, Nicola Hay, permission to use the responses and all data relating to the 
children, in the write up of the study and in future publications or presentations. 
 
I understand that participation in the study is voluntary and that I am free to refuse 
to participate or to give my consent to the use of any data relating to the children 
at my school at any time. I understand that nothing will be held against me or my 
school, should I refuse permission.  
 
I understand that my and my school’s privacy will be maintained, should I choose 
not to have the school’s name included in the study report. I am aware that if I, the 
parents and the children have any questions at any time, they will be answered. It 
has been explained to me that the study procedures will not in any way interfere or 
disrupt the school day.  
 
Please circle your response: I give Nicola Hay permission to use data from: 
 
Initial, pre-injection assessment, completed by the parent and three qualified 
speech therapists.  YES        NO 
 
Post injection assessments, completed at 7 weeks and 24 weeks, completed by the 
parent and three qualified speech therapists.  YES     NO 
 
Assessments by an independent rater, who would be a qualified speech therapist, 
who was not involved with the initial project.  YES         NO 
 
All photographs of the children drooling, taken in such a way that identification of 
a child is impossible.   YES          NO 
 
Medical data obtained from the Ear, Nose and Throat specialist, Professor Joseph, 
concerning the amount of Botox used with a child.     YES       NO 
 
A child’s school file, such as case history details, diagnoses of neurological 
impairment, cognitive abilities and any previous treatment for drooling a child 
may have had, with consent from the child’s parent.     YES       NO 
 
Inclusion of the school’s name in the study report.      YES       NO 
 
I AGREE   DISAGREE to the consent forms being given to the mothers and 
children. 
 
Date:_______________________________ 
 
Signature:___________________________ 
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APPENDIX E 
 
PARENT/CAREGIVER CONSENT FORM 
I hereby consent to the use of all information, relating to my child, obtained from 
the drooling treatment procedure last year. Furthermore, I give the researcher, 
Nicola Hay, permission to use my responses and all information relating to my 
child, in the write up of the study and in future publications or presentations. 
 
I understand that participation in the study is voluntary and that I am free to refuse 
to participate or to give my consent to the use of any information relating to my 
child at any time. I understand that this will not affect the way my child will be 
treated at school, should I refuse permission. I also understand that this also 
applies to my child. In other words he/she may refuse to give consent to use the 
information pertaining to him/her at any time. 
 
I understand that my and my child’s privacy will be maintained and that any 
information my child and I choose to divulge will remain strictly confidential. I 
am aware that if I and my child have any questions at any time, they will be 
answered and that appropriate referrals and recommendations will be made 
available to me should I and/or my child require them.  
Please circle your response: I give Nicola Hay permission to use information 
from: 
Initial, pre-injection assessment, completed by myself and three qualified speech 
therapists.  YES        NO 
 
Post injection assessments, completed at 7 weeks and 24 weeks, completed by 
myself and three qualified speech therapists.  YES     NO 
 
Assessments by an independent rater, who would be a qualified speech therapist, 
who was not involved with the initial procedure.  YES         NO 
 
All photographs of my child drooling, taken in such a way that identification of 
my child is impossible.   YES          NO 
 
Post injection questionnaires filled in by me and the interview information.YES    
NO 
 
Medical data obtained from the Ear, Nose and Throat specialist, Professor Joseph, 
concerning the amount of Botox used with my child.     YES       NO 
 
My child’s school file, such as case history details, diagnosis of neurological 
impairment, cognitive ability and any previous treatment for drooling my child 
may have had.     YES       NO 
 
I do / do not wish to attend the second interview, scheduled for late June at Forest 
Town School. 
 
Date:_______________________________ 
 
Signature:___________________________ 
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APPENDIX F 
 
CHILD ASSENT FORM 
 
 
 
My name is Nicola Hay and I am doing a study based on the treatment drooling 
project that we did last year. I want to know if you want to be in the study. You do 
not have to say yes and you will not get into trouble if you say no. 
 
You will not have to do anything in the study, but I do need your permission to 
use the results from the drooling treatment project and the photographs that were 
taken.  Nobody will know that it is you in the results or the photographs, as your 
name will not be used and the photographs will just be of your mouth. I will not 
show the results or photographs to anyone if you do not want me to. You may tell 
me at any time that you do not give me permission to use your results and 
photographs. 
 
 
 
Please circle if you want to be in my study and you give me your permission. 
 
 
YES 
 
 
 
 
NO 
 
 
 
My name is _______________________________________ 
 
Today is the _______________________________________ 
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APPENDIX G 
 
SALIVA CONTROL ASSESSMENT FORM 
 
Date:  _____________________ 
Name:_____________________ 
 
1. Communication Skills: 
¨ No problems 
¨ Some speech which is functional 
¨ Uses speech to get message across but with difficulty 
¨ Has difficulty making sounds in words 
¨ Has no speech 
2. Walking: 
¨ No difficulty 
¨ Has some difficulty but walks independently without an aid 
¨ Needs a walking aid 
¨ Uses a wheelchair all or most of the time 
3. Head Position: 
¨ Can hold head up without difficulty 
¨ Tends to sit with head down mostly 
4. Is mouth always open ? 
    ¨   Yes                          ¨   No                               ¨   Unsure 
5. Lips: 
¨ Can hold lips together easily and for a long time  
¨ Can hold lips together with ease for a limited time 
¨ Can hold lips with effort for a limited time 
¨ Can bring lips together only briefly 
¨ Unable to bring lips together  
6. Can he/she pucker lips (as in a kiss) ? 
    ¨  Yes              ¨   No                  ¨   Unsure 
7. Does he/she push the tongue out when swallows ? 
      ¨  Yes              ¨   No                 ¨   Unsure 
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8. Straw: 
¨ Can use straw easily 
¨ Has difficulty using a straw 
¨ Cannot use a straw 
9. Eating/drinking: 
¨ Can eat whole hard foods that are difficult to chew 
¨ Eats a wide range of foods 
¨ Needs to have food cut into small pieces 
¨ Food needs to be mashed/pureed 
¨ Drinks need to be thickened 
¨ Has food through a tube (nasogastric/gastrstomy) 
10. Is he/she a messy eater ? 
     ¨  Yes              ¨   No                 ¨   Unsure 
11. Can he/she swallow saliva when asked to ? 
     ¨  Yes              ¨   No                 ¨   Attempts               ¨   Unsure 
12. Does he/she notice saliva on lips/chin (perhaps tries to wipe chin) ? 
    ¨  Yes              ¨   No                 ¨   Unsure 
13. General Health 
Does he/she have asthma ? 
¨  Yes              ¨   No                 ¨   Unsure 
Does he/she have frequently blocked or runny nose ? 
¨  Yes              ¨   No                 ¨   Unsure 
Does he/she have bouts of pneumonia ? 
¨  Yes              ¨   No                 ¨   Unsure 
14. Are there any difficulties with teeth cleaning ? 
      ¨  Yes              ¨   No                 ¨   Unsure 
15. Has there been a recent dental check ? 
      ¨  Yes              ¨   No                 ¨   Unsure 
      If Yes, who with ? 
16. Are there any problems with bleeding gums or decayed teeth ? 
    ¨  Yes              ¨   No                 ¨   Unsure 
Thank you for completing this questionnaire
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GLOSSARY: 
JAW POSITION FOR CONSONANT AND VOWEL PRODUCTIONS 
 
HIGH m b p f v n s z sh tch r 
closed 
open 
MEDIUM th    1     t     d 
LOW g    k    h 
SENSORY AWARENESS 
Is the child able to feel the saliva pooling in the mouth or running down the lips and 
chin? 
Hyposensitivity - inability or reduced ability to react to sensory input 
Hypersensitivity - increased / abnormally heightened reaction to sensory input 
Tactile Defensiveness - a learned tendency to respond negatively to sensory input 
BODY POSTURE 
Optimal body positioning will allow for better control of saliva  
DROOLING 
The inability or reduced ability to organise and swallow saliva 
  
PARENTS' ASSESSMENT FORM 
Name: 
APPENDIX I 
Date: 
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1. GENERAL APPEARANCE OF CHILD - when not doing an activity 
 
 RATING 
FREQUENCY OF DROOLING  
SEVERITY OF DROOLING  
2. CHILD PARTICIPATING IN TABLE TOP ACTIVITY 
 
 RATING 
FREQUENCY OF DROOLING  
SEVERITY OF DROOLING  
3. CHILD EATING - independent feeding / assisted feeding (with help) 
 
 RATING - indep RATING - with help 
FREQUENCY OF DROOLING   
SEVERITY OF DROOLING   
4. CHILD DRINKING - cup / straw 
 
 RATING - cup RATING - straw 
FREQUENCY OF DROOLING   
SEVERITY OF DROOLING   
5. COMMENT ON CHILD WHEN COMMUNICATING 
 
 RATING 
FREQUENCY OF DROOLING  
SEVERITY OF DROOLING  
 
SEVERITY OF DROOLING                                                  FREQUENCY OF DROOLING 
 
DRY - NEVER DROOLS                                   1                                         NEVER DROOLS                 1 
MILD-WET LIPS ONLY                               2                                   OCCASIONALLY DROOLS       2 
MODERATE - WET LIPS AND CHIN              3                                       FREQUENTLY DROOLS          3         
SEVERE - CLOTHING BECOMES DAMP        4                                        CONSTANTLY DROOLS    4 
PROFUSE - CLOTHING, HANDS, TRAY,         5 
                    TABLE, OBJECTS  ARE  WET                                                                                                
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APPENDIX J 
 
INTERVIEW QUESTIONS FOR PARENTS 
 
 
1.  Do you think the drooling injection was worthwhile?  Yes     No 
 
2. Would you allow your child to have another injection?    Yes     No 
 
3. How many bibs/scarves did your child use in a day before the injection? 
 
4.  How many bibs/scarves did your child use in a day after the injection? 
 
5. Before the injection, how many loads of laundry did you do in a week?  
 
6. Did the number decrease after the injection?   Yes    No   If yes, how many? 
 
Social Consequences of Drooling 
 
1. Before the injection, did your child play with other children at home?   Yes    No 
 
2. Did the amount of time other children played with your child increase after the    
injection?    Yes    No 
 
3. Before the injection, was your child avoided by other children?   Yes    No 
 
4. After the injection, did this improve?   Yes    No 
 
5. Before the injection, did adults avoid contact with your child?    Yes    No 
 
6. After the injection, did this improve?     Yes    No 
 
7. Before the injection, how many hugs or kisses in a day, did you or another family 
member give your child? 
 
8. After the injection, did the number increase?    Yes    No   If yes, how many? 
 
9. Before the injection, did strangers underestimate your child’s mental ability? Yes  
No 
 
10. Did this improve after the injection?  Yes    No   If yes, how? 
 
11. Do you think your child’s quality of life improved after the injection?  Yes    No    If 
yes, how? 
 
12. How do you rate the problem of drooling, as part of your child’s disability? 
 
                      1-------Not really a problem 
                      2------Some problem, but not enough to warrant intervention 
                      3------A problem, would like non-invasive, conservative help 
                      4------A big problem, interferes with all aspects of life, would try  
                                anything to help. 
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13. How do you think your child rates his/her drooling? Use the above rating  
      scale. 
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APPENDIX K 
 
QUESTIONNAIRE TO PARENTS 
 
 
 
1a. Before the injection, at what time during the day did your child drool? 
                                                                       
              Morning                                        Afternoon                                      Night   
 
 
1b. After the injection, at what time during the day did your child drool the most? 
                                                                       
              Morning                                        Afternoon                                      Night   
 
                                                                                                  
2a. Before the injection, during what activities did he/she drool? 
 
 Concentrated activity       Relaxed, watching TV       Walking         Doing sports   
 
 Sitting          Sleeping          Drinking        Eating        Talking        Brushing teeth  
 with support 
 
 Sitting              Smell or taste of          When tired           When ill          Crying   
 without support     certain foods 
 
 When happy         When anxious         Lying on back           Lying on tummy   
 or laughing 
 
 
2b. After the injection, during what activities did he/she drool? 
 
 Concentrated activity       Relaxed, watching TV       Walking         Doing sports   
 
 Sitting          Sleeping          Drinking        Eating        Talking        Brushing teeth  
 with support 
 
 Sitting              Smell or taste of          When tired           When ill          Crying 
 without support     certain foods  
 
  When happy         When anxious         Lying on back           Lying on tummy   
 or laughing 
 
 
 
Severity of drooling: 1----no drooling 
       2----mild, wet lips only 
                                  3----moderate, wet lips and chin 
                                  4----severe, clothing becomes damp 
            5----profuse, clothing, hands, tray, table, objects are wet 
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APPENDIX L 
 
INDEPENDENT RATER’S ASSESSMENT FORM 
 
 
NAME OF RATER:____________________                    DATE:___________________ 
 
PHOTOGRAPH_______                                                                  
RATING 
 SEVERITY OF DROOLING  
 
 
PHOTOGRAPH_______ 
RATING 
SEVERITY OF DROOLING  
 
 
PHOTOGRAPH_______ 
RATING 
SEVERITY OF DROOLING  
 
 
PHOTOGRAPH_______ 
RATING 
SEVERITY OF DROOLING  
 
 
PHOTOGRAPH_______ 
RATING 
SEVERITY OF DROOLING  
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